<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Sodium valproate versus phenytoin monotherapy for epilepsy: an individual participant data review - Nevitt, SJ - 2018 | Cochrane Library</title> <meta content="Sodium valproate versus phenytoin monotherapy for epilepsy: an individual participant data review - Nevitt, SJ - 2018 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD001769.pub4/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Sodium valproate versus phenytoin monotherapy for epilepsy: an individual participant data review - Nevitt, SJ - 2018 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD001769.pub4/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD001769.pub4" name="dc.identifier" scheme="DOI"/> <meta content="Sodium valproate versus phenytoin monotherapy for epilepsy: an individual participant data review" name="citation_title"/> <meta content="Sarah J Nevitt" name="citation_author"/> <meta content="University of Liverpool" name="citation_author_institution"/> <meta content="sjn16@liverpool.ac.uk" name="citation_author_email"/> <meta content="Anthony G Marson" name="citation_author"/> <meta content="Institute of Translational Medicine, University of Liverpool" name="citation_author_institution"/> <meta content="Jennifer Weston" name="citation_author"/> <meta content="Institute of Translational Medicine, University of Liverpool" name="citation_author_institution"/> <meta content="Catrin Tudur Smith" name="citation_author"/> <meta content="University of Liverpool" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="8" name="citation_issue"/> <meta content="10.1002/14651858.CD001769.pub4" name="citation_doi"/> <meta content="2018" name="citation_date"/> <meta content="2018/08/09" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD001769.pub4/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD001769.pub4/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD001769.pub4/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Anticonvulsants [*therapeutic use]; Epilepsies, Partial [*drug therapy]; Epilepsy, Generalized [*drug therapy]; Phenytoin [*therapeutic use]; Randomized Controlled Trials as Topic; Seizures [*drug therapy]; Treatment Outcome; Valproic Acid [*therapeutic use]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001769.pub4&amp;doi=10.1002/14651858.CD001769.pub4&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001769.pub4&amp;doi=10.1002/14651858.CD001769.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001769.pub4&amp;doi=10.1002/14651858.CD001769.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001769.pub4&amp;doi=10.1002/14651858.CD001769.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001769.pub4&amp;doi=10.1002/14651858.CD001769.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001769.pub4&amp;doi=10.1002/14651858.CD001769.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001769.pub4&amp;doi=10.1002/14651858.CD001769.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001769.pub4&amp;doi=10.1002/14651858.CD001769.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001769.pub4&amp;doi=10.1002/14651858.CD001769.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001769.pub4&amp;doi=10.1002/14651858.CD001769.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001769.pub4&amp;doi=10.1002/14651858.CD001769.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001769.pub4&amp;doi=10.1002/14651858.CD001769.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001769.pub4&amp;doi=10.1002/14651858.CD001769.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001769.pub4&amp;doi=10.1002/14651858.CD001769.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001769.pub4&amp;doi=10.1002/14651858.CD001769.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001769.pub4&amp;doi=10.1002/14651858.CD001769.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001769.pub4&amp;doi=10.1002/14651858.CD001769.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001769.pub4&amp;doi=10.1002/14651858.CD001769.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001769.pub4&amp;doi=10.1002/14651858.CD001769.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001769.pub4&amp;doi=10.1002/14651858.CD001769.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001769.pub4&amp;doi=10.1002/14651858.CD001769.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001769.pub4&amp;doi=10.1002/14651858.CD001769.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001769.pub4&amp;doi=10.1002/14651858.CD001769.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772874000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772901000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000"}};Liferay.authToken="8ranHhTh";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD001769\x2epub4\x26doi\x3d10\x2e1002\x2f14651858\x2eCD001769\x2epub4\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001769\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD001769\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513679709000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","zh_HANS","ms","fa"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD001769.pub4",title:"Sodium valproate versus phenytoin monotherapy for epilepsy: an individual participant data review",firstPublishedDate:"Aug 9, 2018 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Epilepsy Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734064000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=8ranHhTh&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD001769.pub4&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD001769.pub4';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD001769.pub4/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD001769.pub4/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD001769.pub4%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD001769.pub4/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD001769.pub4/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD001769.pub4/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD001769.pub4/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD001769.PUB4" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;Abstract&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;Plain language summary&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD001769.pub4/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD001769.PUB4" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD001769.pub4/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD001769.pub4/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>3433 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD001769.pub4" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001769.pub4/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001769.pub4/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001769.pub4/full#CD001769-abs-0004"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001769.pub4/full#CD001769-sec-0094"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001769.pub4/full#CD001769-sec-0022"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001769.pub4/full#CD001769-sec-0023"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001769.pub4/full#CD001769-sec-0028"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001769.pub4/full#CD001769-sec-0029"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001769.pub4/full#CD001769-sec-0053"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001769.pub4/full#CD001769-sec-0088"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD001769.pub4/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001769.pub4/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001769.pub4/appendices#CD001769-sec-0099"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001769.pub4/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001769.pub4/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD001769.pub4/media/CDSR/CD001769/table_n/CD001769StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD001769.pub4/media/CDSR/CD001769/table_n/CD001769StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001769.pub4/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001769.pub4/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001769.pub4/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD001769.pub4/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD001769.pub4/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD001769.pub4/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2018 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD001769.pub4/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> <div class="inline-status-wrapper"> <ul class="cochrane-status"> <li aria-label="A new search for studies has been conducted." class="status-item up-to-date custom-tooltip" data-status="newsearch" title="A new search for studies has been conducted."> <a class="btn secondary" href="information#history">New search</a> </li> </ul> </div> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Sodium valproate versus phenytoin monotherapy for epilepsy: an individual participant data review </h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD001769.pub4/information#CD001769-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>Sarah J Nevitt</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD001769.pub4/information#CD001769-cr-0003">Anthony G Marson</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD001769.pub4/information#CD001769-cr-0004">Jennifer Weston</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD001769.pub4/information#CD001769-cr-0005">Catrin Tudur Smith</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD001769.pub4/information/en#CD001769-sec-0107">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 09 August 2018 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD001769.pub4/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD001769.pub4">https://doi.org/10.1002/14651858.CD001769.pub4</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD001769-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD001769-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD001769-abs-0003">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD001769-abs-0008">فارسی</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD001769-abs-0002">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD001769-abs-0001" lang="en"> <section id="CD001769-sec-0001"> <h3 class="title" id="CD001769-sec-0001">Background</h3> <p>Epilepsy is a common neurological condition in which abnormal electrical discharges from the brain cause recurrent unprovoked seizures. It is believed that with effective drug treatment up to 70% of individuals with active epilepsy have the potential to become seizure‐free, and to go into long‐term remission shortly after starting drug therapy with a single antiepileptic drug in monotherapy. </p> <p>Worldwide, sodium valproate and phenytoin are commonly used antiepileptic drugs for monotherapy treatment. It is generally believed that phenytoin is more effective for focal onset seizures, and that sodium pvalproate is more effective for generalised onset tonic‐clonic seizures (with or without other generalised seizure types). This review is one in a series of Cochrane Reviews investigating pair‐wise monotherapy comparisons. This is the latest updated version of the review first published in 2001, and updated in 2013 and 2016. </p> </section> <section id="CD001769-sec-0002"> <h3 class="title" id="CD001769-sec-0002">Objectives</h3> <p>To review the time to treatment failure, remission and first seizure of sodium valproate compared to phenytoin when used as monotherapy in people with focal onset seizures or generalised tonic‐clonic seizures (with or without other generalised seizure types). </p> </section> <section id="CD001769-sec-0003"> <h3 class="title" id="CD001769-sec-0003">Search methods</h3> <p>We searched the Cochrane Epilepsy Group's Specialised Register, the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, ClinicalTrials.gov and the World Health Organization (WHO) International Clinical Trials Registry Platform ICTRP on 19 February 2018. We handsearched relevant journals, contacted pharmaceutical companies, original trial investigators and experts in the field. </p> </section> <section id="CD001769-sec-0004"> <h3 class="title" id="CD001769-sec-0004">Selection criteria</h3> <p>Randomised controlled trials (RCTs) comparing monotherapy with either sodium valproate or phenytoin in children or adults with focal onset seizures or generalised onset tonic‐clonic seizures </p> </section> <section id="CD001769-sec-0005"> <h3 class="title" id="CD001769-sec-0005">Data collection and analysis</h3> <p>This was an individual participant data (IPD) review. Our primary outcome was time to treatment failure and our secondary outcomes were time to first seizure post‐randomisation, time to six‐month, and 12‐month remission, and incidence of adverse events. We used Cox proportional hazards regression models to obtain trial‐specific estimates of hazard ratios (HRs) with 95% confidence intervals (CIs), using the generic inverse variance method to obtain the overall pooled HR and 95% CI. </p> </section> <section id="CD001769-sec-0006"> <h3 class="title" id="CD001769-sec-0006">Main results</h3> <p>We included 11 trials in this review and IPD were available for 669 individuals out of 1119 eligible individuals from five out of 11 trials, 60% of the potential data. Results apply to focal onset seizures (simple, complex and secondary generalised tonic‐clonic seizures), and generalised tonic‐clonic seizures, but not other generalised seizure types (absence or myoclonus seizure types). For remission outcomes, a HR of less than 1 indicates an advantage for phenytoin, and for first seizure and treatment failure outcomes a HR of less than 1 indicates an advantage for sodium valproate. </p> <p>The main overall results were: time to treatment failure for any reason related to treatment (pooled HR adjusted for seizure type 0.88, 95% CI 0.61 to 1.27; 5 studies; 528 participants; moderate‐quality evidence), time to treatment failure due to adverse events (pooled HR adjusted for seizure type 0.77, 95% CI 0.44 to 1.37; 4 studies; 418 participants; moderate‐quality evidence), time to treatment failure due to lack of efficacy (pooled HR for all participants 1.16 (95% CI 0.71 to 1.89; 5 studies; 451 participants; moderate‐quality evidence). These results suggest that treatment failure for any reason related to treatment and treatment failure due to adverse events may occur earlier on phenytoin compared to sodium valproate, while treatment failure due to lack of efficacy may occur earlier on sodium valproate than phenytoin; however none of these results were statistically significant. </p> <p>Results for time to first seizure (pooled HR adjusted for seizure type 1.08, 95% CI 0.88 to 1.33; 5 studies; 639 participants; low‐quality evidence) suggest that first seizure recurrence may occur slightly earlier on sodium valproate compared to phenytoin. There were no clear differences between drugs in terms of time to 12‐month remission (pooled HR adjusted for seizure type 1.02, 95% CI 0.81 to 1.28; 4 studies; 514 participants; moderate‐quality evidence) and time to six‐month remission (pooled HR adjusted for seizure type 1.05, 95% CI 0.86 to 1.27; 5 studies; 639 participants; moderate‐quality evidence). </p> <p>Limited information was available regarding adverse events in the trials and we could not make comparisons between the rates of adverse events on sodium valproate and phenytoin. Some adverse events reported with both drugs were drowsiness, rash, dizziness, nausea and gastrointestinal problems. Weight gain was also reported with sodium valproate and gingival hypertrophy/hyperplasia was reported on phenytoin. </p> <p>The methodological quality of the included trials was generally good, however four out of the five trials providing IPD for analysis were of an open‐label design, therefore all results were at risk of detection bias. There was also evidence that misclassification of seizure type may have confounded the results of this review, particularly for the outcome 'time to first seizure' and heterogeneity was present in analysis of treatment failure outcomes which could not be explained by subgroup analysis by epilepsy type or by sensitivity analysis for misclassification of seizure type. Therefore, for treatment failure outcomes we judged the quality of the evidence to be moderate to low, for 'time to first seizure' we judged the quality of the evidence to be low, and for remission outcomes we judged the quality of the evidence to be moderate. </p> </section> <section id="CD001769-sec-0007"> <h3 class="title" id="CD001769-sec-0007">Authors' conclusions</h3> <p>We have not found evidence that a significant difference exists between valproate and phenytoin for any of the outcomes examined in this review. However detection bias, classification bias and heterogeneity may have impacted on the results of this review. We did not find any outright evidence to support or refute current treatment policies. We recommend that future trials be designed to the highest quality possible with consideration of masking, choice of population, classification of seizure type, duration of follow‐up, choice of outcomes and analysis, and presentation of results. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD001769-abs-0004" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD001769-abs-0004">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD001769-abs-0007">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD001769-abs-0009">فارسی</a> </li> <li class="section-language"> <a class="" href="full/ms#CD001769-abs-0006">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD001769-abs-0005">简体中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD001769-abs-0004" lang="en"> <h3>Sodium valproate versus phenytoin monotherapy (single drug treatment) for epilepsy</h3> <p>This is an updated version of the Cochrane Review previously published in Issue 4, 2016 of the <i>Cochrane Database of Systematic Reviews</i>. </p> <p><b>Background</b> </p> <p>Epilepsy is a common neurological disorder in which abnormal electrical discharges from the brain cause recurrent seizures. We studied two types of epileptic seizures in this review: generalised onset seizures, in which electrical discharges begin in one part of the brain and move throughout the brain; and focal onset seizures, in which the seizure is generated in and affects one part of the brain (the whole hemisphere of the brain or part of a lobe of the brain). Focal seizures may become generalised (secondary generalisation) and move from one part of the brain throughout the brain. For around 70% of people with epilepsy, a single antiepileptic medication can control generalised onset or focal onset seizures. </p> <p><b>Objective</b> </p> <p>Sodium valproate and phenytoin are commonly used treatments for individuals with epilepsy. The aim of this review was to compare how effective these drugs are at controlling seizures and whether individuals choose to stop taking these treatments (treatment failure), to inform a choice between these drugs. </p> <p><b>Methods</b> </p> <p>The last search for trials for this review was 19 February 2018. We assessed the evidence from 11 randomised controlled clinical trials comparing sodium valproate to phenytoin and we were able to combine data for 699 people from five of the 11 trials; for the remaining 450 people from six trials, data were not available to use in this review. </p> <p><b>Key results</b> </p> <p>This review of trials found no difference between these two drugs for the seizure types studied for the outcomes of treatment failure (withdrawal from treatment) and controlling seizures (recurrence of seizures or achievement of a seizure‐free period (remission) of 6 months or 12 months). The review also found no evidence to support or refute the policy of using sodium valproate for generalised onset tonic‐clonic seizures and phenytoin for focal onset seizures. </p> <p>However, up to 49% of people within the trials classified as having generalised seizures may have had their seizure type wrongly diagnosed and these people may have been experiencing focal seizures or an uncertain seizure type, and this misclassification may have influenced the results of this review. We were unable to address the issue of preferring sodium valproate for generalised onset seizure types other than tonic‐clonic, such as absence or myoclonic seizures. </p> <p><b>Quality of the evidence</b> </p> <p>We judged the quality of the evidence as moderate to low for the evidence of treatment failure, moderate for remission outcomes and low for seizure outcomes as it is likely that misclassification of seizure type influenced the results of the review. Within four of the five trials providing data for this review, the design of the trial meant that the people and treating clinicians knew which medication they were taking. This design may have influenced the results. </p> <p><b>Conclusions</b> </p> <p>Sodium valproate and phenytoin are commonly used treatments for individuals with epilepsy, but we found no difference between these treatments for the outcomes of this review or between seizure types. More information is needed and we recommend that all future trials comparing these medications, or any other antiepileptic medications, should be designed using high‐quality methods. Seizure types of people included in trials should also be classified very carefully to ensure that the results are also of high quality. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD001769-sec-0094" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD001769-sec-0094"></div> <h3 class="title" id="CD001769-sec-0095">Implications for practice</h3> <section id="CD001769-sec-0095"> <p>The results of this systematic review do not provide any conclusive evidence for or against the current practice of using valproate as a first‐line treatment for individuals with generalised onset tonic‐clonic seizures, and phenytoin as monotherapy for individuals with focal onset seizures. Guidelines currently recommend lamotrigine and carbamazepine as a first‐line treatment for focal onset seizures (<a href="./references#CD001769-bbs2-0073" title="National Institute for Health and Care Excellence. The epilepsies: the diagnosis and management of the epilepsies in adults and children in primary and secondary care. www.nice.org.uk/guidance/cg137 (accessed 01 08 2018). ">NICE 2012</a>); the results of this review do not inform current treatment policy. </p> </section> <h3 class="title" id="CD001769-sec-0096">Implications for research</h3> <section id="CD001769-sec-0096"> <p>Finding overall differences between these standard antiepileptic drugs has proved elusive. If overall differences do exist across heterogeneous populations of individuals, such as those studied here, those differences are likely to be small, and in order to be clinically useful, future comparative antiepileptic drug trials will need to be powered accordingly. It has been argued that future comparative antiepileptic drug trials be powered to establish equivalence (<a href="./references#CD001769-bbs2-0056" title="JonesB , JarvisP , LewisJA , EbbuttAF . Trials to assess equivalence: the importance of rigorous methods. BMJ1996;313(7048):36‐9. ">Jones 1996</a>), and therefore be capable of detecting what is considered to be the smallest important clinical difference. </p> <p>This review highlights the need for future antiepileptic drug monotherapy trials that recruit individuals with specific epilepsy syndromes, to be designed and powered to detect a difference between particular antiepileptic drugs. An approach likely to reflect and inform clinical practice, as well as being statistically powerful, would be to recruit heterogeneous populations for whom epilepsy syndromes have been adequately defined, with testing for interaction between treatment and epilepsy syndrome. In view of potential problems of misclassification, syndromes will have to be well defined, with adequate checking mechanisms to ensure that classifications are accurate, and with a system to recognise uncertainty surrounding epilepsy syndromes in individuals within trials. </p> <p>Clinical uncertainty about seizure and syndrome classification is often present at the time of diagnosis and initial treatment of epilepsy, and significant numbers of individuals with newly diagnosed epilepsy cannot be classified (<a href="./references#CD001769-bbs2-0032" title="BodensteinerJB , BrownsworthRD , KnapikJR , KanterMC , CowanLD , LevitonA . Interobserver variability in the ILAE classification of seizures in childhood. Epilepsia1988;29(2):123‐8. ">Bodensteiner 1988</a>; <a href="./references#CD001769-bbs2-0083" title="OttmanR , LeeJH , HauserWA , HongS , HesdorfferD , SchupfN , et al. Reliability of seizure classification using a semistructured interview. Neurology1993;43(12):2526‐30. ">Ottman 1993</a>). Seizures may have been few and unwitnessed, and investigations are commonly unhelpful, but there is nevertheless no doubt that seizures have occurred and should be treated. This most commonly applies to tonic‐clonic seizures that may be generalised at onset, or which may be secondarily generalised. In any trial, such unclassified individuals need to be clearly identified, because if they are not they may confound interpretation of results for well classified individuals. We need to know how to manage those whose classification we find more difficult. </p> <p>The choice of outcomes at the design stage of a trial and the presentation of the results of outcomes, particularly of a time‐to‐event nature, require very careful consideration. While the majority of trials of a monotherapy design record an outcome measuring efficacy (seizure control) and an outcome measuring tolerability (adverse events), there is little uniformity between the definition of the outcomes and the reporting of the summary statistics related to the outcomes (<a href="./references#CD001769-bbs2-0102" title="NolanSJ , MarsonAG , PulmanJ , Tudur SmithC . Phenytoin versus valproate monotherapy for partial onset seizures and generalised onset tonic‐clonic seizures. Cochrane Database of Systematic Reviews2013, Issue 8. [DOI: 10.1002/14651858.CD001769.pub2] ">Nolan 2013a</a>), making an aggregate data approach to meta‐analysis in reviews of monotherapy trials impossible. Where trial authors cannot or will not make IPD available for analysis, we are left with no choice but to exclude a proportion of relevant evidence from the review, which may impact upon the interpretation of the results of the review and the applicability of the evidence and conclusions. The International League Against Epilepsy recommends that trials of a monotherapy design should adopt a primary effectiveness outcome of time to treatment failure (i.e. retention time) and should be of a duration of at least 48 weeks to allow for assessment of longer‐term outcomes, such as remission (<a href="./references#CD001769-bbs2-0053" title="ILAE Commission on Antiepileptic Drugs. Considerations on designing clinical trials to evaluate the place of new antiepileptic drugs in the treatment of newly diagnosed and chronic patients with epilepsy. Epilepsia1998;39(7):799‐803. ">ILAE 1998</a>; <a href="./references#CD001769-bbs2-0054" title="GlauserT , Ben‐MenachemE , BourgeoisB , CnaanA , ChadwickD , GuerreiroC , et al. ILAE treatment guidelines: Evidence based analysis of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes. Epilepsia2006;47(7):1094‐120. ">ILAE 2006</a>). If trials followed these recommendations, an aggregate data approach to meta‐analysis may be feasible, reducing the resources and time required from an IPD approach. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD001769-sec-0022" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD001769-sec-0022"></div> <div class="table" id="CD001769-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Sodium valproate compared with phenytoin monotherapy for epilepsy (primary outcome)</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Sodium valproate compared with phenytoin monotherapy for epilepsy</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> adults and children with newly‐onset focal onset or generalised tonic‐clonic seizures </p> <p><b>Settings:</b> outpatients </p> <p><b>Intervention:</b> sodium valproate </p> <p><b>Comparison:</b> phenytoin </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No. of Participants<br/> (studies)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Phenytoin</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Sodium valproate</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Time to treatment failure (any reason related to treatment)</b> </p> <p><i>All participants</i> </p> <p>Range of follow‐up: 0 to 4256 days</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The median time to treatment failure was 2361 days in the phenytoin group</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The median time to treatment failure was 2545 days (184 days longer) in the sodium valproate group </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HR 0.88</b> </p> <p>(0.61 to 1.27)<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>528<br/> (5 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HR &lt; 1 indicates a clinical advantage for valproate</p> <p>There was also no statistically significant difference between drugs in treatment failure due to adverse events: HR 0.77 (95% CI 0.44 to 1.37, P = 0.38) or treatment failure due to lack of efficacy: HR 1.16 (95% CI 0.71 to 1.89, P = 0.55) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Time to treatment failure (any reason related to treatment)</b> </p> <p><i>Subgroup: focal onset seizures</i> </p> <p>Range of follow‐up: 0 to 4256 days</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The median time to treatment failure was 1838 days in the phenytoin group</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The median time to treatment failure was 1772 days (66 days shorter) in the sodium valproate group </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HR 0.83</b> </p> <p>(0.50 to 1.38)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>187</p> <p>(4 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HR &lt; 1 indicates a clinical advantage for valproate</p> <p>There was also no statistically significant difference between drugs in treatment failure due to adverse events: HR 0.81 (95% CI 0.34 to 1.90, P = 0.62) or treatment failure due to lack of efficacy: HR 1.01 (95% CI 0.55 to 1.85, P = 0.98) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Time to treatment failure (any reason related to treatment)</b> </p> <p><i>Subgroup: generalised onset seizures (tonic‐clonic only)</i> </p> <p>Range of follow‐up: 0 to 4394 days</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The 25th percentile** of time to treatment failure was 1488 days in the phenytoin group </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The 25th percentile** of time to treatment failure was 1778 days (290 days longer) in the sodium valproate group </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HR 0.94</b> </p> <p>(0.55 to 1.61)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>341<br/> (5 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Low</b><sup>b, c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HR &lt; 1 indicates a clinical advantage for valproate</p> <p>There was also no statistically significant difference between drugs in treatment failure due to adverse events: HR 0.75 (95% CI 0.35 to 1.60, P = 0.46) or treatment failure due to lack of efficacy: HR 1.51 (95% CI 0.66 to 3.45, P = 0.33) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>* Illustrative risks in the sodium valproate and phenytoin groups are calculated at the median time to treatment failure (i.e. the time to 50% of participants failing or withdrawing from allocated treatment) within each group across all trials. The relative effect (pooled HR) shows the comparison of 'time to treatment failure' between the treatment groups. </p> <p>** The 25th percentile of time to treatment failure (i.e. the time to 25% of participants failing or withdrawing from allocated treatment) is presented for the subgroup with generalised seizures as less than 50% of participants failed/withdrew from treatment, therefore the median time could not be calculated. </p> <p><b>Abbreviations: CI</b> : confidence interval; <b>HR</b>: hazard ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Pooled HR for all participants adjusted for seizure type.<br/> <sup>b</sup>Downgraded once as risk of bias judged high for three unblinded studies (<a href="./references#CD001769-bbs2-0004" title="DeSilvaM , MacArdleB , McGowanM , HughesE , StewartJ , NevilleBGR , et al. Randomised comparative monotherapy trial of phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed childhood epilepsy. Lancet1996;347:709‐13. ">De Silva 1996</a>; <a href="./references#CD001769-bbs2-0006" title="HellerAJ , ChestermanP , ElwesRD , CrawfordP , ChadwickDW , JohnsonAL , et al. Phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed adult epilepsy: a randomised comparative monotherapy trial. Journal of Neurology, Neurosurgery, and Psychiatry1995;58:44‐50. ">Heller 1995</a>; <a href="./references#CD001769-bbs2-0007" title="RamsayRE , WilderBJ , MurphyJV , HolmesGL , UthmanB , SlaterJ , et al. Efficacy and safety of valproic acid versus phenytoin as sole therapy for newly diagnosed primary generalized tonic‐clonic seizures. Journal of Epilepsy1992;5(1):55‐60. ">Ramsay 1992</a>); lack of blinding may have impacted on the withdrawal rates and treatment failure rates in the trials.<br/> <sup>c</sup>Downgraded once due to inconsistency: a large amount of heterogeneity is present within analysis (I² = 59%) which could not be explained by sensitivity analysis for potential misclassification of epilepsy type. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD001769-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Sodium valproate compared with phenytoin monotherapy for epilepsy (secondary outcomes)</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Valproate compared with phenytoin monotherapy for epilepsy</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> adults and children with newly‐onset focal onset or generalised tonic‐clonic seizures </p> <p><b>Settings:</b> outpatients </p> <p><b>Intervention:</b> sodium valproate </p> <p><b>Comparison:</b> phenytoin </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No. of Participants<br/> (studies)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Phenytoin</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Sodium valproate</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Time to first seizure (post‐randomisation)</b> </p> <p><i>All participants</i> </p> <p>Range of follow‐up: 0 to 4859 days</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The median time to first seizure post‐randomisation was 275 days in the phenytoin group </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The median time to first seizure post‐randomisation was 267 days (7 days shorter) in the sodium valproate group </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HR 1.08</b> </p> <p>(0.88 to 1.33)<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>639</p> <p>(5 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>b, c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HR &lt; 1 indicates a clinical<br/> advantage for valproate </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Time to first seizure (post‐randomisation)</b> </p> <p><i>Subgroup: focal onset seizures</i> </p> <p>Range of follow‐up: 0 to 4859 days</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The median time to first seizure post‐randomisation was 75 days in the phenytoin group</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The median time to first seizure post‐randomisation was 41 days (34 days shorter) in the sodium valproate group </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HR 1.20</b> </p> <p>(0.90 to 1.60)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>244</p> <p>(4 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>b, c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HR &lt; 1 indicates a clinical<br/> advantage for valproate </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Time to first seizure (post‐randomisation)</b> </p> <p><i>Subgroup: generalised onset seizures (tonic‐clonic only)</i> </p> <p>Range of follow‐up: 1 to 4520 days</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The median time to first seizure post‐randomisation was 572 days in the phenytoin group </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The median time to first seizure post‐randomisation was 549 days (23 days shorter) in the sodium valproate group </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HR 0.97</b> </p> <p>(0.72 to 1.30)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>395</p> <p>(5 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>b, c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HR &lt; 1 indicates a clinical<br/> advantage for valproate </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Time to achieve 12‐month remission (seizure‐free period)</b> </p> <p><i>All participants</i> </p> <p>Range of follow‐up: 5 to 4614 days</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The median time to achieve 12‐month remission was 380 days in the phenytoin group</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The median time to achieve 12‐month remission was 386 days (6 days longer) in the sodium valproate group </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HR 1.02</b> </p> <p>(0.81 to 1.28)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>514</p> <p>(4 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HR &lt; 1 indicates a clinical<br/> advantage for phenytoin </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Time to achieve 12‐month remission (seizure‐free period)</b> </p> <p><i>Subgroup: focal onset seizures</i> </p> <p>Range of follow‐up: 5 to 4614 days</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The median time to achieve 12‐month remission was 575 days in the phenytoin group</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The median time to achieve 12‐month remission was 549 days (26 days shorter) in the sodium valproate group </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HR 1.11</b> </p> <p>(0.78 to 1.60)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>244</p> <p>(4 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> M<b>oderate</b><sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HR &lt; 1 indicates a clinical<br/> advantage for phenytoin </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Time to achieve 12‐month remission (seizure‐free period)</b> </p> <p><i>Subgroup: generalised onset seizures (tonic‐clonic only)</i> </p> <p>Range of follow‐up: 7 to 4544 days</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The median time to achieve 12‐month remission was 365 days in the phenytoin group</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The median time to achieve 12‐month remission was 366 days (1 day longer) in the sodium valproate group </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HR 0.96</b> </p> <p>(0.71 to 1.29)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>270</p> <p>(4 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> M<b>oderate</b><sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HR &lt; 1 indicates a clinical<br/> advantage for phenytoin </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>* Illustrative risks in the phenytoin and sodium valproate groups are calculated at the median time to first seizure or time to 12‐month remission (i.e. the time to 50% of participants experiencing a first seizure or 12 months of remission) within each group across all trials. The relative effect (pooled HR) shows the comparison of 'time to first seizure' or 'time to 12‐month remission' between the treatment groups. </p> <p><b>Abbreviations: CI</b> : confidence interval; <b>HR</b>: hazard ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Pooled HR for all participants adjusted for seizure type.<br/> <sup>b</sup>Downgraded once as risk of bias judged high for four unblinded studies (<a href="./references#CD001769-bbs2-0002" title="CraigI , TallisR . Impact of valproate and phenytoin on cognitive function in elderly patients: results of a single‐blind randomized comparative study. Epilepsia1994;35(2):381‐90. ">Craig 1994</a>; <a href="./references#CD001769-bbs2-0004" title="DeSilvaM , MacArdleB , McGowanM , HughesE , StewartJ , NevilleBGR , et al. Randomised comparative monotherapy trial of phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed childhood epilepsy. Lancet1996;347:709‐13. ">De Silva 1996</a>; <a href="./references#CD001769-bbs2-0006" title="HellerAJ , ChestermanP , ElwesRD , CrawfordP , ChadwickDW , JohnsonAL , et al. Phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed adult epilepsy: a randomised comparative monotherapy trial. Journal of Neurology, Neurosurgery, and Psychiatry1995;58:44‐50. ">Heller 1995</a>; <a href="./references#CD001769-bbs2-0007" title="RamsayRE , WilderBJ , MurphyJV , HolmesGL , UthmanB , SlaterJ , et al. Efficacy and safety of valproic acid versus phenytoin as sole therapy for newly diagnosed primary generalized tonic‐clonic seizures. Journal of Epilepsy1992;5(1):55‐60. ">Ramsay 1992</a>). <br/> <sup>c</sup>Downgraded once due to applicability: as up to 49% in the 5 trials classified as experiencing generalised onset seizures may have had their seizure type wrongly classified; sensitivity analyses show misclassification has an impact on results and conclusions. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD001769-sec-0023" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD001769-sec-0023"></div> <p>This is an updated version of the original Cochrane review published in 2001 (<a href="./references#CD001769-bbs2-0105" title="Tudur SmithC , MarsonAG , WilliamsonPR . Phenytoin versus valproate monotherapy for partial onset seizures and generalized onset tonic‐clonic seizures. Cochrane Database of Systematic Reviews2001, Issue 4. [DOI: 10.1002/14651858.CD001769] ">Tudur Smith 2001</a>), updated in 2013 and 2016 (<a href="./references#CD001769-bbs2-0102" title="NolanSJ , MarsonAG , PulmanJ , Tudur SmithC . Phenytoin versus valproate monotherapy for partial onset seizures and generalised onset tonic‐clonic seizures. Cochrane Database of Systematic Reviews2013, Issue 8. [DOI: 10.1002/14651858.CD001769.pub2] ">Nolan 2013a</a>; <a href="./references#CD001769-bbs2-0103" title="NolanSJ , MarsonAG , WestonJ , Tudur SmithC . Phenytoin versus valproate monotherapy for partial onset seizures and generalised onset tonic‐clonic seizures: an individual participant data review. Cochrane Database of Systematic Reviews2016, Issue 4. [DOI: 10.1002/14651858.CD001769.pub3] ">Nolan 2016a</a>). </p> <section id="CD001769-sec-0024"> <h3 class="title" id="CD001769-sec-0024">Description of the condition</h3> <p>Epilepsy is a common neurological condition in which abnormal electrical discharges from the brain cause recurrent unprovoked seizures. Epilepsy is a disorder of many heterogenous seizure types, with an estimated incidence of 33 to 57 per 100,000 person‐years worldwide (<a href="./references#CD001769-bbs2-0031" title="AnnegersJF , DubinskyS , CoanSP , NewmarkME , RohtL . The incidence of epilepsy and unprovoked seizures in multiethnic, urban health maintenance organizations. Epilepsia1999;40(4):502‐6. ">Annegers 1999</a>; <a href="./references#CD001769-bbs2-0052" title='HirtzD , ThurmanDJ , Gwinn‐HardyK , MohamedM , ChaudhuriAR , ZalutskyR . How common are the "common" neurologic disorders?. Neurology2007;68:326‐37. '>Hirtz 2007</a>; <a href="./references#CD001769-bbs2-0062" title="MacDonaldBK , JohnsonAL , GoodridgeDM , CockerellOC , SanderJWA , ShorvonSD . Factors predicting prognosis of epilepsy after presentation with seizures. Annals of Neurology2000;48:833‐41. ">MacDonald 2000</a>; <a href="./references#CD001769-bbs2-0081" title="OlafssonE , LudvigssonP , GudmundssonG , HesdorferD , KjartanssonO , HauserWA . Incidence of unprovoked seizures and epilepsy in Iceland and assessment of the epilepsy syndrome classification: a prospective study. Lancet Neurology2005;4:627‐34. ">Olafsson 2005</a>; <a href="./references#CD001769-bbs2-0086" title="SanderJW , ShorvonSD . Epidemiology of the epilepsies. Journal of Neurology, Neurosurgery, and Psychiatry1996;61(5):433‐43. ">Sander 1996</a>), accounting for approximately 1% of the global burden of disease (<a href="./references#CD001769-bbs2-0068" title="MurrayCJL , LopezAD , World Health Organization. Global comparative assessments in the health sector: disease burden, expenditures and intervention packages. apps.who.int/iris/handle/10665/41177 (accessed 01 08 2018). ">Murray 1994</a>). The lifetime risk of epilepsy onset is estimated to be 1300 to 4000 per 100,000 person‐years (<a href="./references#CD001769-bbs2-0049" title="HauserWA , AnnegersJF , KurlandLT . Incidence of epilepsy and unprovoked seizures in Rochester, Minnesota 1935 ‐ 1984. Epilepsia1993;34:453‐68. ">Hauser 1993</a>; <a href="./references#CD001769-bbs2-0057" title="Juul‐JensonP , FoldspangA . Natural history of epileptic seizures. Epilepsia1983;24:297‐312. ">Juul Jenson 1983</a>), and the lifetime prevalence could be as large as 70 million people worldwide (<a href="./references#CD001769-bbs2-0072" title="NgugiAK , BottomleyC , KleinschmidtI , SanderJW , NewtonCR . Estimation of the burden of active and life‐time epilepsy: a meta‐analytic approach. Epilepsia2010;51:883‐90. ">Ngugi 2010</a>). It is believed that with effective drug treatment, up to 70% of individuals with active epilepsy have the potential to go into long‐term remission shortly after starting drug therapy (<a href="./references#CD001769-bbs2-0040" title="CockerellOC , JohnsonAL , SanderJW , HartYM , ShorvonSD . Remission of epilepsy: results from the National General Practice Study of Epilepsy. Lancet1995;346(8968):140‐4. ">Cockerell 1995</a>; <a href="./references#CD001769-bbs2-0049" title="HauserWA , AnnegersJF , KurlandLT . Incidence of epilepsy and unprovoked seizures in Rochester, Minnesota 1935 ‐ 1984. Epilepsia1993;34:453‐68. ">Hauser 1993</a>; <a href="./references#CD001769-bbs2-0087" title="SanderJW . The use of anti‐epileptic drugs ‐ principles and practice. Epilepsia2004;45(6):28‐34. ">Sander 2004</a>), and around 70% of individuals can achieve seizure freedom using a single antiepileptic drug in monotherapy (<a href="./references#CD001769-bbs2-0040" title="CockerellOC , JohnsonAL , SanderJW , HartYM , ShorvonSD . Remission of epilepsy: results from the National General Practice Study of Epilepsy. Lancet1995;346(8968):140‐4. ">Cockerell 1995</a>). Current National Institute for Health and Care Excellence (NICE) guidelines recommend that both adults and children with epilepsy should be treated with monotherapy wherever possible (<a href="./references#CD001769-bbs2-0073" title="National Institute for Health and Care Excellence. The epilepsies: the diagnosis and management of the epilepsies in adults and children in primary and secondary care. www.nice.org.uk/guidance/cg137 (accessed 01 08 2018). ">NICE 2012</a>). The remaining 30% of individuals experience refractory or drug‐resistant seizures, which often require treatment with combinations of antiepileptic drugs or alternative treatments, such as epilepsy surgery (<a href="./references#CD001769-bbs2-0059" title="KwanP , BrodieMJ . Early identification of refractory epilepsy. New England Journal of Medicine2000;342:314‐9. ">Kwan 2000</a>). </p> <p>We studied two seizure types in this review: generalised onset seizures in which electrical discharges begin in one part of the brain and move throughout the brain, and focal onset seizures in which the seizure is generated in and affects one part of the brain (the whole hemisphere of the brain or part of a lobe of the brain). </p> </section> <section id="CD001769-sec-0025"> <h3 class="title" id="CD001769-sec-0025">Description of the intervention</h3> <p>The majority of people with epilepsy have their seizures controlled by a single drug (monotherapy) (<a href="./references#CD001769-bbs2-0040" title="CockerellOC , JohnsonAL , SanderJW , HartYM , ShorvonSD . Remission of epilepsy: results from the National General Practice Study of Epilepsy. Lancet1995;346(8968):140‐4. ">Cockerell 1995</a>). Worldwide, sodium valproate and phenytoin are commonly used antiepileptic drugs licensed for monotherapy. Phenytoin is used as a first‐line drug in low‐ and middle‐income countries as it is a low‐cost drug and can be given as a single daily dose, but is no longer considered a first‐line agent in the USA and much of Europe due to worries over adverse events (<a href="./references#CD001769-bbs2-0096" title="WallaceH , ShorvonSD , HopkinsA , O'DonoghueM . National Society of Epilepsy Guidelines. London: Royal College of Physicians1997. ">Wallace 1997</a>; <a href="./references#CD001769-bbs2-0099" title="WilderBJ . Phenytoin: clinical use. Antiepileptic Drugs. New York: Raven Press, 1995:339‐44. ">Wilder 1995</a>). Phenytoin is associated with long‐term cosmetic changes including gum hyperplasia, acne and coarsening of the facial features (<a href="./references#CD001769-bbs2-0065" title="MattsonRH , CramerJA , CollinsJF , SmithDB , Delgado‐EscuetaAV , BrowneTR , et al. Comparison of carbamazepine, phenobarbital, phenytoin, and primidone in partial and secondarily generalized tonic‐clonic seizures. New England Journal of Medicine1985;313(3):145‐51. ">Mattson 1985</a>; <a href="./references#CD001769-bbs2-0089" title="ScheinfeldN . Phenytoin in cutaneous medicine: Its uses, mechanisms and side effects. Dermatology Online Journal2003;9(3):6. ">Scheinfeld 2003</a>), as well as low folic acid levels, predisposing participants to megaloblastic anaemia (<a href="./references#CD001769-bbs2-0038" title="CarlGF , SmithML . Phenytoin‐folate interactions: differing effects of the sodium salt and the free acid of phenytoin. Epilepsia1992;33(2):372‐5. ">Carl 1992</a>), and is associated with congenital abnormalities (<a href="./references#CD001769-bbs2-0048" title="GladstoneDJ , BologaM , MaguireC , PastuszakA , KorenG . Course of pregnancy and fetal outcome following maternal exposure to carbamazepine and phenytoin: a prospective study. Reproductive Toxicology1992;6(3):257‐61. ">Gladstone 1992</a>; <a href="./references#CD001769-bbs2-0067" title="MorrowJ , RusselA , GuthrieE , ParsonsL , RobertsonI , WaddellR , et al. Pregnancy outcomes in women with epilepsy: A systematic review and meta‐analysis of published pregnancy registries and cohorts. Journal of Neurology, Neurosurgery and Neuropsychiatry 2006;77(2):193‐8. ">Morrow 2006</a>; <a href="./references#CD001769-bbs2-0066" title="MeadorK , ReynoldsM , CreanS , FahrbachK , ProbstC  . Pregnancy outcomes in women with epilepsy: A systematic review and meta‐analysis of published pregnancy registries and cohorts. Epilepsy Research2008;81:1‐13. ">Meador 2008</a>; <a href="./references#CD001769-bbs2-0080" title="NulmanI , ScolnikD , ChitayatD , FarkasLD , KorenG . Findings in children exposed in utero to phenytoin and carbamazepine monotherapy: independent effects of epilepsy and medications. American Journal of Medical Genetics1997;68(1):18‐24. ">Nulman 1997</a>), particularly foetal hydantoin syndrome (<a href="http://www.archie.cochrane.org/sections/documents/view?version=66008337579483720040120822181141%26format=REVMAN#REF-Scheinfeld-2003" target="_blank">Scheinfeld 2003</a>). Furthermore, due to the pharmacokinetic profile of phenytoin, the plasma concentrations are difficult to predict and dosing will usually need to be informed by measuring plasma concentration. Sodium valproate has also been shown to have teratogenic properties (<a href="./references#CD001769-bbs2-0037" title="CangerR , BattinoD , CaneviniMP , FumarolaC , GuidolinL , VignoliA , et al. Malformations in offspring of women with epilepsy: A prospective study. Epilepsia1999;40(9):1231‐6. ">Canger 1999</a>; <a href="./references#CD001769-bbs2-0067" title="MorrowJ , RusselA , GuthrieE , ParsonsL , RobertsonI , WaddellR , et al. Pregnancy outcomes in women with epilepsy: A systematic review and meta‐analysis of published pregnancy registries and cohorts. Journal of Neurology, Neurosurgery and Neuropsychiatry 2006;77(2):193‐8. ">Morrow 2006</a>; <a href="./references#CD001769-bbs2-0092" title="TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , SabersA , et al. Dose‐dependent risk of malformation with antiepileptic drugs: An analysis of data from the EURAP epilepsy and pregnancy registry. Lancet Neurology2011;10(7):609‐17. ">Tomson 2011</a>), and is particularly associated with spina bifida and cardiac, craniofacial, skeletal and limb defects known as 'valproate syndrome' (<a href="./references#CD001769-bbs2-0082" title="OrnoyA . Valproic acid in pregnancy: How much are we endangering the embryo and fetus?. Reproductive Toxicology2009;28(1):1‐10. ">Ornoy 2009</a>). Systematic reviews have found sodium valproate to have the highest incidence of congenital malformations of standard antiepileptic drugs (<a href="./references#CD001769-bbs2-0066" title="MeadorK , ReynoldsM , CreanS , FahrbachK , ProbstC  . Pregnancy outcomes in women with epilepsy: A systematic review and meta‐analysis of published pregnancy registries and cohorts. Epilepsy Research2008;81:1‐13. ">Meador 2008</a>; <a href="./references#CD001769-bbs2-0097" title="WestonJ , BromleyR , JacksonCF , AdabN , Clayton‐SmithJ , GreenhalghJ , et al. Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child. Cochrane Database of Systematic Reviews2017, Issue 4. [DOI: 10.1002/14651858.CD010224.pub2] ">Weston 2017</a>), and recent studies have shown an increased prevalence of neurodevelopmental disorders following prenatal sodium valproate exposure (<a href="./references#CD001769-bbs2-0035" title="BromleyRL , MawerGE , BriggsM , CheyneC , Clayton‐SmithJ , García‐FiñanaM , et al. The prevalence of neurodevelopmental disorders in children prenatally exposed to antiepileptic drugs. Journal of Neurology, Neurosurgery and Psychiatry2013;84(6):637‐43. [DOI: 10.1136/jnnp‐2012‐304270] ">Bromley 2013</a>; <a href="./references#CD001769-bbs2-0036" title="BromleyR , WestonJ , AdabN , GreenhalghJ , SannitiA , McKayAJ , et al. Treatment for epilepsy in pregnancy: neurodevelopmental outcomes in the child. Cochrane Database of Systematic Reviews2014, Issue 10. [DOI: 10.1002/14651858.CD010236.pub2] ">Bromley 2014</a>). Sodium valproate is also associated with weight gain in adults and children (<a href="./references#CD001769-bbs2-0045" title="DinesenH , GramL , AndersenT , DamM . Weight gain during treatment with valproate. Acta Neurologica Scandinavica1984;69:65‐9. ">Dinesen 1984</a>; <a href="./references#CD001769-bbs2-0046" title="EasterD ,  O'Bryan‐TearCG ,  VerityC . Weight gain with valproate or carbamazepine‐a reappraisal. Seizure1997;6(2):121‐5. ">Easter 1997</a>; <a href="./references#CD001769-bbs2-0047" title="EggerJ , BrettEM . Effects of sodium valproate in 100 children with special reference to weight. BMJ1981;283(6291):577‐81. ">Egger 1981</a>; <a href="./references#CD001769-bbs2-0079" title="NovakGP ,  MaytalJ ,  AlshanskyA ,  EviatarL ,  Sy‐KhoR ,  SiddiqueQ . Risk of excessive weight gain in epileptic children treated with valproate. Journal of Child Neurology1999;14(8):490‐5. ">Novak 1999</a>). </p> </section> <section id="CD001769-sec-0026"> <h3 class="title" id="CD001769-sec-0026">How the intervention might work</h3> <p>It is generally believed that sodium valproate monotherapy is more effective than phenytoin monotherapy in generalised onset seizures (generalised tonic‐clonic seizures, absence, and myoclonus), while phenytoin monotherapy is more effective than sodium valproate monotherapy in focal onset seizures (simple focal, complex focal, and secondary generalised tonic‐clonic seizures) (<a href="./references#CD001769-bbs2-0039" title="ChadwickDW . Valproate in the treatment of partial epilepsies. Epilepsia1994;35(5):S96‐8. ">Chadwick 1994</a>), although there is no conclusive evidence from individual randomised controlled trials (RCTs) to support this belief. Evidence in favour of sodium valproate for generalised seizures is predominantly anecdotal from observational studies, suggesting a dramatic benefit with sodium valproate in juvenile myoclonic epilepsy (<a href="./references#CD001769-bbs2-0044" title="Delgado‐EscuetaAV , Enrile‐BascalF . Juvenile myoclonic epilepsy of Janz. Neurology1984;34(3):285‐94. ">Delgado‐Escueta 1984</a>; <a href="./references#CD001769-bbs2-0085" title="PenryJK , DeanJC , RielaAR . Juvenile myoclonic epilepsy: long term response to therapy. Epilepsia1989;30(Suppl 4):S19‐23. ">Penry 1989</a>), and reports of efficacy of sodium valproate against absence seizures (<a href="./references#CD001769-bbs2-0033" title="BourgeoisB , BeaumanoirA , BlajevB , CruzND , DesplandPA , EgliM , et al. Monotherapy with valproate in primary generalized epilepsies. Epilepsia1987;28(Suppl 2):S8‐11. ">Bourgeois 1987</a>; <a href="./references#CD001769-bbs2-0055" title="JeavonsPM . Choice of drug therapy in epilepsy. Practitioner1977;219:542‐56. ">Jeavons 1977</a>). The results of two RCTs, recruiting children indicate that sodium valproate may be better tolerated in children than phenytoin (<a href="./references#CD001769-bbs2-0004" title="DeSilvaM , MacArdleB , McGowanM , HughesE , StewartJ , NevilleBGR , et al. Randomised comparative monotherapy trial of phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed childhood epilepsy. Lancet1996;347:709‐13. ">De Silva 1996</a>; <a href="./references#CD001769-bbs2-0010" title="ThilothammalN , BanuK , RatnamRS . Comparison of phenobarbitone, phenytoin with sodium valproate: randomized, double‐blind study. Indian Pediatrics1996;33:549‐55. ">Thilothammal 1996</a>); twice as many children experienced at least one side effect on phenytoin than sodium valproate in <a href="./references#CD001769-bbs2-0010" title="ThilothammalN , BanuK , RatnamRS . Comparison of phenobarbitone, phenytoin with sodium valproate: randomized, double‐blind study. Indian Pediatrics1996;33:549‐55. ">Thilothammal 1996</a>, and phenytoin was more likely to be withdrawn due to unacceptable side effects than sodium valproate in <a href="./references#CD001769-bbs2-0004" title="DeSilvaM , MacArdleB , McGowanM , HughesE , StewartJ , NevilleBGR , et al. Randomised comparative monotherapy trial of phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed childhood epilepsy. Lancet1996;347:709‐13. ">De Silva 1996</a>. </p> <p>Some animal models have suggested that phenytoin has either no effect in absence seizures or may in fact worsen seizures (<a href="./references#CD001769-bbs2-0061" title="LiporaceJD , SperlingMR , DichterMA . Absence seizures and carbamazepine in adults. Epilepsia1994;35(5):1026‐8. ">Liporace 1994</a>). There is also anecdotal evidence that phenytoin may cause paradoxical intoxication (increased seizure frequency with increased anticonvulsant dose) and encephalopathy (<a href="./references#CD001769-bbs2-0093" title="TroupinAS , OjemannLM . Paradoxical intoxication ‐ a complication of anticonvulsant administration. Epilepsia1975;16:753‐8. ">Troupin 1975</a>; <a href="./references#CD001769-bbs2-0095" title="VallartaJM , BellDB , ReichertA . Progressive encephalopathy due to chronic hydantoin intoxication. American Journal of Diseases of Children1974;128:27‐34. ">Vallarta 1974</a>). </p> </section> <section id="CD001769-sec-0027"> <h3 class="title" id="CD001769-sec-0027">Why it is important to do this review</h3> <p>Accepting that phenytoin should not be a drug of first choice for individuals experiencing absence, myoclonic and atonic seizures, we still have insufficient evidence from RCTs to guide a choice between sodium valproate and phenytoin for individuals with generalised onset tonic‐clonic seizures or focal onset seizures. The aim of this review, therefore, is to summarise efficacy and tolerability data from existing trials comparing valproate and phenytoin when used as monotherapy treatments. </p> <p>There are difficulties in undertaking a systematic review of epilepsy monotherapy trials, as the important efficacy outcomes require analysis of time‐to‐event data (for example, time to first seizure after randomisation). Although methods have been developed to synthesise time‐to‐event data using summary information (<a href="./references#CD001769-bbs2-0084" title="ParmarMKB , TorriV , StewartL . Extracting summary statistics to perform meta‐analysis of the published literature for survival endpoints. Statistics in Medicine1998;17:2815‐34. ">Parmar 1998</a>; <a href="./references#CD001769-bbs2-0101" title="WilliamsonPR , Tudur SmithC , HuttonJL , MarsonAG . Aggregate data meta‐analysis with time‐to‐event outcomes. Statistics in Medicine2002;21(11):3337‐51. ">Williamson 2002</a>), the appropriate statistics are not commonly reported in published epilepsy trials (<a href="./references#CD001769-bbs2-0076" title="NolanSJ , SuttonL , MarsonA , Tudur SmithC . Consistency of outcome and statistical reporting of time‐to‐event data: the impact on Cochrane Reviews and meta‐analyses in epilepsy. 21st Cochrane Colloquium: Better Knowledge for Better Health, Quebec City. 2013:114‐5. ">Nolan 2013d</a>; <a href="./references#CD001769-bbs2-0100" title="WilliamsonPR , MarsonAG , TudurC , HuttonJL , ChadwickDW . Individual patient data meta‐analysis of randomized anti‐epileptic drug monotherapy trials. Journal of Evaluation in Clinical Practice2000;6(2):205‐14. ">Williamson 2000</a>). </p> <p>Furthermore, although seizure data have been collected in most epilepsy monotherapy trials, there has been no uniformity in the definition and reporting of outcomes. For example, trials may report time to 12‐month remission but not time to first seizure or vice versa, or some trials may define time to first seizure from the date of randomisation, while others use date of achieving maintenance dose. Trial investigators have also adopted differing approaches to the analysis, particularly with respect to the censoring of time‐to‐event data. For these reasons, we performed this review using individual participant data (IPD) which helps to overcome these problems. This review is one in a series of Cochrane IPD reviews investigating pair‐wise monotherapy comparisons (<a href="./references#CD001769-bbs2-0064" title="MarsonAG , WilliamsonPR , HuttonJL , CloughHE , ChadwickDW . Carbamazepine versus valproate monotherapy for epilepsy. Cochrane Database of Systematic Reviews2000, Issue 3. [DOI: 10.1002/14651858.CD001030] ">Marson 2000</a>; <a href="./references#CD001769-bbs2-0070" title="NevittSJ , MarsonAG , WestonJ , Tudur‐SmithC . Carbamazepine versus phenytoin monotherapy for epilepsy: an individual participant data review. Cochrane Database of Systematic Reviews2017, Issue 2. [DOI: 10.1002/14651858.CD001911.pub3] ">Nevitt 2017b</a>; <a href="./references#CD001769-bbs2-0074" title="NolanSJ , MullerM , Tudur SmithC , MarsonAG . Oxcarbazepine versus phenytoin monotherapy for epilepsy. Cochrane Database of Systematic Reviews2013, Issue 5. [DOI: 10.1002/14651858.CD003615.pub3] ">Nolan 2013b</a>; <a href="./references#CD001769-bbs2-0075" title="NolanSJ , Tudur SmithC , PulmanJ , MarsonAG . Phenobarbitone versus phenytoin monotherapy for partial onset seizures and generalised onset tonic‐clonic seizures. Cochrane Database of Systematic Reviews2013, Issue 1. [DOI: 10.1002/14651858.CD002217.pub2] ">Nolan 2013c</a>; <a href="./references#CD001769-bbs2-0077" title="NolanSJ , SudellM , Tudur SmithC , MarsonA . Topiramate versus carbamazepine monotherapy for epilepsy: an individual participant data review. Cochrane Database of Systematic Reviews2016, Issue 12. [DOI: 10.1002/14651858.CD012065.pub2] ">Nolan 2016b</a>; <a href="./references#CD001769-bbs2-0078" title="NolanSJ , MarsonAG , WestonJ , Tudur SmithC . Carbamazepine versus phenobarbitone monotherapy for epilepsy: an individual participant data review. Cochrane Database of Systematic Reviews2016, Issue 12. [DOI: 10.1002/14651858.CD001904.pub2] ">Nolan 2016c</a>; <a href="./references#CD001769-bbs2-0071" title="NevittSJ , Tudur SmithC , WestonJ , MarsonAG . Lamotrigine versus carbamazepine monotherapy for epilepsy: an individual participant data review. Cochrane Database of Systematic Reviews2018, Issue 6. [DOI: 10.1002/14651858.CD001031.pub4] ">Nevitt 2018</a>). These data have also been included in IPD network meta‐analyses of antiepileptic drug monotherapy (<a href="./references#CD001769-bbs2-0069" title="NevittSJ , SudellM , WestonJ , Tudur SmithC , MarsonA . Antiepileptic drug monotherapy for epilepsy: a network meta‐analysis of individual participant data. Cochrane Database of Systematic Reviews2017, Issue 12. [DOI: 10.1002/14651858.CD011412.pub3] ">Nevitt 2017a</a>; <a href="./references#CD001769-bbs2-0094" title="Tudur SmithC ,  MarsonAG ,  ChadwickDW ,  WilliamsonPR . Multiple treatment comparisons in epilepsy monotherapy trials. Trials2007;5(8):34. ">Tudur Smith 2007</a>). </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD001769-sec-0028" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD001769-sec-0028"></div> <p>To review the time to treatment failure, remission and first seizure of sodium valproate compared to phenytoin when used as monotherapy in people with focal onset seizures or generalised tonic‐clonic seizures (with or without other generalised seizure types). </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD001769-sec-0029" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD001769-sec-0029"></div> <section id="CD001769-sec-0030"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD001769-sec-0031"> <h4 class="title">Types of studies</h4> <p> <ul id="CD001769-list-0001"> <li> <p>Randomised controlled trials (RCTs) using either:</p> <ul id="CD001769-list-0002"> <li> <p>an adequate method of allocation concealment (e.g. sealed opaque envelopes); or</p> </li> <li> <p>a 'quasi' method of randomisation (e.g. allocation by date of birth).</p> </li> </ul> </li> <li> <p>Studies may be double‐blind, single‐blind or unblinded.</p> </li> <li> <p>Studies must include a comparison of sodium valproate monotherapy with phenytoin monotherapy in individuals with epilepsy. </p> </li> </ul> </p> </section> <section id="CD001769-sec-0032"> <h4 class="title">Types of participants</h4> <p> <ul id="CD001769-list-0003"> <li> <p>We included children or adults with focal onset seizures (simple focal, complex focal or secondarily generalised tonic‐clonic seizures) or generalised onset tonic‐clonic seizures, with or without other generalised seizure types (in other words, those who had only generalised tonic‐clonic seizures and those who had both generalised onset tonic‐clonic seizures and generalised seizures of other types (e.g. absence, myoclonic etc.)). </p> </li> <li> <p>We excluded individuals with other generalised seizure types alone without generalised tonic‐clonic seizures (e.g. those who had only absence seizures without any generalised clonic tonic‐seizures) due to differences in first‐line treatment guidelines for other generalised seizure types (<a href="./references#CD001769-bbs2-0073" title="National Institute for Health and Care Excellence. The epilepsies: the diagnosis and management of the epilepsies in adults and children in primary and secondary care. www.nice.org.uk/guidance/cg137 (accessed 01 08 2018). ">NICE 2012</a>). </p> </li> <li> <p>We included individuals with a new diagnosis of epilepsy, or who have had a relapse following withdrawal of antiepileptic monotherapy. </p> </li> </ul> </p> </section> <section id="CD001769-sec-0033"> <h4 class="title">Types of interventions</h4> <p>Sodium valproate or phenytoin as monotherapy. For brevity, sodium valproate is referred to a 'valproate' herein. </p> </section> <section id="CD001769-sec-0034"> <h4 class="title">Types of outcome measures</h4> <p>Below is a list of outcomes investigated in this review. Reporting of these outcomes in the original trial report was not an eligibility requirement for inclusion in this review. </p> <section id="CD001769-sec-0035"> <h5 class="title">Primary outcomes</h5> <p> <ul id="CD001769-list-0004"> <li> <p>Time to treatment failure (retention time).</p> </li> </ul> </p> <p>This is a combined outcome reflecting both efficacy and tolerability, as the following may have lead to failure of treatment: continued seizures, side effects, noncompliance or the initiation of additional add‐on treatment. This is an outcome to which the participant makes a contribution and is the primary outcome measure recommended by the Commission on Antiepileptic Drugs of the International League Against Epilepsy (<a href="./references#CD001769-bbs2-0053" title="ILAE Commission on Antiepileptic Drugs. Considerations on designing clinical trials to evaluate the place of new antiepileptic drugs in the treatment of newly diagnosed and chronic patients with epilepsy. Epilepsia1998;39(7):799‐803. ">ILAE 1998</a>; <a href="./references#CD001769-bbs2-0054" title="GlauserT , Ben‐MenachemE , BourgeoisB , CnaanA , ChadwickD , GuerreiroC , et al. ILAE treatment guidelines: Evidence based analysis of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes. Epilepsia2006;47(7):1094‐120. ">ILAE 2006</a>). </p> <p>Time to treatment failure is considered according to three definitions.</p> <p> <ul id="CD001769-list-0005"> <li> <p>Time to treatment failure, for any treatment‐related reason (continued seizures, side effects, noncompliance or the initiation of additional add‐on treatment). </p> </li> <li> <p>Time to treatment failure, due to adverse events (i.e. side effects).</p> </li> <li> <p>Time to treatment failure, due to lack of efficacy (i.e. continued seizures).</p> </li> </ul> </p> </section> <section id="CD001769-sec-0036"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD001769-list-0006"> <li> <p>Time to first seizure (post‐randomisation).</p> </li> <li> <p>Time to achieve 12‐month remission (seizure‐free period).</p> </li> <li> <p>Time to achieve six‐month remission (seizure‐free period).</p> </li> <li> <p>Incidence of adverse events.</p> </li> </ul> </p> </section> </section> </section> <section id="CD001769-sec-0037"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD001769-sec-0038"> <h4 class="title">Electronic searches</h4> <p>We searched the following databases. We did not impose any language restrictions.</p> <p> <ul id="CD001769-list-0007"> <li> <p>The Cochrane Epilepsy Group's Specialised Register (19 February 2018) using the search strategy outlined in <a href="./appendices#CD001769-sec-0100">Appendix 1</a>. </p> </li> <li> <p>The Cochrane Central Register of Controlled Trials (CENTRAL; 2018, Issue 2) in the Cochrane Library (searched 19 February 2018) using the search strategy outlined in <a href="./appendices#CD001769-sec-0101">Appendix 2</a>. </p> </li> <li> <p>MEDLINE (Ovid, 1946 to 19 February 2018) using the search strategy outlined in <a href="./appendices#CD001769-sec-0102">Appendix 3</a>. </p> </li> <li> <p>SCOPUS (last search 19 February 2013) using the search strategy outlined in <a href="./appendices#CD001769-sec-0103">Appendix 4</a>. We searched SCOPUS as an alternative to Embase, but this is no longer necessary, because randomised and quasi‐RCTs in Embase are now included in CENTRAL, so we will not be updating the SCOPUS search. </p> </li> <li> <p><a href="http://clinicaltrials.gov/" target="_blank">ClinicalTrials.gov</a> (19 February 2018) using the search terms 'phenytoin AND valproate | Epilepsy'. </p> </li> <li> <p><a href="http://apps.who.int/trialsearch/" target="_blank">WHO International Clinical Trials Registry Platform ICTRP</a> (19 February 2018) using the search terms 'valproate and phenytoin and epilepsy'. </p> </li> </ul> </p> </section> <section id="CD001769-sec-0039"> <h4 class="title">Searching other resources</h4> <p>In addition, we handsearched relevant journals, reviewed the reference lists of retrieved studies to search for additional reports of relevant studies, contacted Sanofi (manufacturers of valproate in Europe), Abbott (manufacturers of valproate in the USA), Parke‐Davis (manufacturers of phenytoin), and experts in the field for information about any ongoing studies. </p> </section> </section> <section id="CD001769-sec-0040"> <h3 class="title" id="CD001769-sec-0040">Data collection and analysis</h3> <section id="CD001769-sec-0041"> <h4 class="title">Selection of studies</h4> <p>Two review authors (SJN and AGM) independently assessed trials for inclusion, resolving any disagreements by mutual discussion. </p> </section> <section id="CD001769-sec-0042"> <h4 class="title">Data extraction and management</h4> <p>We requested the following individual participant data (IPD) for all trials meeting our inclusion criteria. </p> <p> <ul id="CD001769-list-0008"> <li> <p>Trial methods</p> </li> </ul> <ul class="plain" id="CD001769-list-0009"> <li> <ul id="CD001769-list-0010"> <li> <p>method of generation of random list</p> </li> <li> <p>method of concealment of randomisation</p> </li> <li> <p>stratification factors</p> </li> <li> <p>blinding methods</p> </li> </ul> </li> </ul> <ul id="CD001769-list-0011"> <li> <p>Participant covariates</p> </li> </ul> <ul class="plain" id="CD001769-list-0012"> <li> <ul id="CD001769-list-0013"> <li> <p>gender</p> </li> <li> <p>age</p> </li> <li> <p>seizure types</p> </li> <li> <p>time between first seizure and randomisation</p> </li> <li> <p>number of seizures prior to randomisation (with dates)</p> </li> <li> <p>presence of neurological signs</p> </li> <li> <p>electroencephalographic (EEG) results</p> </li> <li> <p>computerised tomography/magnetic resonance imaging (CT/MRI) results</p> </li> </ul> </li> </ul> <ul id="CD001769-list-0014"> <li> <p>Follow‐up data</p> </li> </ul> <ul class="plain" id="CD001769-list-0015"> <li> <ul id="CD001769-list-0016"> <li> <p>treatment allocation</p> </li> <li> <p>date of randomisation</p> </li> <li> <p>dates of follow‐up</p> </li> <li> <p>dates of seizures post‐randomisation or seizure frequency data between follow‐up visits</p> </li> <li> <p>dates of treatment withdrawal or treatment failure and reasons for treatment withdrawal or treatment failure </p> </li> <li> <p>dose</p> </li> <li> <p>dates of dose changes</p> </li> </ul> </li> </ul> </p> <p>For each trial for which IPD were not obtained, we carried out an assessment to see whether any relevant aggregate level data had been reported. If possible, SJN extracted any aggregate level data from publications and extracted data were verified by JW. </p> <p>For three trials, seizure data were provided in terms of the number of seizures recorded between clinic visits rather than specific dates of seizures (<a href="./references#CD001769-bbs2-0002" title="CraigI , TallisR . Impact of valproate and phenytoin on cognitive function in elderly patients: results of a single‐blind randomized comparative study. Epilepsia1994;35(2):381‐90. ">Craig 1994</a>; <a href="./references#CD001769-bbs2-0007" title="RamsayRE , WilderBJ , MurphyJV , HolmesGL , UthmanB , SlaterJ , et al. Efficacy and safety of valproic acid versus phenytoin as sole therapy for newly diagnosed primary generalized tonic‐clonic seizures. Journal of Epilepsy1992;5(1):55‐60. ">Ramsay 1992</a>; <a href="./references#CD001769-bbs2-0011" title="TurnbullDM , HowelD , RawlinsMD , ChadwickDW . Which drug for the adult epileptic patient: phenytoin or valproate?. BMJ1985;290:815‐9. ">Turnbull 1985</a>). To enable time‐to‐event outcomes to be calculated, we applied linear interpolation to approximate the dates on which seizures occurred. For example, if four seizures were recorded between two visits which occurred on 1 March and 1 May (an interval of 61 days), then date of first seizure would be approximately 13 March. This allowed an estimate of the time to achieve six‐month and 12‐month remission and the time to first seizure to be computed. </p> <p>We calculated time to achieve six‐month and 12‐month remission from the date of randomisation to the date (or estimated date) the individual had first been free of seizures for six or 12 months, respectively. If the person had one or more seizure(s) in the titration period, a six‐month or 12‐month seizure‐free period could also occur between the estimated date of the last seizure in the titration period and the estimated date of the first seizure in the maintenance period. </p> <p>We calculated time to first seizure from the date of randomisation to the date that their first seizure was estimated to have occurred. If seizure data were missing for a particular visit, these outcomes were censored at the previous visit. These outcomes were also censored if the individual died or if follow‐up ceased prior to the occurrence of the event of interest. These methods had been used in the remaining two trials for which outcome data were provided directly (<a href="./references#CD001769-bbs2-0004" title="DeSilvaM , MacArdleB , McGowanM , HughesE , StewartJ , NevilleBGR , et al. Randomised comparative monotherapy trial of phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed childhood epilepsy. Lancet1996;347:709‐13. ">De Silva 1996</a>; <a href="./references#CD001769-bbs2-0006" title="HellerAJ , ChestermanP , ElwesRD , CrawfordP , ChadwickDW , JohnsonAL , et al. Phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed adult epilepsy: a randomised comparative monotherapy trial. Journal of Neurology, Neurosurgery, and Psychiatry1995;58:44‐50. ">Heller 1995</a>). </p> <p>Treatment failure data were not available for one trial (<a href="./references#CD001769-bbs2-0002" title="CraigI , TallisR . Impact of valproate and phenytoin on cognitive function in elderly patients: results of a single‐blind randomized comparative study. Epilepsia1994;35(2):381‐90. ">Craig 1994</a>). For two trials, we extracted dates and reason for treatment failure from trial case report forms for the original review (<a href="./references#CD001769-bbs2-0004" title="DeSilvaM , MacArdleB , McGowanM , HughesE , StewartJ , NevilleBGR , et al. Randomised comparative monotherapy trial of phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed childhood epilepsy. Lancet1996;347:709‐13. ">De Silva 1996</a>; <a href="./references#CD001769-bbs2-0006" title="HellerAJ , ChestermanP , ElwesRD , CrawfordP , ChadwickDW , JohnsonAL , et al. Phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed adult epilepsy: a randomised comparative monotherapy trial. Journal of Neurology, Neurosurgery, and Psychiatry1995;58:44‐50. ">Heller 1995</a>). Two review authors (SJN and AGM) independently extracted data from all case report forms, resolving disagreements by discussion and reconsidering the case report forms. For the remaining trials (<a href="./references#CD001769-bbs2-0007" title="RamsayRE , WilderBJ , MurphyJV , HolmesGL , UthmanB , SlaterJ , et al. Efficacy and safety of valproic acid versus phenytoin as sole therapy for newly diagnosed primary generalized tonic‐clonic seizures. Journal of Epilepsy1992;5(1):55‐60. ">Ramsay 1992</a>; <a href="./references#CD001769-bbs2-0011" title="TurnbullDM , HowelD , RawlinsMD , ChadwickDW . Which drug for the adult epileptic patient: phenytoin or valproate?. BMJ1985;290:815‐9. ">Turnbull 1985</a>), data on length of time spent in trial and reason for withdrawal from treatment or treatment failure were provided directly. </p> <p>Time to treatment failure was calculated as date of randomisation to date of treatment failure. For the analysis of time‐to‐event, we defined an 'event' as treatment failure because of reasons related to the treatment (i.e. lack of efficacy, adverse events, or both lack of efficacy and adverse events), non‐compliance with the treatment regimen, withdrawal of consent from the trial, etc.). We censored the outcome if treatment failure or withdrawal of treatment was for reasons not related to the trial treatment: i.e. loss to follow‐up, death (not treatment or epilepsy‐related), withdrawal of treatment due to remission, etc. We also censored individuals who were still on allocated treatment at the date of the end of follow‐up. We considered documented reasons for treatment failure or treatment withdrawal on a case‐by‐case basis in relation to treatment; two authors (SJN and AGM) independently classified reasons for treatment failure as 'events' or 'censored' and resolved any disagreements by discussion. </p> <p>For the analysis of 'time to treatment failure due to adverse events,' only treatment failures which were documented to be due to adverse events (either as a sole reason or due to both a lack of efficacy and adverse events) were classed as an 'event' within time‐to‐event analyses and all other reasons for treatment failure were censored. Similarly, for the analysis of 'time to treatment failure due to lack of efficacy' only treatment failures which were documented to be due to lack of efficacy (i.e. continued seizures, either as a sole reason or due to both a lack of efficacy and adverse events) were classed as an 'event' within time‐to‐event analyses and all other reasons for treatment failure were censored. </p> <p>Two trials presented times at which the allocated drug was withdrawn and the reason for treatment failure in the trial publication for each individual (<a href="./references#CD001769-bbs2-0005" title="ForsytheI , ButlerR , BergI , McGuireR . Cognitive impairment in new cases of epilepsy randomly assigned to carbamazepine, phenytoin and sodium valproate. Developmental Medicine and Child Neurology1991;33:524‐34. ">Forsythe 1991</a>; <a href="./references#CD001769-bbs2-0009" title="ShakirRA , JohnsonRH , LambieDG , MelvilleID , NandaRN . Comparison of sodium valproate and phenytoin as single drug treatment in epilepsy. Epilepsia1981;22:27‐33. ">Shakir 1981</a>). Hence, these two trials could be incorporated into the analysis of 'time to treatment failure'; one of the trials also presented information by seizure type (focal onset or generalised onset seizures) and therefore could also be included in the stratified analysis for 'time to treatment failure' (<a href="./references#CD001769-bbs2-0009" title="ShakirRA , JohnsonRH , LambieDG , MelvilleID , NandaRN . Comparison of sodium valproate and phenytoin as single drug treatment in epilepsy. Epilepsia1981;22:27‐33. ">Shakir 1981</a>). </p> <p><a href="./references#CD001769-bbs2-0009" title="ShakirRA , JohnsonRH , LambieDG , MelvilleID , NandaRN . Comparison of sodium valproate and phenytoin as single drug treatment in epilepsy. Epilepsia1981;22:27‐33. ">Shakir 1981</a> presents 'time on trial drug' in months for each participant; therefore to calculate 'time to treatment failure', we assumed that if 'time spent on trial drug' was five months, the individual spent five full months (152 full days) on the trial drug before treatment failure. <a href="./references#CD001769-bbs2-0005" title="ForsytheI , ButlerR , BergI , McGuireR . Cognitive impairment in new cases of epilepsy randomly assigned to carbamazepine, phenytoin and sodium valproate. Developmental Medicine and Child Neurology1991;33:524‐34. ">Forsythe 1991</a> presents 'withdrawal and time of occurrence by month' for each participant; therefore to calculate 'time to treatment failure', we assumed that if treatment failure occurred during the fifth month, that the treatment failure occurred halfway between the fifth and sixth month (i.e. participants spent 167 full days on treatment before treatment failure). </p> </section> <section id="CD001769-sec-0043"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two review authors (SJN and JW) independently assessed the risk of bias for each trial using the Cochrane 'Risk of bias' tool, as described in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD001769-bbs2-0051" title="HigginsJP , AltmanDG , SterneJAC , editor(s) . Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. The Cochrane Collaboration. ">Higgins 2011</a>). We rated each of the following six domains as low, unclear or high risk of bias: method of generating random sequence, allocation concealment, blinding methods, incomplete outcome data, selective outcome reporting and other sources of bias. Any discrepancies in risk of bias judgements of the two review authors were resolved by discussion. In the event of the presence of high risk of bias in included trials (due to inadequate allocation concealment or lack of blinding), we planned sensitivity analyses excluding these trials. </p> </section> <section id="CD001769-sec-0044"> <h4 class="title">Measures of treatment effect</h4> <p>We measured all outcomes in this review as time‐to‐event outcomes with the hazard ratio (HR) and 95% confidence interval (CI) used as the measure of treatment effect. We calculated outcomes from IPD provided, where possible, or extracted from published trials if possible. </p> </section> <section id="CD001769-sec-0045"> <h4 class="title">Unit of analysis issues</h4> <p>We did not have any unit of analysis issues. The unit of allocation and analysis was the individual for all included trials; and no trials included in meta‐analyses were of a repeated measures (longitudinal) nature or of a cross‐over design. </p> </section> <section id="CD001769-sec-0046"> <h4 class="title">Dealing with missing data</h4> <p>For each trial that supplied IPD, we reproduced results from trial results where possible and performed the following consistency checks. </p> <p> <ul id="CD001769-list-0017"> <li> <p>We cross‐checked trial details against any published report of the trial and contacted original trial authors if we found missing data, errors or inconsistencies. If trial authors could not resolve inconsistencies between the IPD and the published data, depending on the extent of the inconsistencies, we planned to perform sensitivity analysis or excluded the data from the meta‐analysis. </p> </li> <li> <p>We reviewed the chronological randomisation sequence and checked the balance of prognostic factors, taking account of factors stratified for in the randomisation procedure. </p> </li> </ul> </p> </section> <section id="CD001769-sec-0047"> <h4 class="title">Assessment of heterogeneity</h4> <p>We assessed heterogeneity statistically using the Q test (P &lt; 0.10 for significance) and the I² statistic (greater than 50% indicating considerable heterogeneity; <a href="./references#CD001769-bbs2-0050" title="HigginsJP , ThompsonSG , DeeksJJ , AltmanDG . Measuring inconsistency in meta‐analyses. BMJ2003;327:557‐60. ">Higgins 2003</a>), and visually by inspecting forest plots. </p> </section> <section id="CD001769-sec-0048"> <h4 class="title">Assessment of reporting biases</h4> <p>Two review authors (SJN and JW) undertook all full quality and risk of bias assessments. In theory, a review using IPD should overcome issues of reporting biases, as unpublished data can be provided and unpublished outcomes calculated. Any selective reporting bias detected could be assessed with the ORBIT classification system (<a href="./references#CD001769-bbs2-0058" title="KirkhamJJ , DwanKM , AltmanDG , GambleC , DoddS , SmythR , et al. The impact of outcome reporting bias in randomised controlled trials on a cohort of systematic reviews. BMJ2010;340:c365. ">Kirkham 2010</a>). </p> </section> <section id="CD001769-sec-0049"> <h4 class="title">Data synthesis</h4> <p>We carried out our analysis on an intention‐to‐treat basis (that is, we analysed participants in the group to which they were randomised, irrespective of which treatment they actually received). Therefore, for the time‐to‐event outcomes, 'time to six‐month remission', 'time to 12‐month remission', 'time to 24 month remission' and 'time to first seizure post‐randomisation', we did not censor participants if treatment was withdrawn or if treatment failure occurred but follow‐up within the trial continued (e.g. if a participant continued to be followed up on a different treatment). </p> <p>For all outcomes, we investigated the relationship between the time‐to‐event and treatment effect of the antiepileptic drugs. We used Cox proportional hazards regression models to obtain trial‐specific estimates of log (HR) or treatment effect and associated standard errors in Stata Statistical Software, version 14 (<a href="./references#CD001769-bbs2-0091" title="StataCorp . Stata Statistical Software: Release 14. College Station, TX: StataCorp LP, 2015. ">Stata 2015</a>). The model assumes that the ratio of hazards (risks) between the two treatment groups is constant over time (i.e. hazards are proportional). We tested this proportional hazards assumption of the Cox regression model for each outcome of each trial by testing the statistical significance of a time varying covariate in the model. We evaluated overall pooled estimates of HRs (with 95% CIs) using the generic inverse variance method. We expressed results as a HR and a 95% CI. </p> <p>By convention, a HR greater than 1 indicates that an event is more likely to occur earlier on valproate than on phenytoin. Hence, for time to treatment failure or time to first seizure, a HR less than 1 indicates a clinical advantage for valproate (e.g. HR = 0.8 would suggest a 20% reduction in hazard of treatment failure from valproate compared to phenytoin), and for time to achieve six‐month and 12‐month remission, a HR less than 1 indicates a clinical advantage for phenytoin. </p> </section> <section id="CD001769-sec-0050"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>Due to the strong clinical belief that valproate is more effective in generalised onset seizures, while phenytoin is more effective in focal onset seizures, we have stratified all analyses by seizure type (focal onset versus generalised onset), according to the classification of main seizure type at baseline. We classified focal seizures (simple or complex) and focal secondarily generalised seizures as 'focal epilepsy'. We classified primarily generalised seizures as 'generalised epilepsy'. We conducted a Chi² test of interaction between treatment and epilepsy type. </p> <p>If we found significant statistical heterogeneity to be present, we performed meta‐analysis with a random‐effects model in addition to a fixed‐effect model, presenting the result of both models and performing sensitivity analyses to investigate differences in study characteristics. </p> </section> <section id="CD001769-sec-0051"> <h4 class="title">Sensitivity analysis</h4> <p>One trial recruited only individuals with generalised onset tonic‐clonic seizures, some of whom were experiencing other generalised seizure types, such as absence or myoclonus (<a href="./references#CD001769-bbs2-0007" title="RamsayRE , WilderBJ , MurphyJV , HolmesGL , UthmanB , SlaterJ , et al. Efficacy and safety of valproic acid versus phenytoin as sole therapy for newly diagnosed primary generalized tonic‐clonic seizures. Journal of Epilepsy1992;5(1):55‐60. ">Ramsay 1992</a>), and all generalised seizure types were recorded during follow‐up for this trial. The remaining four trials recruited individuals with focal onset seizures (simple/complex focal or secondarily generalised tonic‐clonic) and individuals with generalised onset tonic‐clonic seizures. For the individuals with generalised onset tonic‐clonic seizures recruited into these four trials, other generalised seizure types were not recorded during follow‐up. As a result, the majority of the data from the five trials does not address the treatment of generalised seizure types, such as absence or myoclonus, but applies only to generalised onset tonic‐clonic seizures. In our primary analysis, we use only the data for generalised onset tonic‐clonic seizures during follow‐up as this is the most consistent approach; we also report a sensitivity analysis which includes data on all generalised seizure types from <a href="./references#CD001769-bbs2-0007" title="RamsayRE , WilderBJ , MurphyJV , HolmesGL , UthmanB , SlaterJ , et al. Efficacy and safety of valproic acid versus phenytoin as sole therapy for newly diagnosed primary generalized tonic‐clonic seizures. Journal of Epilepsy1992;5(1):55‐60. ">Ramsay 1992</a> for the outcomes 'time to first seizure' and 'time to six‐month remission' (<a href="./references#CD001769-bbs2-0007" title="RamsayRE , WilderBJ , MurphyJV , HolmesGL , UthmanB , SlaterJ , et al. Efficacy and safety of valproic acid versus phenytoin as sole therapy for newly diagnosed primary generalized tonic‐clonic seizures. Journal of Epilepsy1992;5(1):55‐60. ">Ramsay 1992</a> was less than one year duration so does not contribute to 'time to‐12 month remission'). </p> <p>Misclassification of seizure type is a recognised problem in epilepsy, whereby some people with generalised seizures have been mistakenly classed as having focal onset seizures and vice versa. There is clinical evidence that individuals with generalised onset seizures are unlikely to have an 'age of onset' greater than 25 to 30 years (<a href="./references#CD001769-bbs2-0063" title="MalafosseA , GentonP , HirschE , MarescauxC , BroglinD , BernasconiR , editor(s) , et al. Idiopathic Generalised Epilepsies: Clinical, Experimental and Genetic Aspects. Eastleigh: John Libbey and Company, 1994. [0861964365] ">Malafosse 1994</a>). Such misclassification impacted upon the results of three reviews in our series of pair‐wise reviews for monotherapy in epilepsy comparing carbamazepine to phenobarbitone, phenytoin and sodium valproate in which around 30% to 50% of participants analysed may have had their seizure type misclassified as generalised onset (<a href="./references#CD001769-bbs2-0064" title="MarsonAG , WilliamsonPR , HuttonJL , CloughHE , ChadwickDW . Carbamazepine versus valproate monotherapy for epilepsy. Cochrane Database of Systematic Reviews2000, Issue 3. [DOI: 10.1002/14651858.CD001030] ">Marson 2000</a>; <a href="./references#CD001769-bbs2-0078" title="NolanSJ , MarsonAG , WestonJ , Tudur SmithC . Carbamazepine versus phenobarbitone monotherapy for epilepsy: an individual participant data review. Cochrane Database of Systematic Reviews2016, Issue 12. [DOI: 10.1002/14651858.CD001904.pub2] ">Nolan 2016c</a>; <a href="./references#CD001769-bbs2-0070" title="NevittSJ , MarsonAG , WestonJ , Tudur‐SmithC . Carbamazepine versus phenytoin monotherapy for epilepsy: an individual participant data review. Cochrane Database of Systematic Reviews2017, Issue 2. [DOI: 10.1002/14651858.CD001911.pub3] ">Nevitt 2017b</a>). Given the potential biases introduced into those reviews, we examined the distribution of age at onset for individuals with generalised seizures in the trials included in this review, to assess the potential impact of misclassification of seizure type on the outcomes: </p> <p> <ul id="CD001769-list-0018"> <li> <p>84 out of 86 individuals classified as having generalised onset seizures (98%) in <a href="./references#CD001769-bbs2-0002" title="CraigI , TallisR . Impact of valproate and phenytoin on cognitive function in elderly patients: results of a single‐blind randomized comparative study. Epilepsia1994;35(2):381‐90. ">Craig 1994</a>; </p> </li> <li> <p>37 out of 71 individuals (52%) in <a href="./references#CD001769-bbs2-0006" title="HellerAJ , ChestermanP , ElwesRD , CrawfordP , ChadwickDW , JohnsonAL , et al. Phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed adult epilepsy: a randomised comparative monotherapy trial. Journal of Neurology, Neurosurgery, and Psychiatry1995;58:44‐50. ">Heller 1995</a>; </p> </li> <li> <p>30 out of 136 (22%) in <a href="./references#CD001769-bbs2-0007" title="RamsayRE , WilderBJ , MurphyJV , HolmesGL , UthmanB , SlaterJ , et al. Efficacy and safety of valproic acid versus phenytoin as sole therapy for newly diagnosed primary generalized tonic‐clonic seizures. Journal of Epilepsy1992;5(1):55‐60. ">Ramsay 1992</a>; </p> </li> <li> <p>2 out of 14 (14%) in <a href="./references#CD001769-bbs2-0009" title="ShakirRA , JohnsonRH , LambieDG , MelvilleID , NandaRN . Comparison of sodium valproate and phenytoin as single drug treatment in epilepsy. Epilepsia1981;22:27‐33. ">Shakir 1981</a>; and </p> </li> <li> <p>35 out of 77 (45%) in <a href="./references#CD001769-bbs2-0011" title="TurnbullDM , HowelD , RawlinsMD , ChadwickDW . Which drug for the adult epileptic patient: phenytoin or valproate?. BMJ1985;290:815‐9. ">Turnbull 1985</a>. </p> </li> </ul> </p> <p>Therefore, a total of up to 188 out of 384 individuals (49%) classified as having generalised onset seizures may have had their seizure type misclassified (<a href="./references#CD001769-bbs2-0004" title="DeSilvaM , MacArdleB , McGowanM , HughesE , StewartJ , NevilleBGR , et al. Randomised comparative monotherapy trial of phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed childhood epilepsy. Lancet1996;347:709‐13. ">De Silva 1996</a> was a paediatric trial so no individuals over the age of 30 were recruited). Such a misclassification could bias our results against finding an interaction between treatment and seizure types (focal onset versus generalised onset). We undertook the following two analyses to investigate misclassification. </p> <p> <ul id="CD001769-list-0019"> <li> <p>We reclassified all individuals with generalised seizures and age at onset greater than 30 into an 'uncertain seizure type' group. </p> </li> <li> <p>We reclassified individuals with generalised seizures and age at onset greater than 30 as having focal onset seizures. </p> </li> </ul> </p> <section id="CD001769-sec-0052"> <h5 class="title">Summary of findings and quality of the evidence (GRADE)</h5> <p>For the 2013 update, in a post hoc change from protocol, we have added two 'Summary of findings' tables to the review (outcomes in the tables decided before the update started based on clinical relevance). </p> <p><a href="./full#CD001769-tbl-0001">summary of findings Table for the main comparison</a> reports the primary outcome of 'time to treatment failure' in the subgroups of participants with focal onset seizures, generalised onset seizures and overall adjusted by epilepsy type. </p> <p><a href="./full#CD001769-tbl-0002">summary of findings Table 2</a> reports the secondary outcomes of 'time to first seizure' and 'time to 12‐month remission' in the subgroups of participants with focal onset seizures, generalised onset seizures and overall adjusted by epilepsy type. </p> <p>We determined the quality of the evidence using the GRADE approach (<a href="./references#CD001769-bbs2-0090" title="SchünemannH , BrożekJ , GuyattG , OxmanA , editor(s) . Handbook for grading the quality of evidence and the strength of recommendations using the GRADE approach (updated October 2013). Available from gdt.guidelinedevelopment.org/app/handbook/handbook.html. GRADE Working Group, 2013. ">Schünemann 2013</a>), where we downgraded evidence in the presence of high risk of bias in at least one trial, indirectness of the evidence, unexplained heterogeneity or inconsistency, imprecision of results and high probability of publication bias. We downgraded evidence by one level if the limitation was considered serious and two levels if considered very serious, as judged by the review authors. </p> </section> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD001769-sec-0053" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD001769-sec-0053"></div> <section id="CD001769-sec-0054"> <h3 class="title">Description of studies</h3> <section id="CD001769-sec-0055"> <h4 class="title">Results of the search</h4> <p>We identified 334 records from the databases and search strategies outlined in <a href="#CD001769-sec-0038">Electronic searches</a>. We found no further records by searching other resources. We removed 126 duplicate records and screened 208 records (title and abstract) for inclusion in the review. We excluded 178 records based on title and abstract and assessed 30 full‐text articles for inclusion in the review. We excluded 19 studies from the review (see <a href="#CD001769-sec-0057">Excluded studies</a> below) and included 11 trials in the review (see <a href="#CD001769-sec-0056">Included studies</a> below). We updated the searches in May 2015, resulting in 35 hits. We removed seven duplicate records and screened 28 records (title and abstract); we excluded all 28 records. </p> <p>For the 2018 update of this review we identified 129 records from the databases and search strategies outlined in <a href="#CD001769-sec-0038">Electronic searches</a>. We removed 21 duplicate records and screened 108 records (title and abstract) for inclusion in the review. All 108 records were clearly irrelevant and we excluded them. </p> <p>See <a href="#CD001769-fig-0001">Figure 1</a> for PRISMA study flow diagram for the eligibility screening of all studies identified in searches for all versions of this review (previous searches and the most recent search in February 2018). </p> <div class="figure" id="CD001769-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD001769-fig-0001" src="/cdsr/doi/10.1002/14651858.CD001769.pub4/media/CDSR/CD001769/image_n/nCD001769-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> </section> <section id="CD001769-sec-0056"> <h4 class="title">Included studies</h4> <p>We included 11 trials in the review (<a href="./references#CD001769-bbs2-0001" title="CallaghanN , KennyRA , O'NeillB , CrowleyM , GogginT . A prospective study between carbamazepine, phenytoin and sodium valproate as monotherapy in previously untreated and recently diagnosed patients with epilepsy. Journal of Neurology, Neurosurgery and Psychiatry1985;48:639‐44. ">Callaghan 1985</a>; <a href="./references#CD001769-bbs2-0003" title="CzapinskiP , TerczynskiA , CzapinskaE . Randomised 36‐month comparative study of valproic acid, phenytoin, phenobarbital and carbamazepine efficacy in patients with newly diagnosed epilepsy with partial complex seizures. Epilepsia1997;38(Suppl 3):42. ">Czapinski 1997a</a>; <a href="./references#CD001769-bbs2-0002" title="CraigI , TallisR . Impact of valproate and phenytoin on cognitive function in elderly patients: results of a single‐blind randomized comparative study. Epilepsia1994;35(2):381‐90. ">Craig 1994</a>; <a href="./references#CD001769-bbs2-0004" title="DeSilvaM , MacArdleB , McGowanM , HughesE , StewartJ , NevilleBGR , et al. Randomised comparative monotherapy trial of phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed childhood epilepsy. Lancet1996;347:709‐13. ">De Silva 1996</a>; <a href="./references#CD001769-bbs2-0005" title="ForsytheI , ButlerR , BergI , McGuireR . Cognitive impairment in new cases of epilepsy randomly assigned to carbamazepine, phenytoin and sodium valproate. Developmental Medicine and Child Neurology1991;33:524‐34. ">Forsythe 1991</a>; <a href="./references#CD001769-bbs2-0006" title="HellerAJ , ChestermanP , ElwesRD , CrawfordP , ChadwickDW , JohnsonAL , et al. Phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed adult epilepsy: a randomised comparative monotherapy trial. Journal of Neurology, Neurosurgery, and Psychiatry1995;58:44‐50. ">Heller 1995</a>; <a href="./references#CD001769-bbs2-0007" title="RamsayRE , WilderBJ , MurphyJV , HolmesGL , UthmanB , SlaterJ , et al. Efficacy and safety of valproic acid versus phenytoin as sole therapy for newly diagnosed primary generalized tonic‐clonic seizures. Journal of Epilepsy1992;5(1):55‐60. ">Ramsay 1992</a>; <a href="./references#CD001769-bbs2-0008" title="RastogiP , MehrotraTN , AgarwalaRK , SinghVS . Comparison of sodium valproate and phenytoin as single drug treatment in generalised and partial epilepsy. Journal of the Association of Physicians of India1991;39(8):606‐8. ">Rastogi 1991</a>; <a href="./references#CD001769-bbs2-0009" title="ShakirRA , JohnsonRH , LambieDG , MelvilleID , NandaRN . Comparison of sodium valproate and phenytoin as single drug treatment in epilepsy. Epilepsia1981;22:27‐33. ">Shakir 1981</a>; <a href="./references#CD001769-bbs2-0010" title="ThilothammalN , BanuK , RatnamRS . Comparison of phenobarbitone, phenytoin with sodium valproate: randomized, double‐blind study. Indian Pediatrics1996;33:549‐55. ">Thilothammal 1996</a>; <a href="./references#CD001769-bbs2-0011" title="TurnbullDM , HowelD , RawlinsMD , ChadwickDW . Which drug for the adult epileptic patient: phenytoin or valproate?. BMJ1985;290:815‐9. ">Turnbull 1985</a>). One trial was available in abstract form only (<a href="./references#CD001769-bbs2-0003" title="CzapinskiP , TerczynskiA , CzapinskaE . Randomised 36‐month comparative study of valproic acid, phenytoin, phenobarbital and carbamazepine efficacy in patients with newly diagnosed epilepsy with partial complex seizures. Epilepsia1997;38(Suppl 3):42. ">Czapinski 1997a</a>). </p> <p>Four trials recruited individuals of all ages (<a href="./references#CD001769-bbs2-0001" title="CallaghanN , KennyRA , O'NeillB , CrowleyM , GogginT . A prospective study between carbamazepine, phenytoin and sodium valproate as monotherapy in previously untreated and recently diagnosed patients with epilepsy. Journal of Neurology, Neurosurgery and Psychiatry1985;48:639‐44. ">Callaghan 1985</a>; <a href="./references#CD001769-bbs2-0007" title="RamsayRE , WilderBJ , MurphyJV , HolmesGL , UthmanB , SlaterJ , et al. Efficacy and safety of valproic acid versus phenytoin as sole therapy for newly diagnosed primary generalized tonic‐clonic seizures. Journal of Epilepsy1992;5(1):55‐60. ">Ramsay 1992</a>; <a href="./references#CD001769-bbs2-0008" title="RastogiP , MehrotraTN , AgarwalaRK , SinghVS . Comparison of sodium valproate and phenytoin as single drug treatment in generalised and partial epilepsy. Journal of the Association of Physicians of India1991;39(8):606‐8. ">Rastogi 1991</a>; <a href="./references#CD001769-bbs2-0009" title="ShakirRA , JohnsonRH , LambieDG , MelvilleID , NandaRN . Comparison of sodium valproate and phenytoin as single drug treatment in epilepsy. Epilepsia1981;22:27‐33. ">Shakir 1981</a>), three trials recruited adults only (<a href="./references#CD001769-bbs2-0003" title="CzapinskiP , TerczynskiA , CzapinskaE . Randomised 36‐month comparative study of valproic acid, phenytoin, phenobarbital and carbamazepine efficacy in patients with newly diagnosed epilepsy with partial complex seizures. Epilepsia1997;38(Suppl 3):42. ">Czapinski 1997a</a>; <a href="./references#CD001769-bbs2-0006" title="HellerAJ , ChestermanP , ElwesRD , CrawfordP , ChadwickDW , JohnsonAL , et al. Phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed adult epilepsy: a randomised comparative monotherapy trial. Journal of Neurology, Neurosurgery, and Psychiatry1995;58:44‐50. ">Heller 1995</a>; <a href="./references#CD001769-bbs2-0011" title="TurnbullDM , HowelD , RawlinsMD , ChadwickDW . Which drug for the adult epileptic patient: phenytoin or valproate?. BMJ1985;290:815‐9. ">Turnbull 1985</a>), three trials recruited children only (<a href="./references#CD001769-bbs2-0004" title="DeSilvaM , MacArdleB , McGowanM , HughesE , StewartJ , NevilleBGR , et al. Randomised comparative monotherapy trial of phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed childhood epilepsy. Lancet1996;347:709‐13. ">De Silva 1996</a>; <a href="./references#CD001769-bbs2-0005" title="ForsytheI , ButlerR , BergI , McGuireR . Cognitive impairment in new cases of epilepsy randomly assigned to carbamazepine, phenytoin and sodium valproate. Developmental Medicine and Child Neurology1991;33:524‐34. ">Forsythe 1991</a>; <a href="./references#CD001769-bbs2-0010" title="ThilothammalN , BanuK , RatnamRS . Comparison of phenobarbitone, phenytoin with sodium valproate: randomized, double‐blind study. Indian Pediatrics1996;33:549‐55. ">Thilothammal 1996</a>), and one trial recruited elderly individuals only (<a href="./references#CD001769-bbs2-0002" title="CraigI , TallisR . Impact of valproate and phenytoin on cognitive function in elderly patients: results of a single‐blind randomized comparative study. Epilepsia1994;35(2):381‐90. ">Craig 1994</a>). </p> <p>One trial recruited individuals with focal onset seizures only (<a href="./references#CD001769-bbs2-0003" title="CzapinskiP , TerczynskiA , CzapinskaE . Randomised 36‐month comparative study of valproic acid, phenytoin, phenobarbital and carbamazepine efficacy in patients with newly diagnosed epilepsy with partial complex seizures. Epilepsia1997;38(Suppl 3):42. ">Czapinski 1997a</a>), two trials recruited individuals with generalised onset seizures only (<a href="./references#CD001769-bbs2-0007" title="RamsayRE , WilderBJ , MurphyJV , HolmesGL , UthmanB , SlaterJ , et al. Efficacy and safety of valproic acid versus phenytoin as sole therapy for newly diagnosed primary generalized tonic‐clonic seizures. Journal of Epilepsy1992;5(1):55‐60. ">Ramsay 1992</a>; <a href="./references#CD001769-bbs2-0010" title="ThilothammalN , BanuK , RatnamRS . Comparison of phenobarbitone, phenytoin with sodium valproate: randomized, double‐blind study. Indian Pediatrics1996;33:549‐55. ">Thilothammal 1996</a>), seven trials recruited individuals with focal onset seizures and generalised onset seizures (<a href="./references#CD001769-bbs2-0001" title="CallaghanN , KennyRA , O'NeillB , CrowleyM , GogginT . A prospective study between carbamazepine, phenytoin and sodium valproate as monotherapy in previously untreated and recently diagnosed patients with epilepsy. Journal of Neurology, Neurosurgery and Psychiatry1985;48:639‐44. ">Callaghan 1985</a>; <a href="./references#CD001769-bbs2-0002" title="CraigI , TallisR . Impact of valproate and phenytoin on cognitive function in elderly patients: results of a single‐blind randomized comparative study. Epilepsia1994;35(2):381‐90. ">Craig 1994</a>; <a href="./references#CD001769-bbs2-0004" title="DeSilvaM , MacArdleB , McGowanM , HughesE , StewartJ , NevilleBGR , et al. Randomised comparative monotherapy trial of phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed childhood epilepsy. Lancet1996;347:709‐13. ">De Silva 1996</a>; <a href="./references#CD001769-bbs2-0006" title="HellerAJ , ChestermanP , ElwesRD , CrawfordP , ChadwickDW , JohnsonAL , et al. Phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed adult epilepsy: a randomised comparative monotherapy trial. Journal of Neurology, Neurosurgery, and Psychiatry1995;58:44‐50. ">Heller 1995</a>; <a href="./references#CD001769-bbs2-0008" title="RastogiP , MehrotraTN , AgarwalaRK , SinghVS . Comparison of sodium valproate and phenytoin as single drug treatment in generalised and partial epilepsy. Journal of the Association of Physicians of India1991;39(8):606‐8. ">Rastogi 1991</a>; <a href="./references#CD001769-bbs2-0009" title="ShakirRA , JohnsonRH , LambieDG , MelvilleID , NandaRN . Comparison of sodium valproate and phenytoin as single drug treatment in epilepsy. Epilepsia1981;22:27‐33. ">Shakir 1981</a>; <a href="./references#CD001769-bbs2-0011" title="TurnbullDM , HowelD , RawlinsMD , ChadwickDW . Which drug for the adult epileptic patient: phenytoin or valproate?. BMJ1985;290:815‐9. ">Turnbull 1985</a>), and one trial did not provide information on the seizure types of individuals recruited (<a href="./references#CD001769-bbs2-0005" title="ForsytheI , ButlerR , BergI , McGuireR . Cognitive impairment in new cases of epilepsy randomly assigned to carbamazepine, phenytoin and sodium valproate. Developmental Medicine and Child Neurology1991;33:524‐34. ">Forsythe 1991</a>). </p> <p>Nine trials recruited individuals with new onset seizures only (<a href="./references#CD001769-bbs2-0001" title="CallaghanN , KennyRA , O'NeillB , CrowleyM , GogginT . A prospective study between carbamazepine, phenytoin and sodium valproate as monotherapy in previously untreated and recently diagnosed patients with epilepsy. Journal of Neurology, Neurosurgery and Psychiatry1985;48:639‐44. ">Callaghan 1985</a>; <a href="./references#CD001769-bbs2-0002" title="CraigI , TallisR . Impact of valproate and phenytoin on cognitive function in elderly patients: results of a single‐blind randomized comparative study. Epilepsia1994;35(2):381‐90. ">Craig 1994</a>; <a href="./references#CD001769-bbs2-0003" title="CzapinskiP , TerczynskiA , CzapinskaE . Randomised 36‐month comparative study of valproic acid, phenytoin, phenobarbital and carbamazepine efficacy in patients with newly diagnosed epilepsy with partial complex seizures. Epilepsia1997;38(Suppl 3):42. ">Czapinski 1997a</a>; <a href="./references#CD001769-bbs2-0004" title="DeSilvaM , MacArdleB , McGowanM , HughesE , StewartJ , NevilleBGR , et al. Randomised comparative monotherapy trial of phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed childhood epilepsy. Lancet1996;347:709‐13. ">De Silva 1996</a>; <a href="./references#CD001769-bbs2-0005" title="ForsytheI , ButlerR , BergI , McGuireR . Cognitive impairment in new cases of epilepsy randomly assigned to carbamazepine, phenytoin and sodium valproate. Developmental Medicine and Child Neurology1991;33:524‐34. ">Forsythe 1991</a>; <a href="./references#CD001769-bbs2-0006" title="HellerAJ , ChestermanP , ElwesRD , CrawfordP , ChadwickDW , JohnsonAL , et al. Phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed adult epilepsy: a randomised comparative monotherapy trial. Journal of Neurology, Neurosurgery, and Psychiatry1995;58:44‐50. ">Heller 1995</a>; <a href="./references#CD001769-bbs2-0007" title="RamsayRE , WilderBJ , MurphyJV , HolmesGL , UthmanB , SlaterJ , et al. Efficacy and safety of valproic acid versus phenytoin as sole therapy for newly diagnosed primary generalized tonic‐clonic seizures. Journal of Epilepsy1992;5(1):55‐60. ">Ramsay 1992</a>; <a href="./references#CD001769-bbs2-0010" title="ThilothammalN , BanuK , RatnamRS . Comparison of phenobarbitone, phenytoin with sodium valproate: randomized, double‐blind study. Indian Pediatrics1996;33:549‐55. ">Thilothammal 1996</a>; <a href="./references#CD001769-bbs2-0011" title="TurnbullDM , HowelD , RawlinsMD , ChadwickDW . Which drug for the adult epileptic patient: phenytoin or valproate?. BMJ1985;290:815‐9. ">Turnbull 1985</a>), 64% of individuals in one trial had new onset seizures, while the remaining individuals had uncontrolled seizures on current therapy (<a href="./references#CD001769-bbs2-0009" title="ShakirRA , JohnsonRH , LambieDG , MelvilleID , NandaRN . Comparison of sodium valproate and phenytoin as single drug treatment in epilepsy. Epilepsia1981;22:27‐33. ">Shakir 1981</a>), and one trial did not specify whether individuals were newly diagnosed (<a href="./references#CD001769-bbs2-0008" title="RastogiP , MehrotraTN , AgarwalaRK , SinghVS . Comparison of sodium valproate and phenytoin as single drug treatment in generalised and partial epilepsy. Journal of the Association of Physicians of India1991;39(8):606‐8. ">Rastogi 1991</a>). Seven trials were conducted in Europe (<a href="./references#CD001769-bbs2-0001" title="CallaghanN , KennyRA , O'NeillB , CrowleyM , GogginT . A prospective study between carbamazepine, phenytoin and sodium valproate as monotherapy in previously untreated and recently diagnosed patients with epilepsy. Journal of Neurology, Neurosurgery and Psychiatry1985;48:639‐44. ">Callaghan 1985</a>; <a href="./references#CD001769-bbs2-0002" title="CraigI , TallisR . Impact of valproate and phenytoin on cognitive function in elderly patients: results of a single‐blind randomized comparative study. Epilepsia1994;35(2):381‐90. ">Craig 1994</a>; <a href="./references#CD001769-bbs2-0003" title="CzapinskiP , TerczynskiA , CzapinskaE . Randomised 36‐month comparative study of valproic acid, phenytoin, phenobarbital and carbamazepine efficacy in patients with newly diagnosed epilepsy with partial complex seizures. Epilepsia1997;38(Suppl 3):42. ">Czapinski 1997a</a>; <a href="./references#CD001769-bbs2-0004" title="DeSilvaM , MacArdleB , McGowanM , HughesE , StewartJ , NevilleBGR , et al. Randomised comparative monotherapy trial of phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed childhood epilepsy. Lancet1996;347:709‐13. ">De Silva 1996</a>; <a href="./references#CD001769-bbs2-0005" title="ForsytheI , ButlerR , BergI , McGuireR . Cognitive impairment in new cases of epilepsy randomly assigned to carbamazepine, phenytoin and sodium valproate. Developmental Medicine and Child Neurology1991;33:524‐34. ">Forsythe 1991</a>; <a href="./references#CD001769-bbs2-0006" title="HellerAJ , ChestermanP , ElwesRD , CrawfordP , ChadwickDW , JohnsonAL , et al. Phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed adult epilepsy: a randomised comparative monotherapy trial. Journal of Neurology, Neurosurgery, and Psychiatry1995;58:44‐50. ">Heller 1995</a>; <a href="./references#CD001769-bbs2-0011" title="TurnbullDM , HowelD , RawlinsMD , ChadwickDW . Which drug for the adult epileptic patient: phenytoin or valproate?. BMJ1985;290:815‐9. ">Turnbull 1985</a>), one trial in the USA (<a href="./references#CD001769-bbs2-0007" title="RamsayRE , WilderBJ , MurphyJV , HolmesGL , UthmanB , SlaterJ , et al. Efficacy and safety of valproic acid versus phenytoin as sole therapy for newly diagnosed primary generalized tonic‐clonic seizures. Journal of Epilepsy1992;5(1):55‐60. ">Ramsay 1992</a>), two trials in India (<a href="./references#CD001769-bbs2-0008" title="RastogiP , MehrotraTN , AgarwalaRK , SinghVS . Comparison of sodium valproate and phenytoin as single drug treatment in generalised and partial epilepsy. Journal of the Association of Physicians of India1991;39(8):606‐8. ">Rastogi 1991</a>; <a href="./references#CD001769-bbs2-0010" title="ThilothammalN , BanuK , RatnamRS . Comparison of phenobarbitone, phenytoin with sodium valproate: randomized, double‐blind study. Indian Pediatrics1996;33:549‐55. ">Thilothammal 1996</a>), and one trial in two centres in Europe and New Zealand (<a href="./references#CD001769-bbs2-0009" title="ShakirRA , JohnsonRH , LambieDG , MelvilleID , NandaRN . Comparison of sodium valproate and phenytoin as single drug treatment in epilepsy. Epilepsia1981;22:27‐33. ">Shakir 1981</a>). </p> <p>Individual participant data (IPD) were provided by trial authors for five trials which recruited a total of 669 participants, representing 60% of individuals from all 1119 eligible participants identified in eligible trials (<a href="./references#CD001769-bbs2-0002" title="CraigI , TallisR . Impact of valproate and phenytoin on cognitive function in elderly patients: results of a single‐blind randomized comparative study. Epilepsia1994;35(2):381‐90. ">Craig 1994</a>; <a href="./references#CD001769-bbs2-0004" title="DeSilvaM , MacArdleB , McGowanM , HughesE , StewartJ , NevilleBGR , et al. Randomised comparative monotherapy trial of phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed childhood epilepsy. Lancet1996;347:709‐13. ">De Silva 1996</a>; <a href="./references#CD001769-bbs2-0006" title="HellerAJ , ChestermanP , ElwesRD , CrawfordP , ChadwickDW , JohnsonAL , et al. Phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed adult epilepsy: a randomised comparative monotherapy trial. Journal of Neurology, Neurosurgery, and Psychiatry1995;58:44‐50. ">Heller 1995</a>; <a href="./references#CD001769-bbs2-0007" title="RamsayRE , WilderBJ , MurphyJV , HolmesGL , UthmanB , SlaterJ , et al. Efficacy and safety of valproic acid versus phenytoin as sole therapy for newly diagnosed primary generalized tonic‐clonic seizures. Journal of Epilepsy1992;5(1):55‐60. ">Ramsay 1992</a>; <a href="./references#CD001769-bbs2-0011" title="TurnbullDM , HowelD , RawlinsMD , ChadwickDW . Which drug for the adult epileptic patient: phenytoin or valproate?. BMJ1985;290:815‐9. ">Turnbull 1985</a>). Data were converted from paper format to computer datasets in two trials (<a href="./references#CD001769-bbs2-0007" title="RamsayRE , WilderBJ , MurphyJV , HolmesGL , UthmanB , SlaterJ , et al. Efficacy and safety of valproic acid versus phenytoin as sole therapy for newly diagnosed primary generalized tonic‐clonic seizures. Journal of Epilepsy1992;5(1):55‐60. ">Ramsay 1992</a>; <a href="./references#CD001769-bbs2-0011" title="TurnbullDM , HowelD , RawlinsMD , ChadwickDW . Which drug for the adult epileptic patient: phenytoin or valproate?. BMJ1985;290:815‐9. ">Turnbull 1985</a>), computerised data were provided directly in one trial (<a href="./references#CD001769-bbs2-0002" title="CraigI , TallisR . Impact of valproate and phenytoin on cognitive function in elderly patients: results of a single‐blind randomized comparative study. Epilepsia1994;35(2):381‐90. ">Craig 1994</a>), and a combination of both (although mostly computerised) were supplied by the authors of two trials (<a href="./references#CD001769-bbs2-0004" title="DeSilvaM , MacArdleB , McGowanM , HughesE , StewartJ , NevilleBGR , et al. Randomised comparative monotherapy trial of phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed childhood epilepsy. Lancet1996;347:709‐13. ">De Silva 1996</a>; <a href="./references#CD001769-bbs2-0006" title="HellerAJ , ChestermanP , ElwesRD , CrawfordP , ChadwickDW , JohnsonAL , et al. Phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed adult epilepsy: a randomised comparative monotherapy trial. Journal of Neurology, Neurosurgery, and Psychiatry1995;58:44‐50. ">Heller 1995</a>). </p> <p>Data were available for the following participant characteristics (percentage of participants with data available): seizure type (100%); gender (99.6%) age at randomisation (99.3%); number of seizures in the six months prior to randomisation (79%); and epilepsy duration (i.e. time since first seizure to randomisation, 73%). Electroencephalographic (EEG) data had been recorded for all five trials, but only computerised in two trials (<a href="./references#CD001769-bbs2-0002" title="CraigI , TallisR . Impact of valproate and phenytoin on cognitive function in elderly patients: results of a single‐blind randomized comparative study. Epilepsia1994;35(2):381‐90. ">Craig 1994</a>; <a href="./references#CD001769-bbs2-0011" title="TurnbullDM , HowelD , RawlinsMD , ChadwickDW . Which drug for the adult epileptic patient: phenytoin or valproate?. BMJ1985;290:815‐9. ">Turnbull 1985</a>). Similar difficulties were encountered with computerised tomography/magnetic resonance imaging (CT/MRI) data available for only one trial (<a href="./references#CD001769-bbs2-0011" title="TurnbullDM , HowelD , RawlinsMD , ChadwickDW . Which drug for the adult epileptic patient: phenytoin or valproate?. BMJ1985;290:815‐9. ">Turnbull 1985</a>), and neurological examination findings, available for only two trials (<a href="./references#CD001769-bbs2-0004" title="DeSilvaM , MacArdleB , McGowanM , HughesE , StewartJ , NevilleBGR , et al. Randomised comparative monotherapy trial of phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed childhood epilepsy. Lancet1996;347:709‐13. ">De Silva 1996</a>; <a href="./references#CD001769-bbs2-0006" title="HellerAJ , ChestermanP , ElwesRD , CrawfordP , ChadwickDW , JohnsonAL , et al. Phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed adult epilepsy: a randomised comparative monotherapy trial. Journal of Neurology, Neurosurgery, and Psychiatry1995;58:44‐50. ">Heller 1995</a>). See the <a href="./references#CD001769-sec-0114" title="">Characteristics of included studies</a> tables, <a href="#CD001769-tbl-0003">Table 1</a> and <a href="#CD001769-tbl-0004">Table 2</a> for further details. </p> <div class="table" id="CD001769-tbl-0003"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Demographic characteristics of trial participants (trials providing individual participant data (IPD))</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""></td> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Focal seizures: n (%)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Male gender: n (%)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Age at entry (years):</b> </p> <p><b>Mean (SD), range</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Aged &gt; 30 years and generalised seizures: n (%)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Epilepsy duration (years): mean (SD), range</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Number of seizures in prior 6 months: median (range)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>SV</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>PHT</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Missing</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>SV</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>PHT</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Missing</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>SV</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>PHT</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Missing</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>SV</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>PHT</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Missing</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>SV</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>PHT</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Missing</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>SV</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>PHT</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Missing</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001769-bbs2-0002" title="CraigI , TallisR . Impact of valproate and phenytoin on cognitive function in elderly patients: results of a single‐blind randomized comparative study. Epilepsia1994;35(2):381‐90. ">Craig 1994</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>37 (44%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>43 (53%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38 (46%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33 (41%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>77.6 (7.2), 61 to 95</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>78.7 (7.0), 64 to 95</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>46</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>166</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 (0 to 60)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 (1 to 99)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001769-bbs2-0004" title="DeSilvaM , MacArdleB , McGowanM , HughesE , StewartJ , NevilleBGR , et al. Randomised comparative monotherapy trial of phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed childhood epilepsy. Lancet1996;347:709‐13. ">De Silva 1996</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25 (51%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30 (56%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18 (37%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34 (63%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11.3 (3.3), 2 to 15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9.5 (3.4), 3 to 15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.2 (1.5), 0 to 4.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.0 (2.1), 0 to 13.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 (1 to 900)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 (1 to 404)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001769-bbs2-0006" title="HellerAJ , ChestermanP , ElwesRD , CrawfordP , ChadwickDW , JohnsonAL , et al. Phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed adult epilepsy: a randomised comparative monotherapy trial. Journal of Neurology, Neurosurgery, and Psychiatry1995;58:44‐50. ">Heller 1995</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25 (41%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28 (44%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28 (46%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34 (54%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32.0 (15.6), 14 to 67</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33.5 (14.3), 14 to 72</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.6 (3.9), 0 to 17.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.8 (5.4), 0 to 24.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 (1 to 181)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 (1 to 575)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001769-bbs2-0007" title="RamsayRE , WilderBJ , MurphyJV , HolmesGL , UthmanB , SlaterJ , et al. Efficacy and safety of valproic acid versus phenytoin as sole therapy for newly diagnosed primary generalized tonic‐clonic seizures. Journal of Epilepsy1992;5(1):55‐60. ">Ramsay 1992</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 (0%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 (0%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48 (56%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25 (50%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21.1 (14.4), 3 to 64</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20.6 (14.0), 4 to 63</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.1 (0.3), 0 to 1.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.2 (0.5), 0 to 3.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>136</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001769-bbs2-0011" title="TurnbullDM , HowelD , RawlinsMD , ChadwickDW . Which drug for the adult epileptic patient: phenytoin or valproate?. BMJ1985;290:815‐9. ">Turnbull 1985</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32 (46%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31 (44%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34 (49%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>39 (56%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35.1 (16.5), 14 to 69</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35.3 (15.9), 16 to 70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.2 (2.9), 0.1 to 11.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.1 (4.2), 0.1 to 30.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 (0 to 60)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 (1 to 60)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>SV= sodium valproate; PHT= Phenytoin; n = number of participants; NA = not available; SD = standard deviation. </p> <p>Proportions (%) are calculated based on non‐missing data.</p> </div> </div> <div class="table" id="CD001769-tbl-0004"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Baseline neurologic characteristics of participants (trials providing individual participant data (IPD))</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""></td> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>EEG normal: n (%)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>CT scan normal: n (%)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>Neurological exam normal: n (%)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>SV</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>PHT</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Missing</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>SV</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>PHT</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Missing</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>SV</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>PHT</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Missing</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001769-bbs2-0002" title="CraigI , TallisR . Impact of valproate and phenytoin on cognitive function in elderly patients: results of a single‐blind randomized comparative study. Epilepsia1994;35(2):381‐90. ">Craig 1994</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20 (30%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8 (16%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>64</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>166</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>166</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001769-bbs2-0004" title="DeSilvaM , MacArdleB , McGowanM , HughesE , StewartJ , NevilleBGR , et al. Randomised comparative monotherapy trial of phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed childhood epilepsy. Lancet1996;347:709‐13. ">De Silva 1996</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>103</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>103</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>43 (88%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>48 (89%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001769-bbs2-0006" title="HellerAJ , ChestermanP , ElwesRD , CrawfordP , ChadwickDW , JohnsonAL , et al. Phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed adult epilepsy: a randomised comparative monotherapy trial. Journal of Neurology, Neurosurgery, and Psychiatry1995;58:44‐50. ">Heller 1995</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>124</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>124</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>56 (95%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>54 (86%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001769-bbs2-0007" title="RamsayRE , WilderBJ , MurphyJV , HolmesGL , UthmanB , SlaterJ , et al. Efficacy and safety of valproic acid versus phenytoin as sole therapy for newly diagnosed primary generalized tonic‐clonic seizures. Journal of Epilepsy1992;5(1):55‐60. ">Ramsay 1992</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>136</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>136</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>136</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001769-bbs2-0011" title="TurnbullDM , HowelD , RawlinsMD , ChadwickDW . Which drug for the adult epileptic patient: phenytoin or valproate?. BMJ1985;290:815‐9. ">Turnbull 1985</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30 (46%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>38 (54%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6 (50%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11 (73%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>70</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>EEG = electroencephalographic; SV= sodium valproate; PHT= Phenytoin; n = number of participants; NA = not available. </p> <p>Proportions (%) are calculated based on non‐missing data.</p> </div> </div> <p>IIPD were not provided for the remaining six of these trials (<a href="./references#CD001769-bbs2-0001" title="CallaghanN , KennyRA , O'NeillB , CrowleyM , GogginT . A prospective study between carbamazepine, phenytoin and sodium valproate as monotherapy in previously untreated and recently diagnosed patients with epilepsy. Journal of Neurology, Neurosurgery and Psychiatry1985;48:639‐44. ">Callaghan 1985</a>; <a href="./references#CD001769-bbs2-0003" title="CzapinskiP , TerczynskiA , CzapinskaE . Randomised 36‐month comparative study of valproic acid, phenytoin, phenobarbital and carbamazepine efficacy in patients with newly diagnosed epilepsy with partial complex seizures. Epilepsia1997;38(Suppl 3):42. ">Czapinski 1997a</a>; <a href="./references#CD001769-bbs2-0005" title="ForsytheI , ButlerR , BergI , McGuireR . Cognitive impairment in new cases of epilepsy randomly assigned to carbamazepine, phenytoin and sodium valproate. Developmental Medicine and Child Neurology1991;33:524‐34. ">Forsythe 1991</a>; <a href="./references#CD001769-bbs2-0008" title="RastogiP , MehrotraTN , AgarwalaRK , SinghVS . Comparison of sodium valproate and phenytoin as single drug treatment in generalised and partial epilepsy. Journal of the Association of Physicians of India1991;39(8):606‐8. ">Rastogi 1991</a>; <a href="./references#CD001769-bbs2-0009" title="ShakirRA , JohnsonRH , LambieDG , MelvilleID , NandaRN . Comparison of sodium valproate and phenytoin as single drug treatment in epilepsy. Epilepsia1981;22:27‐33. ">Shakir 1981</a>; <a href="./references#CD001769-bbs2-0010" title="ThilothammalN , BanuK , RatnamRS . Comparison of phenobarbitone, phenytoin with sodium valproate: randomized, double‐blind study. Indian Pediatrics1996;33:549‐55. ">Thilothammal 1996</a>), in which a total of 450 individuals had been randomised to either phenytoin or valproate. Sufficient participant level data were presented in the trial publications of <a href="./references#CD001769-bbs2-0005" title="ForsytheI , ButlerR , BergI , McGuireR . Cognitive impairment in new cases of epilepsy randomly assigned to carbamazepine, phenytoin and sodium valproate. Developmental Medicine and Child Neurology1991;33:524‐34. ">Forsythe 1991</a> and <a href="./references#CD001769-bbs2-0009" title="ShakirRA , JohnsonRH , LambieDG , MelvilleID , NandaRN . Comparison of sodium valproate and phenytoin as single drug treatment in epilepsy. Epilepsia1981;22:27‐33. ">Shakir 1981</a> to include these studies within the analysis of 'time to treatment failure' (see <a href="#CD001769-sec-0042">Data extraction and management</a> and <a href="#CD001769-sec-0072">Effects of interventions</a>). We could not extract sufficient aggregate data from the trial publication in any other trial, or for any other outcomes to include in data synthesis. Full details of outcomes considered and a summary of results of each trial for which IPD were not available to us can be found in <a href="#CD001769-tbl-0005">Table 3</a>. </p> <div class="table" id="CD001769-tbl-0005"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Outcomes considered and summary of results for trials with no individual participant data (IPD)</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Trial</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Outcomes reported</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Summary of results</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001769-bbs2-0001" title="CallaghanN , KennyRA , O'NeillB , CrowleyM , GogginT . A prospective study between carbamazepine, phenytoin and sodium valproate as monotherapy in previously untreated and recently diagnosed patients with epilepsy. Journal of Neurology, Neurosurgery and Psychiatry1985;48:639‐44. ">Callaghan 1985</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD001769-list-0020"> <li> <p>Seizure control</p> <ul id="CD001769-list-0021"> <li> <p>excellent (seizure‐free)</p> </li> <li> <p>good (&gt; 50% reduction)</p> </li> <li> <p>poor (&lt; 50% reduction)</p> </li> </ul> </li> </ul> <ul id="CD001769-list-0022"> <li> <p>Adverse events</p> </li> </ul> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD001769-list-0023"> <li> <p>PHT (n = 58); SV (n = 64)</p> <ul id="CD001769-list-0024"> <li> <p>39 (67%); 34 (53%)</p> </li> <li> <p>7 (12%); 16 (25%)</p> </li> <li> <p>12 (21%); 14 (22%)</p> </li> </ul> </li> </ul> <ul id="CD001769-list-0025"> <li> <p>2.6 (10%); 7 (11%)</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001769-bbs2-0003" title="CzapinskiP , TerczynskiA , CzapinskaE . Randomised 36‐month comparative study of valproic acid, phenytoin, phenobarbital and carbamazepine efficacy in patients with newly diagnosed epilepsy with partial complex seizures. Epilepsia1997;38(Suppl 3):42. ">Czapinski 1997a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD001769-list-0026"> <li> <p>Proportion achieving 24‐month remission at 3 years (PHT: 59%; SV: 64%)</p> </li> <li> <p>Proportion excluded after randomisation due to adverse events or no efficacy (PHT: 23%; SV: 23%) </p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001769-bbs2-0005" title="ForsytheI , ButlerR , BergI , McGuireR . Cognitive impairment in new cases of epilepsy randomly assigned to carbamazepine, phenytoin and sodium valproate. Developmental Medicine and Child Neurology1991;33:524‐34. ">Forsythe 1991</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD001769-list-0027"> <li> <p>Cognitive assessments</p> </li> <li> <p>Withdrawals from randomised drug</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD001769-list-0028"> <li> <p>Significant difference favouring SV test of speed of information processing (P &lt; 0.01)</p> </li> </ul> </p> <p>No significant differences between treatment groups for any other cognitive tests</p> <p> <ul id="CD001769-list-0029"> <li> <p>PHT: 6/20 (30%); SV: 7/21 (33%)</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001769-bbs2-0008" title="RastogiP , MehrotraTN , AgarwalaRK , SinghVS . Comparison of sodium valproate and phenytoin as single drug treatment in generalised and partial epilepsy. Journal of the Association of Physicians of India1991;39(8):606‐8. ">Rastogi 1991</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD001769-list-0030"> <li> <p>Reduction in frequency of seizures at 24 weeks</p> <ul id="CD001769-list-0031"> <li> <p>excellent (100% reduction)</p> </li> <li> <p>good (75% ‐ 99% reduction)</p> </li> <li> <p>fair (50% ‐ 74% reduction)</p> </li> <li> <p>poor (&lt; 50% reduction)</p> </li> </ul> </li> </ul> <ul id="CD001769-list-0032"> <li> <p>Adverse events</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD001769-list-0033"> <li> <p>PHT (n = 45); SV (n = 49)</p> <ul id="CD001769-list-0034"> <li> <p>23 (51%); 24 (49%)</p> </li> <li> <p>13 (24%); 17 (35%)</p> </li> <li> <p>8 (18%); 5(10%)</p> </li> <li> <p>1 (2%); 3 (6%)</p> </li> </ul> </li> <li> <p>All reported adverse events were minor</p> <ul id="CD001769-list-0035"> <li> <p>PHT: gum hyperplasia (18%), nystagmus (13%), gastrointestinal symptoms (4%), drowsiness (4%), ataxia (2%) </p> </li> <li> <p>SV: gastrointestinal symptoms (12%), drowsiness (6%), weight gain (2%)</p> </li> </ul> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001769-bbs2-0009" title="ShakirRA , JohnsonRH , LambieDG , MelvilleID , NandaRN . Comparison of sodium valproate and phenytoin as single drug treatment in epilepsy. Epilepsia1981;22:27‐33. ">Shakir 1981</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD001769-list-0036"> <li> <p>Seizures during treatment</p> </li> <li> <p>Adverse events</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD001769-list-0037"> <li> <p>PHT: 5 (33%); SV: 7 (39%)</p> </li> <li> <p>PHT: 1 case of ataxia, 5 cases of acne</p> </li> <li> <p>SV: 2 cases of gastrointestinal symptoms, 2 cases of hair loss, 4 cases of weight gain </p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001769-bbs2-0010" title="ThilothammalN , BanuK , RatnamRS . Comparison of phenobarbitone, phenytoin with sodium valproate: randomized, double‐blind study. Indian Pediatrics1996;33:549‐55. ">Thilothammal 1996</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD001769-list-0038"> <li> <p>Recurrence of seizures</p> </li> <li> <p>Adverse events</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD001769-list-0039"> <li> <p>PHT: 14/52 (27%)/SV: 10/48 (21%)</p> </li> <li> <p>PHT: 33/52 (63%)/SV: 15/48 (31%)</p> </li> </ul> </p> <p>           </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>n = number of participants; PHT: phenytoin; SV: sodium valproate.</p> </div> </div> </section> <section id="CD001769-sec-0057"> <h4 class="title">Excluded studies</h4> <p>We excluded 14 duplicate trials (<a href="./references#CD001769-bbs2-0012" title="BergI , ButlerA , EllisM , FosterJ . Psychiatric aspects of epilepsy in childhood treated with carbamazepine, phenytoin or sodium valproate: a random trial. Developmental Medicine and Child Neurology1993;35:149‐57. ">Berg 1993</a>; <a href="./references#CD001769-bbs2-0013" title="CallaghanN , O'NeillB , KennyRA . A comparison between carbamazepine, phenytoin and sodium valproate as single drug treatment in epilepsy [abstract]. Irish Journal of Medical Science1981;150(6):194. ">Callaghan 1981</a>; <a href="./references#CD001769-bbs2-0014" title="CallaghanN , KennyRA , O'NeillB , CrowleyM , GogginT . A comparative study between carbamazepine, phenytoin and sodium valproate as monotherapy in previously untreated and recently diagnosed patients with epilepsy: a preliminary communication. British Journal of Clinical Practice1983;27:7‐9. ">Callaghan 1983</a>; <a href="./references#CD001769-bbs2-0015" title="CallaghanN , KennyRA , O'NeillB , CrowleyM , GogginT . A comparative study of carbamazepine, sodium valproate and phenytoin as monotherapy in epilepsy: an updated report [abstract]. Irish Journal of Medical Science1984;153(4):154. ">Callaghan 1984</a>; <a href="./references#CD001769-bbs2-0016" title="CraigIR , TallisRC . The impact of sodium valproate and phenytoin on cognitive function in elderly patients: results of a single‐blind comparative study. Age and Ageing1993;22(Suppl 2):10. ">Craig 1993</a>; <a href="./references#CD001769-bbs2-0017" title="CzapinskiP , TerczynskiA , CzapinskaE . Comparative study of valproic acid (VPA), phenytoin (PHT), phenobarbital (PB) and carbamazepine (CBZ) in patients with newly diagnosed epilepsy with partial complex seizures [abstract]. Journal of Neurology1997;244(Suppl 3):S95‐6. ">Czapinski 1997b</a>; <a href="./references#CD001769-bbs2-0018" title="CzapinskiP , TerczynskiA , CzapinskaE . Randomized 36‐month comparative study of valproic acid (VPA), phenytoin (PHT), phenobarbital (PB) and carbamazepine (CBZ) efficacy in patients with newly diagnosed epilepsy with partial complex seizures. Journal of the Neurological Sciences1997;150(Suppl):S162‐3. ">Czapinski 1997c</a>; <a href="./references#CD001769-bbs2-0019" title="GogginT . A re‐appraisal by control and seizure type of serum levels in previously untreated patients taking part in a prospective study comparing sodium valproate, phenytoin and carbamazepine as mono‐therapy in epilepsy [abstract]. Irish Journal of Medical Science1984;153(4):154. ">Goggin 1984</a>; <a href="./references#CD001769-bbs2-0020" title="GogginT , CaseyC , CallaghanN . Serum levels of sodium valproate, phenytoin and carbamazepine and seizure control in epilepsy. Irish Medical Journal1986;79(6):150‐6. ">Goggin 1986</a>; <a href="./references#CD001769-bbs2-0025" title="ShakirRA . Sodium valproate, phenytoin and carbamazepine as sole anticonvulsants. Royal Society of Medicine International Congress and Symposium1980;30:7‐16. ">Shakir 1980</a>; <a href="./references#CD001769-bbs2-0026" title="TallisR , CraigI , EasterD . Multicentre comparative trial of sodium valproate and phenytoin in elderly patients with newly diagnosed epilepsy. Age and Ageing1994;23:S5. ">Tallis 1994a</a>; <a href="./references#CD001769-bbs2-0027" title="TallisR , EasterD . Multicenter comparative trial of valproate and phenytoin. Epilepsia1994;35(Suppl 7):62. ">Tallis 1994b</a>; <a href="./references#CD001769-bbs2-0028" title="TurnbullDM , RawlinsMD , WeightmanD , ChadwickDW . A comparison of phenytoin and valproate in previously untreated adult epileptic patients. Journal of Neurology, Neurosurgery and Psychiatry1982;45(1):55‐9. ">Turnbull 1982</a>; <a href="./references#CD001769-bbs2-0029" title="WilderBJ , RamsayRE , MurphyJV , KarasBJ , MarquardtK , HammondEJ . Comparison of valproic acid and phenytoin in newly diagnosed tonic‐clonic seizures. Neurology1983;33(11):1474‐6. ">Wilder 1983</a>), and we retained the most relevant primary reference for each trial in the review. One trial was not randomised (<a href="./references#CD001769-bbs2-0030" title="ZengK , WangX , XiZ , YanY . Adverse effects of carbamazepine, phenytoin, valproate and lamotrigine monotherapy in epileptic adult Chinese patients. Clinical Neurology and Neurosurgery2010;112:291‐5. ">Zeng 2010</a>), and four did not make a randomised comparison between valproate and phenytoin (<a href="./references#CD001769-bbs2-0021" title="JannuzziG , CianP , FattoreC , GattiG , BartoliA , MonacoF , et al. A multicenter randomized controlled trial on the clinical impact of therapeutic drug monitoring in patients with newly diagnosed epilepsy. The Italian TDM Study Group in Epilepsy. Epilepsia2000;41(2):222‐30. ">Jannuzzi 2000</a>; <a href="./references#CD001769-bbs2-0022" title="KaminowL , SchimschockJR , HammerAE , VuongA . Lamotrigine monotherapy compared with carbamazepine, phenytoin, or valproate monotherapy in patients with epilepsy. Epilepsy and Behaviour2003;4(6):659‐66. ">Kaminow 2003</a>; <a href="./references#CD001769-bbs2-0023" title="SabersA , MøllerA , DamM , SmedA , Arlien‐SøborgP , BuchmanJ , et al. Cognitive function and anticonvulsant therapy: effect of monotherapy in epilepsy. Acta Neurologica Scandinavica1995;92(1):19‐27. ">Sabers 1995</a>; <a href="./references#CD001769-bbs2-0024" title="SchmidtD . How reliable is early treatment response in predicting long‐term seizure outcome?. Epilepsy and Behaviour2007;10(4):588‐94. ">Schmidt 2007</a>; see <a href="./references#CD001769-sec-0115" title="">Characteristics of excluded studies</a> for detailed reasons for exclusion). </p> </section> </section> <section id="CD001769-sec-0058"> <h3 class="title">Risk of bias in included studies</h3> <p>For further details see <a href="./references#CD001769-sec-0114" title="">Characteristics of included studies</a>, <a href="#CD001769-fig-0002">Figure 2</a> and <a href="#CD001769-fig-0003">Figure 3</a>. </p> <div class="figure" id="CD001769-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD001769-fig-0002" src="/cdsr/doi/10.1002/14651858.CD001769.pub4/media/CDSR/CD001769/image_n/nCD001769-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <div class="figure" id="CD001769-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study." data-id="CD001769-fig-0003" src="/cdsr/doi/10.1002/14651858.CD001769.pub4/media/CDSR/CD001769/image_n/nCD001769-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <section id="CD001769-sec-0059"> <h4 class="title">Allocation</h4> <section id="CD001769-sec-0060"> <h5 class="title">(1) Trials for which individual participant data (IPD) were provided</h5> <p>Three trials reported adequate methods of randomisation and allocation concealment; two trials used permuted blocks to generate a random list and concealed allocation by using sealed opaque envelopes (<a href="./references#CD001769-bbs2-0004" title="DeSilvaM , MacArdleB , McGowanM , HughesE , StewartJ , NevilleBGR , et al. Randomised comparative monotherapy trial of phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed childhood epilepsy. Lancet1996;347:709‐13. ">De Silva 1996</a>; <a href="./references#CD001769-bbs2-0006" title="HellerAJ , ChestermanP , ElwesRD , CrawfordP , ChadwickDW , JohnsonAL , et al. Phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed adult epilepsy: a randomised comparative monotherapy trial. Journal of Neurology, Neurosurgery, and Psychiatry1995;58:44‐50. ">Heller 1995</a>). One trial used a computer minimisation programme and a pharmacy‐controlled allocation (<a href="./references#CD001769-bbs2-0002" title="CraigI , TallisR . Impact of valproate and phenytoin on cognitive function in elderly patients: results of a single‐blind randomized comparative study. Epilepsia1994;35(2):381‐90. ">Craig 1994</a>); we judged these trials to be at low risk of bias for random sequence generation and allocation concealment. One trail reported that random number tables were used but did not report sufficient information about methods of allocation concealment (<a href="./references#CD001769-bbs2-0007" title="RamsayRE , WilderBJ , MurphyJV , HolmesGL , UthmanB , SlaterJ , et al. Efficacy and safety of valproic acid versus phenytoin as sole therapy for newly diagnosed primary generalized tonic‐clonic seizures. Journal of Epilepsy1992;5(1):55‐60. ">Ramsay 1992</a>). One trial did not report sufficient information about methods of randomisation and allocation concealment (<a href="./references#CD001769-bbs2-0011" title="TurnbullDM , HowelD , RawlinsMD , ChadwickDW . Which drug for the adult epileptic patient: phenytoin or valproate?. BMJ1985;290:815‐9. ">Turnbull 1985</a>). </p> </section> <section id="CD001769-sec-0061"> <h5 class="title">(2) Trials for which no IPD were available</h5> <p>Two trials reported adequate methods of randomisation: telephone randomisation in <a href="./references#CD001769-bbs2-0009" title="ShakirRA , JohnsonRH , LambieDG , MelvilleID , NandaRN . Comparison of sodium valproate and phenytoin as single drug treatment in epilepsy. Epilepsia1981;22:27‐33. ">Shakir 1981</a>, and a computer‐generated list of randomised numbers in <a href="./references#CD001769-bbs2-0010" title="ThilothammalN , BanuK , RatnamRS . Comparison of phenobarbitone, phenytoin with sodium valproate: randomized, double‐blind study. Indian Pediatrics1996;33:549‐55. ">Thilothammal 1996</a>; we judged these studies at low risk of bias for random sequence generation. Two trials reported no information on methods of randomisation (<a href="./references#CD001769-bbs2-0003" title="CzapinskiP , TerczynskiA , CzapinskaE . Randomised 36‐month comparative study of valproic acid, phenytoin, phenobarbital and carbamazepine efficacy in patients with newly diagnosed epilepsy with partial complex seizures. Epilepsia1997;38(Suppl 3):42. ">Czapinski 1997a</a>; <a href="./references#CD001769-bbs2-0008" title="RastogiP , MehrotraTN , AgarwalaRK , SinghVS . Comparison of sodium valproate and phenytoin as single drug treatment in generalised and partial epilepsy. Journal of the Association of Physicians of India1991;39(8):606‐8. ">Rastogi 1991</a>) (unclear risk of bias), one trial reported unclear information on randomisation (<a href="./references#CD001769-bbs2-0001" title="CallaghanN , KennyRA , O'NeillB , CrowleyM , GogginT . A prospective study between carbamazepine, phenytoin and sodium valproate as monotherapy in previously untreated and recently diagnosed patients with epilepsy. Journal of Neurology, Neurosurgery and Psychiatry1985;48:639‐44. ">Callaghan 1985</a>) (unclear risk of bias), and one trial reported an inadequate method of randomisation, i.e. quota allocation (<a href="./references#CD001769-bbs2-0005" title="ForsytheI , ButlerR , BergI , McGuireR . Cognitive impairment in new cases of epilepsy randomly assigned to carbamazepine, phenytoin and sodium valproate. Developmental Medicine and Child Neurology1991;33:524‐34. ">Forsythe 1991</a>) (high risk of bias). We judged five of the six trials to be at unclear risk of bias as they reported no information on allocation concealment (<a href="./references#CD001769-bbs2-0003" title="CzapinskiP , TerczynskiA , CzapinskaE . Randomised 36‐month comparative study of valproic acid, phenytoin, phenobarbital and carbamazepine efficacy in patients with newly diagnosed epilepsy with partial complex seizures. Epilepsia1997;38(Suppl 3):42. ">Czapinski 1997a</a>; <a href="./references#CD001769-bbs2-0005" title="ForsytheI , ButlerR , BergI , McGuireR . Cognitive impairment in new cases of epilepsy randomly assigned to carbamazepine, phenytoin and sodium valproate. Developmental Medicine and Child Neurology1991;33:524‐34. ">Forsythe 1991</a>; <a href="./references#CD001769-bbs2-0008" title="RastogiP , MehrotraTN , AgarwalaRK , SinghVS . Comparison of sodium valproate and phenytoin as single drug treatment in generalised and partial epilepsy. Journal of the Association of Physicians of India1991;39(8):606‐8. ">Rastogi 1991</a>; <a href="./references#CD001769-bbs2-0009" title="ShakirRA , JohnsonRH , LambieDG , MelvilleID , NandaRN . Comparison of sodium valproate and phenytoin as single drug treatment in epilepsy. Epilepsia1981;22:27‐33. ">Shakir 1981</a>; <a href="./references#CD001769-bbs2-0010" title="ThilothammalN , BanuK , RatnamRS . Comparison of phenobarbitone, phenytoin with sodium valproate: randomized, double‐blind study. Indian Pediatrics1996;33:549‐55. ">Thilothammal 1996</a>), and one trial at high risk of bias as it reported an inadequate method of allocation concealment based on 'drug of first preference' (<a href="./references#CD001769-bbs2-0001" title="CallaghanN , KennyRA , O'NeillB , CrowleyM , GogginT . A prospective study between carbamazepine, phenytoin and sodium valproate as monotherapy in previously untreated and recently diagnosed patients with epilepsy. Journal of Neurology, Neurosurgery and Psychiatry1985;48:639‐44. ">Callaghan 1985</a>). </p> </section> </section> <section id="CD001769-sec-0062"> <h4 class="title">Blinding</h4> <section id="CD001769-sec-0063"> <h5 class="title">(1) Trials for which IPD were provided</h5> <p>One trial was single‐blinded (outcome assessor for cognitive testing) (<a href="./references#CD001769-bbs2-0002" title="CraigI , TallisR . Impact of valproate and phenytoin on cognitive function in elderly patients: results of a single‐blind randomized comparative study. Epilepsia1994;35(2):381‐90. ">Craig 1994</a>) (low risk of bias), three trials were unblinded for "practical and ethical reasons" (<a href="./references#CD001769-bbs2-0004" title="DeSilvaM , MacArdleB , McGowanM , HughesE , StewartJ , NevilleBGR , et al. Randomised comparative monotherapy trial of phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed childhood epilepsy. Lancet1996;347:709‐13. ">De Silva 1996</a>; <a href="./references#CD001769-bbs2-0006" title="HellerAJ , ChestermanP , ElwesRD , CrawfordP , ChadwickDW , JohnsonAL , et al. Phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed adult epilepsy: a randomised comparative monotherapy trial. Journal of Neurology, Neurosurgery, and Psychiatry1995;58:44‐50. ">Heller 1995</a>; <a href="./references#CD001769-bbs2-0007" title="RamsayRE , WilderBJ , MurphyJV , HolmesGL , UthmanB , SlaterJ , et al. Efficacy and safety of valproic acid versus phenytoin as sole therapy for newly diagnosed primary generalized tonic‐clonic seizures. Journal of Epilepsy1992;5(1):55‐60. ">Ramsay 1992</a>) (high risk of bias), and one trial provided no information on blinding (<a href="./references#CD001769-bbs2-0011" title="TurnbullDM , HowelD , RawlinsMD , ChadwickDW . Which drug for the adult epileptic patient: phenytoin or valproate?. BMJ1985;290:815‐9. ">Turnbull 1985</a>) (unclear risk of bias). </p> </section> <section id="CD001769-sec-0064"> <h5 class="title">(2) Trials for which no IPD were available</h5> <p>One trial was described as double‐blinded (<a href="./references#CD001769-bbs2-0010" title="ThilothammalN , BanuK , RatnamRS . Comparison of phenobarbitone, phenytoin with sodium valproate: randomized, double‐blind study. Indian Pediatrics1996;33:549‐55. ">Thilothammal 1996</a>) but it was unclear who was blinded, one trial was single‐blinded (outcome assessor for cognitive testing) (<a href="./references#CD001769-bbs2-0005" title="ForsytheI , ButlerR , BergI , McGuireR . Cognitive impairment in new cases of epilepsy randomly assigned to carbamazepine, phenytoin and sodium valproate. Developmental Medicine and Child Neurology1991;33:524‐34. ">Forsythe 1991</a>), and no information was provided on blinding in the other trials (<a href="./references#CD001769-bbs2-0001" title="CallaghanN , KennyRA , O'NeillB , CrowleyM , GogginT . A prospective study between carbamazepine, phenytoin and sodium valproate as monotherapy in previously untreated and recently diagnosed patients with epilepsy. Journal of Neurology, Neurosurgery and Psychiatry1985;48:639‐44. ">Callaghan 1985</a>; <a href="./references#CD001769-bbs2-0003" title="CzapinskiP , TerczynskiA , CzapinskaE . Randomised 36‐month comparative study of valproic acid, phenytoin, phenobarbital and carbamazepine efficacy in patients with newly diagnosed epilepsy with partial complex seizures. Epilepsia1997;38(Suppl 3):42. ">Czapinski 1997a</a>; <a href="./references#CD001769-bbs2-0008" title="RastogiP , MehrotraTN , AgarwalaRK , SinghVS . Comparison of sodium valproate and phenytoin as single drug treatment in generalised and partial epilepsy. Journal of the Association of Physicians of India1991;39(8):606‐8. ">Rastogi 1991</a>; <a href="./references#CD001769-bbs2-0009" title="ShakirRA , JohnsonRH , LambieDG , MelvilleID , NandaRN . Comparison of sodium valproate and phenytoin as single drug treatment in epilepsy. Epilepsia1981;22:27‐33. ">Shakir 1981</a>). </p> </section> </section> <section id="CD001769-sec-0065"> <h4 class="title">Incomplete outcome data</h4> <section id="CD001769-sec-0066"> <h5 class="title">(1) Trials for which IPD were provided</h5> <p>In theory, a review using IPD should overcome issues of attrition bias, as unpublished data can be provided, unpublished outcomes calculated and all randomised participants can be analysed by an intention‐to‐treat approach. All five trials reported attrition rates and provided IPD for all randomised individuals (<a href="./references#CD001769-bbs2-0002" title="CraigI , TallisR . Impact of valproate and phenytoin on cognitive function in elderly patients: results of a single‐blind randomized comparative study. Epilepsia1994;35(2):381‐90. ">Craig 1994</a>; <a href="./references#CD001769-bbs2-0004" title="DeSilvaM , MacArdleB , McGowanM , HughesE , StewartJ , NevilleBGR , et al. Randomised comparative monotherapy trial of phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed childhood epilepsy. Lancet1996;347:709‐13. ">De Silva 1996</a>; <a href="./references#CD001769-bbs2-0006" title="HellerAJ , ChestermanP , ElwesRD , CrawfordP , ChadwickDW , JohnsonAL , et al. Phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed adult epilepsy: a randomised comparative monotherapy trial. Journal of Neurology, Neurosurgery, and Psychiatry1995;58:44‐50. ">Heller 1995</a>; <a href="./references#CD001769-bbs2-0007" title="RamsayRE , WilderBJ , MurphyJV , HolmesGL , UthmanB , SlaterJ , et al. Efficacy and safety of valproic acid versus phenytoin as sole therapy for newly diagnosed primary generalized tonic‐clonic seizures. Journal of Epilepsy1992;5(1):55‐60. ">Ramsay 1992</a>; <a href="./references#CD001769-bbs2-0011" title="TurnbullDM , HowelD , RawlinsMD , ChadwickDW . Which drug for the adult epileptic patient: phenytoin or valproate?. BMJ1985;290:815‐9. ">Turnbull 1985</a>); we judged all five trials at low risk of attrition bias. </p> </section> <section id="CD001769-sec-0067"> <h5 class="title">(2) Trials for which no IPD were available</h5> <p>Four trials reported attrition rates and analysed all randomised participants using an intention‐to‐treat approach (<a href="./references#CD001769-bbs2-0001" title="CallaghanN , KennyRA , O'NeillB , CrowleyM , GogginT . A prospective study between carbamazepine, phenytoin and sodium valproate as monotherapy in previously untreated and recently diagnosed patients with epilepsy. Journal of Neurology, Neurosurgery and Psychiatry1985;48:639‐44. ">Callaghan 1985</a>; <a href="./references#CD001769-bbs2-0005" title="ForsytheI , ButlerR , BergI , McGuireR . Cognitive impairment in new cases of epilepsy randomly assigned to carbamazepine, phenytoin and sodium valproate. Developmental Medicine and Child Neurology1991;33:524‐34. ">Forsythe 1991</a>; <a href="./references#CD001769-bbs2-0009" title="ShakirRA , JohnsonRH , LambieDG , MelvilleID , NandaRN . Comparison of sodium valproate and phenytoin as single drug treatment in epilepsy. Epilepsia1981;22:27‐33. ">Shakir 1981</a>; <a href="./references#CD001769-bbs2-0010" title="ThilothammalN , BanuK , RatnamRS . Comparison of phenobarbitone, phenytoin with sodium valproate: randomized, double‐blind study. Indian Pediatrics1996;33:549‐55. ">Thilothammal 1996</a>); low risk of attrition bias. Two trials did not provide sufficient information to assess attrition bias (<a href="./references#CD001769-bbs2-0003" title="CzapinskiP , TerczynskiA , CzapinskaE . Randomised 36‐month comparative study of valproic acid, phenytoin, phenobarbital and carbamazepine efficacy in patients with newly diagnosed epilepsy with partial complex seizures. Epilepsia1997;38(Suppl 3):42. ">Czapinski 1997a</a>; <a href="./references#CD001769-bbs2-0008" title="RastogiP , MehrotraTN , AgarwalaRK , SinghVS . Comparison of sodium valproate and phenytoin as single drug treatment in generalised and partial epilepsy. Journal of the Association of Physicians of India1991;39(8):606‐8. ">Rastogi 1991</a>); unclear risk of attrition bias. </p> </section> </section> <section id="CD001769-sec-0068"> <h4 class="title">Selective reporting</h4> <p>The authors of <a href="./references#CD001769-bbs2-0002" title="CraigI , TallisR . Impact of valproate and phenytoin on cognitive function in elderly patients: results of a single‐blind randomized comparative study. Epilepsia1994;35(2):381‐90. ">Craig 1994</a> provided a protocol; the outcomes specified in the protocol were consistent with the outcomes reported in the publication, and we therefore judged the risk of selective reporting bias to be low. Protocols were not available for any of the other 10 included trials so we made a judgement of the risk of bias based on the information included in the publications (see <a href="./references#CD001769-sec-0114" title="">Characteristics of included studies</a> for more information). We judged eight of the other 10 studies at low risk of reporting bias; <a href="./references#CD001769-bbs2-0003" title="CzapinskiP , TerczynskiA , CzapinskaE . Randomised 36‐month comparative study of valproic acid, phenytoin, phenobarbital and carbamazepine efficacy in patients with newly diagnosed epilepsy with partial complex seizures. Epilepsia1997;38(Suppl 3):42. ">Czapinski 1997a</a> and <a href="./references#CD001769-bbs2-0005" title="ForsytheI , ButlerR , BergI , McGuireR . Cognitive impairment in new cases of epilepsy randomly assigned to carbamazepine, phenytoin and sodium valproate. Developmental Medicine and Child Neurology1991;33:524‐34. ">Forsythe 1991</a> were judged at unclear risk of reporting bias. </p> <section id="CD001769-sec-0069"> <h5 class="title">(1) Trials for which IPD were provided</h5> <p>In theory, a review using IPD should overcome issues of reporting biases, as unpublished data can be provided and unpublished outcomes calculated. Sufficient IPD were provided to calculate the four outcomes: 'time to treatment failure', 'time to achieve six‐month remission', 'time to achieve 12‐month remission' and 'time to first seizure' for four of the five trials (<a href="./references#CD001769-bbs2-0004" title="DeSilvaM , MacArdleB , McGowanM , HughesE , StewartJ , NevilleBGR , et al. Randomised comparative monotherapy trial of phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed childhood epilepsy. Lancet1996;347:709‐13. ">De Silva 1996</a>; <a href="./references#CD001769-bbs2-0006" title="HellerAJ , ChestermanP , ElwesRD , CrawfordP , ChadwickDW , JohnsonAL , et al. Phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed adult epilepsy: a randomised comparative monotherapy trial. Journal of Neurology, Neurosurgery, and Psychiatry1995;58:44‐50. ">Heller 1995</a>; <a href="./references#CD001769-bbs2-0007" title="RamsayRE , WilderBJ , MurphyJV , HolmesGL , UthmanB , SlaterJ , et al. Efficacy and safety of valproic acid versus phenytoin as sole therapy for newly diagnosed primary generalized tonic‐clonic seizures. Journal of Epilepsy1992;5(1):55‐60. ">Ramsay 1992</a>; <a href="./references#CD001769-bbs2-0011" title="TurnbullDM , HowelD , RawlinsMD , ChadwickDW . Which drug for the adult epileptic patient: phenytoin or valproate?. BMJ1985;290:815‐9. ">Turnbull 1985</a>). Treatment failure information was not provided for one trial (<a href="./references#CD001769-bbs2-0002" title="CraigI , TallisR . Impact of valproate and phenytoin on cognitive function in elderly patients: results of a single‐blind randomized comparative study. Epilepsia1994;35(2):381‐90. ">Craig 1994</a>), so we could not calculate 'time to treatment failure', but we had sufficient information to calculate the other three outcomes. </p> </section> <section id="CD001769-sec-0070"> <h5 class="title">(2) Trials for which no IPD were available</h5> <p>Seizure outcomes and adverse events were well reported in four trials (<a href="./references#CD001769-bbs2-0001" title="CallaghanN , KennyRA , O'NeillB , CrowleyM , GogginT . A prospective study between carbamazepine, phenytoin and sodium valproate as monotherapy in previously untreated and recently diagnosed patients with epilepsy. Journal of Neurology, Neurosurgery and Psychiatry1985;48:639‐44. ">Callaghan 1985</a>; <a href="./references#CD001769-bbs2-0008" title="RastogiP , MehrotraTN , AgarwalaRK , SinghVS . Comparison of sodium valproate and phenytoin as single drug treatment in generalised and partial epilepsy. Journal of the Association of Physicians of India1991;39(8):606‐8. ">Rastogi 1991</a>; <a href="./references#CD001769-bbs2-0009" title="ShakirRA , JohnsonRH , LambieDG , MelvilleID , NandaRN . Comparison of sodium valproate and phenytoin as single drug treatment in epilepsy. Epilepsia1981;22:27‐33. ">Shakir 1981</a>; <a href="./references#CD001769-bbs2-0010" title="ThilothammalN , BanuK , RatnamRS . Comparison of phenobarbitone, phenytoin with sodium valproate: randomized, double‐blind study. Indian Pediatrics1996;33:549‐55. ">Thilothammal 1996</a>); low risk of reporting bias. One trial reported cognitive outcomes and adverse events, but no seizure outcomes (<a href="./references#CD001769-bbs2-0005" title="ForsytheI , ButlerR , BergI , McGuireR . Cognitive impairment in new cases of epilepsy randomly assigned to carbamazepine, phenytoin and sodium valproate. Developmental Medicine and Child Neurology1991;33:524‐34. ">Forsythe 1991</a>); however as no protocol was available for this trial we do not know whether seizure outcomes were planned a priori, and we judged this trial at unclear risk of reporting bias. One trial was in abstract form only and did not provide sufficient information to assess selective reporting bias (<a href="./references#CD001769-bbs2-0003" title="CzapinskiP , TerczynskiA , CzapinskaE . Randomised 36‐month comparative study of valproic acid, phenytoin, phenobarbital and carbamazepine efficacy in patients with newly diagnosed epilepsy with partial complex seizures. Epilepsia1997;38(Suppl 3):42. ">Czapinski 1997a</a>); also judged at unclear risk of reporting bias. </p> </section> </section> <section id="CD001769-sec-0071"> <h4 class="title">Other potential sources of bias</h4> <p>We detected no other potential sources of bias in any of the 10 of the 11 trials included in the review, however limited information was available for <a href="./references#CD001769-bbs2-0003" title="CzapinskiP , TerczynskiA , CzapinskaE . Randomised 36‐month comparative study of valproic acid, phenytoin, phenobarbital and carbamazepine efficacy in patients with newly diagnosed epilepsy with partial complex seizures. Epilepsia1997;38(Suppl 3):42. ">Czapinski 1997a</a> which was only available as an abstract so we judged this trial to be at unclear risk of other bias. </p> </section> </section> <section id="CD001769-sec-0072"> <h3 class="title" id="CD001769-sec-0072">Effects of interventions</h3> <p>See: <a href="./full#CD001769-tbl-0001"><b>Summary of findings for the main comparison</b> Sodium valproate compared with phenytoin monotherapy for epilepsy (primary outcome)</a>; <a href="./full#CD001769-tbl-0002"><b>Summary of findings 2</b> Sodium valproate compared with phenytoin monotherapy for epilepsy (secondary outcomes)</a> </p> <p>A summary of the outcomes reported in trials for which no IPD were available are reported in <a href="#CD001769-tbl-0005">Table 3</a>. </p> <p>See <a href="#CD001769-tbl-0006">Table 4</a> for details regarding the number of individuals (with IPD) contributing to each analysis, <a href="./full#CD001769-tbl-0001">summary of findings Table for the main comparison</a> for a summary of the results for the primary outcome 'time to treatment failure' (stratified by epilepsy type), and <a href="./full#CD001769-tbl-0002">summary of findings Table 2</a> for a summary of results for the secondary outcomes 'time to first seizure' and 'time to 12‐month remission'. Survival curve plots are shown in <a href="#CD001769-fig-0004">Figure 4</a>; <a href="#CD001769-fig-0005">Figure 5</a>; <a href="#CD001769-fig-0006">Figure 6</a>; <a href="#CD001769-fig-0007">Figure 7</a>; <a href="#CD001769-fig-0008">Figure 8</a>; <a href="#CD001769-fig-0009">Figure 9</a>; <a href="#CD001769-fig-0010">Figure 10</a>; <a href="#CD001769-fig-0011">Figure 11</a>; <a href="#CD001769-fig-0012">Figure 12</a>; <a href="#CD001769-fig-0013">Figure 13</a>; <a href="#CD001769-fig-0014">Figure 14</a> and <a href="#CD001769-fig-0015">Figure 15</a> . All survival curve plots were produced in Stata software version 14 (<a href="./references#CD001769-bbs2-0091" title="StataCorp . Stata Statistical Software: Release 14. College Station, TX: StataCorp LP, 2015. ">Stata 2015</a>). using data from all trials providing IPD combined. </p> <div class="figure" id="CD001769-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Time to treatment failure ‐ any reason related to the treatment (PHT: phenytoin; SV: sodium valproate)" data-id="CD001769-fig-0004" src="/cdsr/doi/10.1002/14651858.CD001769.pub4/media/CDSR/CD001769/image_n/nCD001769-AFig-FIG04.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Time to treatment failure ‐ any reason related to the treatment (PHT: phenytoin; SV: sodium valproate) </p> </div> </div> </div> <div class="figure" id="CD001769-fig-0005"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 5</div> </div> <hr class="top"/><img alt="Time to treatment failure ‐ any reason related to the treatment, by epilepsy type (PHT: phenytoin; SV: sodium valproate)" data-id="CD001769-fig-0005" src="/cdsr/doi/10.1002/14651858.CD001769.pub4/media/CDSR/CD001769/image_n/nCD001769-AFig-FIG05.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Time to treatment failure ‐ any reason related to the treatment, by epilepsy type (PHT: phenytoin; SV: sodium valproate) </p> </div> </div> </div> <div class="figure" id="CD001769-fig-0006"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 6</div> </div> <hr class="top"/><img alt="Time to treatment failure due to adverse events (PHT: phenytoin; SV: sodium valproate)" data-id="CD001769-fig-0006" src="/cdsr/doi/10.1002/14651858.CD001769.pub4/media/CDSR/CD001769/image_n/nCD001769-AFig-FIG06.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Time to treatment failure due to adverse events (PHT: phenytoin; SV: sodium valproate)</p> </div> </div> </div> <div class="figure" id="CD001769-fig-0007"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 7</div> </div> <hr class="top"/><img alt="Time to treatment failure due to adverse events, by epilepsy type (PHT: phenytoin; SV: sodium valproate)" data-id="CD001769-fig-0007" src="/cdsr/doi/10.1002/14651858.CD001769.pub4/media/CDSR/CD001769/image_n/nCD001769-AFig-FIG07.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Time to treatment failure due to adverse events, by epilepsy type (PHT: phenytoin; SV: sodium valproate) </p> </div> </div> </div> <div class="figure" id="CD001769-fig-0008"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 8</div> </div> <hr class="top"/><img alt="Time to treatment failure due to lack of efficacy (PHT: phenytoin; SV: sodium valproate)" data-id="CD001769-fig-0008" src="/cdsr/doi/10.1002/14651858.CD001769.pub4/media/CDSR/CD001769/image_n/nCD001769-AFig-FIG08.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Time to treatment failure due to lack of efficacy (PHT: phenytoin; SV: sodium valproate)</p> </div> </div> </div> <div class="figure" id="CD001769-fig-0009"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 9</div> </div> <hr class="top"/><img alt="Time to treatment failure due to lack of efficacy, by epilepsy type (PHT: phenytoin; SV: sodium valproate)" data-id="CD001769-fig-0009" src="/cdsr/doi/10.1002/14651858.CD001769.pub4/media/CDSR/CD001769/image_n/nCD001769-AFig-FIG09.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Time to treatment failure due to lack of efficacy, by epilepsy type (PHT: phenytoin; SV: sodium valproate) </p> </div> </div> </div> <div class="figure" id="CD001769-fig-0010"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 10</div> </div> <hr class="top"/><img alt="Time to first seizure (PHT: phenytoin; SV: sodium valproate)" data-id="CD001769-fig-0010" src="/cdsr/doi/10.1002/14651858.CD001769.pub4/media/CDSR/CD001769/image_n/nCD001769-AFig-FIG10.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Time to first seizure (PHT: phenytoin; SV: sodium valproate)</p> </div> </div> </div> <div class="figure" id="CD001769-fig-0011"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 11</div> </div> <hr class="top"/><img alt="Time to first seizure ‐ by epilepsy type. (PHT: phenytoin; SV: sodium valproate)" data-id="CD001769-fig-0011" src="/cdsr/doi/10.1002/14651858.CD001769.pub4/media/CDSR/CD001769/image_n/nCD001769-AFig-FIG11.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Time to first seizure ‐ by epilepsy type. (PHT: phenytoin; SV: sodium valproate)</p> </div> </div> </div> <div class="figure" id="CD001769-fig-0012"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 12</div> </div> <hr class="top"/><img alt="Time to achieve 12‐month remission (PHT: phenytoin; SV: sodium valproate)" data-id="CD001769-fig-0012" src="/cdsr/doi/10.1002/14651858.CD001769.pub4/media/CDSR/CD001769/image_n/nCD001769-AFig-FIG12.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Time to achieve 12‐month remission (PHT: phenytoin; SV: sodium valproate)</p> </div> </div> </div> <div class="figure" id="CD001769-fig-0013"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 13</div> </div> <hr class="top"/><img alt="Time to achieve 12‐month remission ‐ by epilepsy type. (PHT: phenytoin; SV: sodium valproate)" data-id="CD001769-fig-0013" src="/cdsr/doi/10.1002/14651858.CD001769.pub4/media/CDSR/CD001769/image_n/nCD001769-AFig-FIG13.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Time to achieve 12‐month remission ‐ by epilepsy type. (PHT: phenytoin; SV: sodium valproate) </p> </div> </div> </div> <div class="figure" id="CD001769-fig-0014"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 14</div> </div> <hr class="top"/><img alt="Time to achieve six‐month remission (PHT: phenytoin; SV: sodium valproate)" data-id="CD001769-fig-0014" src="/cdsr/doi/10.1002/14651858.CD001769.pub4/media/CDSR/CD001769/image_n/nCD001769-AFig-FIG14.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Time to achieve six‐month remission (PHT: phenytoin; SV: sodium valproate)</p> </div> </div> </div> <div class="figure" id="CD001769-fig-0015"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 15</div> </div> <hr class="top"/><img alt="Time to achieve six‐month remission (PHT: phenytoin; SV: sodium valproate)" data-id="CD001769-fig-0015" src="/cdsr/doi/10.1002/14651858.CD001769.pub4/media/CDSR/CD001769/image_n/nCD001769-AFig-FIG15.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Time to achieve six‐month remission (PHT: phenytoin; SV: sodium valproate)</p> </div> </div> </div> <div class="table" id="CD001769-tbl-0006"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Number of individuals contributing to each analysis</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Trial</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>Number randomised</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>Time to treatment failure (for any reason related to treatment)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>Time to achieve 12‐month remission</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>Time to achieve 6‐month remission</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>Time to first seizure</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>PHT</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>SV</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Total</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>PHT</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>SV</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Total</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>PHT</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>SV</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Total</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>PHT</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>SV</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Total</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>PHT</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>SV</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Total</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001769-bbs2-0002" title="CraigI , TallisR . Impact of valproate and phenytoin on cognitive function in elderly patients: results of a single‐blind randomized comparative study. Epilepsia1994;35(2):381‐90. ">Craig 1994</a><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>81</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>85</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>166</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>71</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>76</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>147</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>71</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>76</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>147</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>71</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>76</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>147</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001769-bbs2-0004" title="DeSilvaM , MacArdleB , McGowanM , HughesE , StewartJ , NevilleBGR , et al. Randomised comparative monotherapy trial of phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed childhood epilepsy. Lancet1996;347:709‐13. ">De Silva 1996</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>54</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>49</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>103</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>53</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>47</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>54</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>49</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>103</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>54</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>49</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>103</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>54</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>49</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>103</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001769-bbs2-0005" title="ForsytheI , ButlerR , BergI , McGuireR . Cognitive impairment in new cases of epilepsy randomly assigned to carbamazepine, phenytoin and sodium valproate. Developmental Medicine and Child Neurology1991;33:524‐34. ">Forsythe 1991</a><sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001769-bbs2-0006" title="HellerAJ , ChestermanP , ElwesRD , CrawfordP , ChadwickDW , JohnsonAL , et al. Phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed adult epilepsy: a randomised comparative monotherapy trial. Journal of Neurology, Neurosurgery, and Psychiatry1995;58:44‐50. ">Heller 1995</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>63</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>61</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>124</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>61</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>58</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>119</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>63</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>61</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>124</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>63</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>61</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>124</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>63</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>61</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>124</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001769-bbs2-0007" title="RamsayRE , WilderBJ , MurphyJV , HolmesGL , UthmanB , SlaterJ , et al. Efficacy and safety of valproic acid versus phenytoin as sole therapy for newly diagnosed primary generalized tonic‐clonic seizures. Journal of Epilepsy1992;5(1):55‐60. ">Ramsay 1992</a><sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>86</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>136</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>86</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>136</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>77</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>125</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>77</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>125</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001769-bbs2-0011" title="TurnbullDM , HowelD , RawlinsMD , ChadwickDW . Which drug for the adult epileptic patient: phenytoin or valproate?. BMJ1985;290:815‐9. ">Turnbull 1985</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>140</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>140</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>140</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>140</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>140</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001769-bbs2-0009" title="ShakirRA , JohnsonRH , LambieDG , MelvilleID , NandaRN . Comparison of sodium valproate and phenytoin as single drug treatment in epilepsy. Epilepsia1981;22:27‐33. ">Shakir 1981</a><sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Total</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>353</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>390</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>743</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>269</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>300</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>569</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>258</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>256</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>514</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>306</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>333</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>639</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>306</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>333</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>639</b> </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><sup>a</sup>Treatment failure information not provided for <a href="./references#CD001769-bbs2-0002" title="CraigI , TallisR . Impact of valproate and phenytoin on cognitive function in elderly patients: results of a single‐blind randomized comparative study. Epilepsia1994;35(2):381‐90. ">Craig 1994</a>, so cannot contribute to 'time to treatment failure'.<br/> <sup>b</sup>Data extracted from <a href="./references#CD001769-bbs2-0005" title="ForsytheI , ButlerR , BergI , McGuireR . Cognitive impairment in new cases of epilepsy randomly assigned to carbamazepine, phenytoin and sodium valproate. Developmental Medicine and Child Neurology1991;33:524‐34. ">Forsythe 1991</a> and <a href="./references#CD001769-bbs2-0009" title="ShakirRA , JohnsonRH , LambieDG , MelvilleID , NandaRN . Comparison of sodium valproate and phenytoin as single drug treatment in epilepsy. Epilepsia1981;22:27‐33. ">Shakir 1981</a> publications to calculate time to treatment failure. Insufficient published data to calculate other outcomes.<br/> <sup>c</sup>Follow‐up for <a href="./references#CD001769-bbs2-0007" title="RamsayRE , WilderBJ , MurphyJV , HolmesGL , UthmanB , SlaterJ , et al. Efficacy and safety of valproic acid versus phenytoin as sole therapy for newly diagnosed primary generalized tonic‐clonic seizures. Journal of Epilepsy1992;5(1):55‐60. ">Ramsay 1992</a> is less than 12 months so cannot contribute to 'time to achieve 12‐month remission'. </p> <p>PHT: phenytoin; SV: sodium valproate.</p> </div> </div> <p>We note that participants with event times of zero (i.e. those who experienced treatment failure or experienced seizure recurrence on the day of randomisation) are not included in the 'numbers at risk' on the graphs and that data is not stratified by trial within these survival curve plots. All figures are intended to provide a visual representation of outcomes, extent of follow‐up and visual differences between seizure types. These graphs are not intended to show statistical significance and numerical values may vary compared to the text due to differences in methodology. </p> <p>We calculated all HRs presented below by generic inverse variance fixed‐effect meta‐analysis unless otherwise stated. All analyses met the assumption of proportional hazards (the addition of a time‐varying covariate into the model was non‐significant). </p> <section id="CD001769-sec-0073"> <h4 class="title">Primary outcome</h4> <section id="CD001769-sec-0074"> <h5 class="title">Time to treatment failure (retention time)</h5> <p>For this outcome, a HR less than one indicates a clinical advantage for valproate.</p> <p>Time to treatment failure and reason for treatment withdrawal or treatment failure were available for 495 individuals from four trials (<a href="./references#CD001769-bbs2-0004" title="DeSilvaM , MacArdleB , McGowanM , HughesE , StewartJ , NevilleBGR , et al. Randomised comparative monotherapy trial of phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed childhood epilepsy. Lancet1996;347:709‐13. ">De Silva 1996</a>; <a href="./references#CD001769-bbs2-0006" title="HellerAJ , ChestermanP , ElwesRD , CrawfordP , ChadwickDW , JohnsonAL , et al. Phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed adult epilepsy: a randomised comparative monotherapy trial. Journal of Neurology, Neurosurgery, and Psychiatry1995;58:44‐50. ">Heller 1995</a>; <a href="./references#CD001769-bbs2-0007" title="RamsayRE , WilderBJ , MurphyJV , HolmesGL , UthmanB , SlaterJ , et al. Efficacy and safety of valproic acid versus phenytoin as sole therapy for newly diagnosed primary generalized tonic‐clonic seizures. Journal of Epilepsy1992;5(1):55‐60. ">Ramsay 1992</a>; <a href="./references#CD001769-bbs2-0011" title="TurnbullDM , HowelD , RawlinsMD , ChadwickDW . Which drug for the adult epileptic patient: phenytoin or valproate?. BMJ1985;290:815‐9. ">Turnbull 1985</a>); 74% of individuals from five trials providing IPD (44% of all 1119 eligible individuals). Treatment failure data were not available for the fifth trial (<a href="./references#CD001769-bbs2-0002" title="CraigI , TallisR . Impact of valproate and phenytoin on cognitive function in elderly patients: results of a single‐blind randomized comparative study. Epilepsia1994;35(2):381‐90. ">Craig 1994</a>). Sufficient IPD were available in the trial publications for a further 74 individuals from two trials (<a href="./references#CD001769-bbs2-0005" title="ForsytheI , ButlerR , BergI , McGuireR . Cognitive impairment in new cases of epilepsy randomly assigned to carbamazepine, phenytoin and sodium valproate. Developmental Medicine and Child Neurology1991;33:524‐34. ">Forsythe 1991</a>; <a href="./references#CD001769-bbs2-0009" title="ShakirRA , JohnsonRH , LambieDG , MelvilleID , NandaRN . Comparison of sodium valproate and phenytoin as single drug treatment in epilepsy. Epilepsia1981;22:27‐33. ">Shakir 1981</a>). Therefore, a total of 569 individuals (51% of 1119 eligible individuals) from six trials could contribute to the analysis of this outcome. </p> <p>Reasons for premature discontinuation of treatment (treatment failure) were provided for 571 participants in the six trials (reasons for treatment failure but no date of treatment failure provided for two participants). See <a href="#CD001769-tbl-0007">Table 5</a> for reasons for premature termination of the study by treatment and how we classified these reasons in analysis. </p> <div class="table" id="CD001769-tbl-0007"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Reasons for premature discontinuation (treatment failure)</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Reason for early termination</b> </p> <p><b>(and classification in time‐to‐event analysis)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><a href="./references#CD001769-bbs2-0004" title="DeSilvaM , MacArdleB , McGowanM , HughesE , StewartJ , NevilleBGR , et al. Randomised comparative monotherapy trial of phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed childhood epilepsy. Lancet1996;347:709‐13. ">De Silva 1996</a><b><sup>b</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><a href="./references#CD001769-bbs2-0006" title="HellerAJ , ChestermanP , ElwesRD , CrawfordP , ChadwickDW , JohnsonAL , et al. Phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed adult epilepsy: a randomised comparative monotherapy trial. Journal of Neurology, Neurosurgery, and Psychiatry1995;58:44‐50. ">Heller 1995</a><b><sup>b, c</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><a href="./references#CD001769-bbs2-0007" title="RamsayRE , WilderBJ , MurphyJV , HolmesGL , UthmanB , SlaterJ , et al. Efficacy and safety of valproic acid versus phenytoin as sole therapy for newly diagnosed primary generalized tonic‐clonic seizures. Journal of Epilepsy1992;5(1):55‐60. "><b>Ramsay 1992</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><a href="./references#CD001769-bbs2-0011" title="TurnbullDM , HowelD , RawlinsMD , ChadwickDW . Which drug for the adult epileptic patient: phenytoin or valproate?. BMJ1985;290:815‐9. "><b>Turnbull 1985</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><a href="./references#CD001769-bbs2-0005" title="ForsytheI , ButlerR , BergI , McGuireR . Cognitive impairment in new cases of epilepsy randomly assigned to carbamazepine, phenytoin and sodium valproate. Developmental Medicine and Child Neurology1991;33:524‐34. "><b>Forsythe 1991</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><a href="./references#CD001769-bbs2-0009" title="ShakirRA , JohnsonRH , LambieDG , MelvilleID , NandaRN . Comparison of sodium valproate and phenytoin as single drug treatment in epilepsy. Epilepsia1981;22:27‐33. ">Shakir 1981</a><b><sup>d</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Total<sup>a</sup> </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>SV</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>PHT</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>SV</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>PHT</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>SV</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>PHT</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>SV</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>PHT</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>SV</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>PHT</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>SV</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>PHT</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>SV</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>PHT</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>All</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse events (event)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>42</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lack of efficacy (event)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>54</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Both adverse events and lack of efficacy (event)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Non‐compliance/protocol violation (event)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Illness or death (not treatment‐related, censored)<sup>e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participant went into remission (censored)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>67</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lost to follow‐up (censored)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>27</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Other (censored)<sup>f</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Completed the study (censored)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>49</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>178</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>150</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>328</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Total</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>47</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>53</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>58</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>63</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>86</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>50</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>70</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>70</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>21</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>20</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>18</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>15</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>300</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>271</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>571</b> </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>PHT: phenytoin; SV: sodium valproate<br/> <sup>a</sup>IPD for 'time to treatment failure' was not provided for <a href="./references#CD001769-bbs2-0002" title="CraigI , TallisR . Impact of valproate and phenytoin on cognitive function in elderly patients: results of a single‐blind randomized comparative study. Epilepsia1994;35(2):381‐90. ">Craig 1994</a>.<br/> <sup>b</sup>Three participants for <a href="./references#CD001769-bbs2-0006" title="HellerAJ , ChestermanP , ElwesRD , CrawfordP , ChadwickDW , JohnsonAL , et al. Phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed adult epilepsy: a randomised comparative monotherapy trial. Journal of Neurology, Neurosurgery, and Psychiatry1995;58:44‐50. ">Heller 1995</a> (all SV) and three for <a href="./references#CD001769-bbs2-0004" title="DeSilvaM , MacArdleB , McGowanM , HughesE , StewartJ , NevilleBGR , et al. Randomised comparative monotherapy trial of phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed childhood epilepsy. Lancet1996;347:709‐13. ">De Silva 1996</a> (one PHT and two SV) have missing reasons for treatment failure.<br/> <sup>c</sup>Four participants from <a href="./references#CD001769-bbs2-0006" title="HellerAJ , ChestermanP , ElwesRD , CrawfordP , ChadwickDW , JohnsonAL , et al. Phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed adult epilepsy: a randomised comparative monotherapy trial. Journal of Neurology, Neurosurgery, and Psychiatry1995;58:44‐50. ">Heller 1995</a> had missing treatment failure times and did not contribute to analysis but reasons for treatment failure are given.<br/> <sup>d</sup>Nine participants in <a href="./references#CD001769-bbs2-0009" title="ShakirRA , JohnsonRH , LambieDG , MelvilleID , NandaRN . Comparison of sodium valproate and phenytoin as single drug treatment in epilepsy. Epilepsia1981;22:27‐33. ">Shakir 1981</a> were listed as having started on a second drug due to 'failure to respond.' This reason was classified as treatment failure due to lack of efficacy.<br/> <sup>e</sup>Death due to reasons not related to the study drug.<br/> <sup>f</sup>Other reasons from <a href="./references#CD001769-bbs2-0007" title="RamsayRE , WilderBJ , MurphyJV , HolmesGL , UthmanB , SlaterJ , et al. Efficacy and safety of valproic acid versus phenytoin as sole therapy for newly diagnosed primary generalized tonic‐clonic seizures. Journal of Epilepsy1992;5(1):55‐60. ">Ramsay 1992</a> – two participants withdrew due to pregnancy and one for personal reasons. </p> </div> </div> <p>Out of 571 participants for whom we had reasons for treatment failure or withdrawal, 243 participants prematurely withdrew from treatment (43%): 122 out of 300 (41%) participants randomised to valproate and 121 out of 271 (45%) participants randomised to phenytoin. </p> <p>We deemed 138 participants (57% of total treatment failures) to have withdrawn for reasons related to the allocated drug: 69 (57% of treatment failures) on valproate and 69 (57% of treatment failures) on phenytoin and we classified these reasons as 'events' in the analysis. The most common treatment‐related reasons for treatment failure were lack of efficacy: 54 withdrawals (22% of total treatment failures), 28 (23% of total treatment failures) on valproate and 26 (21% of total treatment failures) on phenytoin; and adverse events: 42 withdrawals (17% of total treatment failures), 16 (13% of total treatment failures) on valproate and 26 (21% of total treatment failures) on phenytoin. </p> <p>We classed the other 105 reasons (53 on valproate and 52 on phenytoin), which were mostly withdrawal from treatment due to seizure remission (64% of other withdrawals), to be not related to the treatment and censored these participants in the analysis, in addition to the 328 participants (178 on valproate and 150 on carbamazepine) who completed the trial without withdrawing or failing treatment. </p> <p>Considering time to treatment failure for any reason related to the treatment, the overall pooled HR (for 569 participants providing IPD from 6 trials) was 0.94 (95% confidence interval (CI) 0.67 to 1.32, P = 0.17; moderate‐quality evidence) indicating no clear advantage for either drug (<a href="./references#CD001769-fig-0016" title="">Analysis 1.1</a>). No important heterogeneity was present between trials (I<sup>2</sup>= 15%). </p> <p>Considering time to treatment failure due to adverse events (all other reasons for treatment failure or treatment withdrawal censored in analysis), 495 participants provided IPD from four trials; no participants withdrew from one or both of the drugs due to lack of efficacy in two of the trials (<a href="./references#CD001769-bbs2-0005" title="ForsytheI , ButlerR , BergI , McGuireR . Cognitive impairment in new cases of epilepsy randomly assigned to carbamazepine, phenytoin and sodium valproate. Developmental Medicine and Child Neurology1991;33:524‐34. ">Forsythe 1991</a>; <a href="./references#CD001769-bbs2-0009" title="ShakirRA , JohnsonRH , LambieDG , MelvilleID , NandaRN . Comparison of sodium valproate and phenytoin as single drug treatment in epilepsy. Epilepsia1981;22:27‐33. ">Shakir 1981</a>, see <a href="#CD001769-tbl-0007">Table 5</a>). The overall pooled HR was 0.68 (95% CI 0.40 to 1.17, P = 0.16; moderate‐quality evidence) which suggests a slight advantage towards valproate (i.e. a suggestion that treatment failures due to adverse events may occur later on valproate than on phenytoin), but this is not statistically significant (<a href="./references#CD001769-fig-0017" title="">Analysis 1.2</a>). A substantial amount of heterogeneity was present between trials (I<sup>2</sup>= 67%) and when analysis is repeated with random‐effects, the CIs of the pooled HR are substantially wider 0.75 (95% CI 0.28 to 1.98). This heterogeneity is investigated further in subgroup analysis by epilepsy type below. </p> <p>Considering time to treatment failure due to lack of efficacy (all other reasons for treatment failure or treatment withdrawal censored in analysis), the overall pooled HR (for 569 participants providing IPD from 6 trials) was 1.23 (95% CI 0.77 to 1.97, P = 0.38; moderate‐quality evidence) which suggests a slight advantage towards phenytoin (i.e. a suggestion that treatment failures due to lack of efficacy may occur later on phenytoin than on valproate), but this is not statistically significant (<a href="./references#CD001769-fig-0018" title="">Analysis 1.3</a>). No heterogeneity was present between trials (I<sup>2</sup>= 0%). </p> <section id="CD001769-sec-0075"> <h6 class="title">Subgroup analyses: epilepsy type (focal versus generalised onset)</h6> <p>Treatment failure data for 41 participants extracted from <a href="./references#CD001769-bbs2-0005" title="ForsytheI , ButlerR , BergI , McGuireR . Cognitive impairment in new cases of epilepsy randomly assigned to carbamazepine, phenytoin and sodium valproate. Developmental Medicine and Child Neurology1991;33:524‐34. ">Forsythe 1991</a> did not distinguish between epilepsy type (focal onset or generalised onset) and therefore could not be included in the meta‐analysis stratified by epilepsy type. </p> <p>Considering time to treatment failure for any reason related to the treatment, the overall pooled HR (adjusted by epilepsy type for 528 participants from 5 trials) was 0.88 (95% CI 0.61 to 1.27, P = 0.51, I<sup>2</sup>= 29%; moderate‐quality evidence; <a href="./references#CD001769-fig-0019" title="">Analysis 1.4</a>). This result is similar to the unadjusted pooled HR (<a href="./references#CD001769-fig-0016" title="">Analysis 1.1</a>), and conclusions remain unchanged following the exclusion of 41 individuals in the stratified analysis (<a href="./references#CD001769-bbs2-0005" title="ForsytheI , ButlerR , BergI , McGuireR . Cognitive impairment in new cases of epilepsy randomly assigned to carbamazepine, phenytoin and sodium valproate. Developmental Medicine and Child Neurology1991;33:524‐34. ">Forsythe 1991</a>). </p> <p>For individuals with generalised onset seizures (341 participants from 5 trials), the pooled HR was 0.94 (95% CI 0.55 to 1.61, P = 0.82, I² = 59%; low‐quality evidence), indicating no clear advantage for either drug. For individuals with focal onset seizures (187 participants from 4 trials), the pooled HR was 0.83 (95% CI 0.50 to 1.38, P = 0.48, I² = 0%; moderate‐quality evidence), suggesting a slight advantage for valproate which is not statistically significant. There was no evidence of an interaction between epilepsy type (focal onset versus generalised onset) and treatment effect (Chi² = 0.10, df = 1, P = 0.75, I² = 0%; <a href="./references#CD001769-fig-0019" title="">Analysis 1.4</a>). </p> <p>A large amount of heterogeneity was present between trials within the generalised onset seizure subgroup (I² = 59%) and when analysis is repeated with random‐effects, the CIs of the pooled HR become much wider: 0.93 (95% CI 0.37 to 231). On visual inspection of the forest plot (see <a href="./references#CD001769-fig-0019" title="">Analysis 1.4</a>), one trial appears to be the source of this variability (<a href="./references#CD001769-bbs2-0006" title="HellerAJ , ChestermanP , ElwesRD , CrawfordP , ChadwickDW , JohnsonAL , et al. Phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed adult epilepsy: a randomised comparative monotherapy trial. Journal of Neurology, Neurosurgery, and Psychiatry1995;58:44‐50. ">Heller 1995</a>), as this trial shows a large statistically significant treatment effect in favour of phenytoin, while the other four trials show general non‐significant results, mostly in favour of valproate (<a href="./references#CD001769-bbs2-0004" title="DeSilvaM , MacArdleB , McGowanM , HughesE , StewartJ , NevilleBGR , et al. Randomised comparative monotherapy trial of phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed childhood epilepsy. Lancet1996;347:709‐13. ">De Silva 1996</a>; <a href="./references#CD001769-bbs2-0007" title="RamsayRE , WilderBJ , MurphyJV , HolmesGL , UthmanB , SlaterJ , et al. Efficacy and safety of valproic acid versus phenytoin as sole therapy for newly diagnosed primary generalized tonic‐clonic seizures. Journal of Epilepsy1992;5(1):55‐60. ">Ramsay 1992</a>; <a href="./references#CD001769-bbs2-0009" title="ShakirRA , JohnsonRH , LambieDG , MelvilleID , NandaRN . Comparison of sodium valproate and phenytoin as single drug treatment in epilepsy. Epilepsia1981;22:27‐33. ">Shakir 1981</a>; <a href="./references#CD001769-bbs2-0011" title="TurnbullDM , HowelD , RawlinsMD , ChadwickDW . Which drug for the adult epileptic patient: phenytoin or valproate?. BMJ1985;290:815‐9. ">Turnbull 1985</a>). Additionally, this heterogeneity may be due to misclassification of epilepsy type (specifically where generalised onset seizures have been incorrectly classified); this is investigated further in sensitivity analysis below. </p> <p>Considering time to treatment failure due to adverse events, no individuals withdrew from either drug due to adverse events in <a href="./references#CD001769-bbs2-0009" title="ShakirRA , JohnsonRH , LambieDG , MelvilleID , NandaRN . Comparison of sodium valproate and phenytoin as single drug treatment in epilepsy. Epilepsia1981;22:27‐33. ">Shakir 1981</a> so this trial is not included in this analysis and no individuals with generalised onset seizures withdrew from valproate due to adverse events in <a href="./references#CD001769-bbs2-0011" title="TurnbullDM , HowelD , RawlinsMD , ChadwickDW . Which drug for the adult epileptic patient: phenytoin or valproate?. BMJ1985;290:815‐9. ">Turnbull 1985</a> so this epilepsy type subgroup was not included in this analysis. The overall pooled HR (adjusted by epilepsy type for 418 participants from 4 trials) was 0.77 (95% CI 0.44 to 1.37, P = 0.38, I<sup>2</sup>=37%; moderate‐quality evidence; <a href="./references#CD001769-fig-0020" title="">Analysis 1.5</a>). This result is similar to the unadjusted pooled HR (<a href="./references#CD001769-fig-0017" title="">Analysis 1.2</a>), and conclusions remain unchanged following the exclusion of participants from <a href="./references#CD001769-bbs2-0009" title="ShakirRA , JohnsonRH , LambieDG , MelvilleID , NandaRN . Comparison of sodium valproate and phenytoin as single drug treatment in epilepsy. Epilepsia1981;22:27‐33. ">Shakir 1981</a> and <a href="./references#CD001769-bbs2-0011" title="TurnbullDM , HowelD , RawlinsMD , ChadwickDW . Which drug for the adult epileptic patient: phenytoin or valproate?. BMJ1985;290:815‐9. ">Turnbull 1985</a>. </p> <p>For individuals with generalised onset seizures (250 participants from 3 trials), the pooled HR was 0.75 (95% CI 0.35 to 1.60, P = 0.46, I² = 71%; low‐quality evidence), suggesting a slight advantage for valproate which is not statistically significant. For individuals with focal onset seizures (168 participants from 3 trials), the pooled HR was 0.81 (95% CI 0.34 to 1.90, P = 0.62, I² = 0%; moderate‐quality evidence), again suggesting a slight advantage for valproate which is not statistically significant. There was no evidence of an interaction between epilepsy type (focal onset versus generalised onset) and treatment effect (Chi² = 0.02, df = 1, P = 0.90, I² = 0%; <a href="./references#CD001769-fig-0020" title="">Analysis 1.5</a>). </p> <p>Again, a large amount of heterogeneity was present between trials within the generalised onset seizure subgroup (I² = 71%), and when analysis is repeated with random‐effects, the CIs of the pooled HR are substantially wider 1.15 (95% CI 0.21 to 6.23). This variability may also originate from fairly small numbers of individuals with generalised seizures failing treatment due to adverse events (see <a href="#CD001769-tbl-0007">Table 5</a>), or similarly to the analysis of 'time to treatment failure' for any reason related to treatment, this may be due to potential misclassification of epilepsy type; this is investigated further in sensitivity analysis below. </p> <p>Considering time to treatment failure due to lack of efficacy, no individuals with generalised onset seizures withdrew from either drug due to lack of efficacy in <a href="./references#CD001769-bbs2-0011" title="TurnbullDM , HowelD , RawlinsMD , ChadwickDW . Which drug for the adult epileptic patient: phenytoin or valproate?. BMJ1985;290:815‐9. ">Turnbull 1985</a> so this epilepsy type subgroup was not included in this analysis. The overall pooled HR (adjusted by epilepsy type for 451 participants from 5 trials) was 1.16 (95% CI 0.71 to 1.89, P = 0.55, I<sup>2</sup>=0%; moderate‐quality evidence; <a href="./references#CD001769-fig-0021" title="">Analysis 1.6</a>). This result is similar to the unadjusted pooled HR (<a href="./references#CD001769-fig-0018" title="">Analysis 1.3</a>), and conclusions remain unchanged following the exclusion of participants from <a href="./references#CD001769-bbs2-0011" title="TurnbullDM , HowelD , RawlinsMD , ChadwickDW . Which drug for the adult epileptic patient: phenytoin or valproate?. BMJ1985;290:815‐9. ">Turnbull 1985</a>. </p> <p>For individuals with generalised onset seizures (264 participants from 4 trials), the pooled HR was 1.51 (95% CI 0.66 to 3.45, P = 0.33, I² = 23%; low‐quality evidence), suggesting a slight advantage for phenytoin which is not statistically significant. For individuals with focal onset seizures (187 participants from 4 trials), the pooled HR was 1.01 (95% CI 0.55 to 1.85, P = 0.98, I² = 0%; moderate‐quality evidence), indicating no clear advantage for either drug. There was no evidence of an interaction between epilepsy type (focal onset versus generalised onset) and treatment effect (Chi² = 0.60, df = 1, P = 0.44, I² = 0%; <a href="./references#CD001769-fig-0021" title="">Analysis 1.6</a>). No important heterogeneity was present in overall analysis or within epilepsy type subgroups (I<sup>2</sup> &lt; 25% for all analyses). </p> </section> <section id="CD001769-sec-0076"> <h6 class="title">Sensitivity analysis</h6> <p>Sensitivity analyses were conducted to investigate misclassification of seizure type, reclassifying up to 100 individuals from four trials (<a href="./references#CD001769-bbs2-0006" title="HellerAJ , ChestermanP , ElwesRD , CrawfordP , ChadwickDW , JohnsonAL , et al. Phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed adult epilepsy: a randomised comparative monotherapy trial. Journal of Neurology, Neurosurgery, and Psychiatry1995;58:44‐50. ">Heller 1995</a>; <a href="./references#CD001769-bbs2-0007" title="RamsayRE , WilderBJ , MurphyJV , HolmesGL , UthmanB , SlaterJ , et al. Efficacy and safety of valproic acid versus phenytoin as sole therapy for newly diagnosed primary generalized tonic‐clonic seizures. Journal of Epilepsy1992;5(1):55‐60. ">Ramsay 1992</a>; <a href="./references#CD001769-bbs2-0009" title="ShakirRA , JohnsonRH , LambieDG , MelvilleID , NandaRN . Comparison of sodium valproate and phenytoin as single drug treatment in epilepsy. Epilepsia1981;22:27‐33. ">Shakir 1981</a>; <a href="./references#CD001769-bbs2-0011" title="TurnbullDM , HowelD , RawlinsMD , ChadwickDW . Which drug for the adult epileptic patient: phenytoin or valproate?. BMJ1985;290:815‐9. ">Turnbull 1985</a>) aged 30 or older with new onset generalised seizures to focal onset seizures or an uncertain seizure type. The results of the two sensitivity analyses are shown in <a href="#CD001769-tbl-0008">Table 6</a>. </p> <div class="table" id="CD001769-tbl-0008"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 6.</span> <span class="table-title">Sensitivity analysis ‐ epilepsy type misclassification</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Outcome</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Original analysis</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Generalised onset and age at onset &gt; 30 years</b> </p> <p><b>classified as focal onset</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Generalised onset and age at onset &gt; 30 years</b> </p> <p><b>classified as uncertain seizure type</b> </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Pooled HR (95% CI)</b> </p> <p><b>fixed‐effects</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Test of subgroup</b> </p> <p><b>differences</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Pooled HR (95% CI)</b> </p> <p><b>fixed‐effects</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Test of subgroup</b> </p> <p><b>differences</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Pooled HR (95% CI)</b> </p> <p><b>fixed‐effects</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Test of subgroup</b> </p> <p><b>differences</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Time to treatment failure</p> <p>(for any reason related to treatment)<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>F: 0.83 (0.50 to 1.38)</p> <p>G: 0.94 (0.55 to 1.61)</p> <p>O: 0.88 (0.61 to 1.27)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Chi² = 0.10, df = 1</p> <p>(P = 0.75), I² = 0%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>F: 0.95 (0.59 to 1.52)</p> <p>G: 0.77 (0.42 to 1.41)</p> <p>O: 0.88 (0.60 to 1.27)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Chi² = 0.29, df = 1</p> <p>(P = 0.59), I² = 0%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>F: 0.83 (0.50 to 1.38)</p> <p>G: 0.77 (0.42 to 1.41)</p> <p>U: 6.83 (0.82 to 57.16)</p> <p>O: 0.86 (0.59 to 1.27)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Chi² = 3.80, df = 2</p> <p>(P = 0.15), I² = 47.3%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Time to treatment failure due to adverse events<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>F: 0.75 (0.35 to 1.60)</p> <p>G: 0.81 (0.34 to 1.90)</p> <p>O: 0.77 (0.44 to 1.37)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Chi² = 0.02, df = 1</p> <p>(P = 0.90), I² = 0%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>F: 0.87 (0.42 to 1.80)</p> <p>G: 0.64 (0.26 to 1.59)</p> <p>O: 0.77 (0.44 to 1.36)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Chi² = 0.26, df = 1</p> <p>(P = 0.61), I² = 0%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not calculated<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not calculated<sup>b</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Time to treatment failure due to lack of efficacy<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>F: 1.01 (0.55 to 1.85)</p> <p>G: 1.51 (0.66 to 3.45)</p> <p>O: 1.16 (0.71 to 1.89)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Chi² = 0.60, df = 1</p> <p>(P = 0.44), I² = 0%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>F: 1.00 (0.51 to 1.96)</p> <p>G: 1.73 (0.56 to 5.35)</p> <p>O: 1.16 (0.65 to 2.06)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Chi² = 0.66, df = 1</p> <p>(P = 0.42), I² = 0%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not calculated<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not calculated<sup>b</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Time to first seizure<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>F: 1.20 (0.90 to 1.60)</p> <p>G: 0.97 (0.72 to 1.30)</p> <p>O: 1.08 (0.88 to 1.33)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Chi² = 1.06, df = 1</p> <p>(P = 0.30), I² = 5.6%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>F: 1.23 (0.96 to 1.57)</p> <p>G: 0.72 (0.50 to 1.05)</p> <p>O: 1.05 (0.86 to 1.29)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Chi² = 5.46, df = 1</p> <p>(P = 0.02), I² = 81.7%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>F: 1.20 (0.90 to 1.60)</p> <p>G: 0.72 (0.50 to 1.05)</p> <p>U: 1.35 (0.85 to 2.14)</p> <p>O: 1.06 (0.86 to 1.30)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Chi² = 5.79, df = 2</p> <p>(P = 0.06), I² = 65.5%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Time to 12‐month remission<sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>F: 1.11 (0.78 to 1.60)</p> <p>G: 0.96 (0.71 to 1.29)</p> <p>O: 1.02 (0.81 to 1.28)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Chi² = 0.39, df = 1</p> <p>(P = 0.53), I² = 0%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>F: 0.99 (0.75 to 1.32)</p> <p>G: 1.07 (0.72 to 1.59)</p> <p>O: 1.02 (0.81 to 1.28)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Chi² = 0.10, df = 1</p> <p>(P = 0.75), I² = 0%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>F: 1.11 (0.78 to 1.60)</p> <p>G: 1.07 (0.72 to 1.59)</p> <p>U: 0.74 (0.46 to 1.18)</p> <p>O: 0.99 (0.79 to 1.25)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Chi² = 2.07, df = 2</p> <p>(P = 0.36), I² = 3.3%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Time to 6‐month remission<sup>e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>F: 1.00 (0.73 to 1.35)</p> <p>G: 1.08 (0.84 to 1.38)</p> <p>O: 1.05 (0.86 to 1.27)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Chi² = 0.16, df = 1</p> <p>(P = 0.69), I² = 0%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>F: 1.00 (0.79 to 1.26)</p> <p>G: 1.14 (0.80 to 1.61)</p> <p>O: 1.04 (0.85 to 1.26)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Chi² = 0.38, df = 1</p> <p>(P = 0.54), I² = 0%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>F: 1.00 (0.73 to 1.35)</p> <p>G: 1.14 (0.80 to 1.61)</p> <p>U: 0.90 (0.62 to 1.31)</p> <p>O: 1.01 (0.83 to 1.23)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Chi² = 0.80, df = 2</p> <p>(P = 0.67), I² = 0%</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>Chi²: Chi² statistic; df: degrees of freedom of Chi² distribution; F: focal epilepsy; G: generalised epilepsy; O: overall (all participants); U: uncertain epilepsy; P: P value (&lt; 0.05 are classified as statistically significant). </p> <p><sup>a</sup>100 participants reclassified to focal epilepsy or uncertain epilepsy type for outcome 'time to treatment failure (for any reason related to treatment)'; see <a href="./references#CD001769-fig-0019" title="">Analysis 1.4</a> for original analysis.<br/> <sup>b</sup>100 participants reclassified to focal epilepsy or uncertain epilepsy type for outcomes 'time to treatment failure due to adverse events' and 'time to treatment failure due to lack of efficacy'; see <a href="./references#CD001769-fig-0020" title="">Analysis 1.5</a> and <a href="./references#CD001769-fig-0021" title="">Analysis 1.6</a> for original analyses. Forest plots not presented for sensitivity analysis for generalised and age at onset &gt; 30 years reclassified as focal epilepsy as results were numerically similar and conclusions are unchanged. Sensitivity analysis for generalised and age at onset &gt; 30 years reclassified as uncertain epilepsy type not performed due to small numbers of participants failing treatment for these reasons in the uncertain epilepsy type groups in each trial.<br/> <sup>c</sup>171 participants reclassified to focal epilepsy or uncertain epilepsy type for outcome 'time to first seizure'; see <a href="./references#CD001769-fig-0023" title="">Analysis 1.8</a> for original analysis and see <a href="./references#CD001769-fig-0025" title="">Analysis 1.10</a> and <a href="./references#CD001769-fig-0024" title="">Analysis 1.9</a> for forest plots of 'time to first seizure' sensitivity analyses for generalised and age at onset &gt; 30 years reclassified as focal epilepsy and uncertain epilepsy type, respectively.<br/> <sup>d</sup>145 participants reclassified to focal epilepsy or uncertain epilepsy type for outcome 'time to achieve 12‐month remission', see <a href="./references#CD001769-fig-0027" title="">Analysis 1.12</a> for original analysis. As results were numerically similar and conclusions are unchanged, forest plots are not presented.<br/> <sup>e</sup>171 participants reclassified to focal epilepsy or uncertain epilepsy type for outcome 'time to achieve 6‐month remission', see <a href="./references#CD001769-fig-0029" title="">Analysis 1.14</a> for original analysis. As results were numerically similar and conclusions are unchanged, forest plots are not presented. </p> </div> </div> <p>For all three treatment failure outcomes: time to treatment failure for any reason related to treatment; due to adverse events; and due to lack of efficacy, sensitivity analyses in which individuals classified as experiencing generalised onset seizures and age at onset &gt; 30 years reclassified as experiencing focal onset seizures, show numerically similar results and conclusions remain unchanged. There was no evidence of an association between epilepsy type and treatment effect following reclassification for any of the treatment failure outcomes </p> <p>Sensitivity analysis in which individuals classified as experiencing generalised onset seizures and age at onset &gt; 30 years were reclassified as experiencing uncertain seizure type was performed only for time to treatment failure for any reason related to treatment. </p> <p>In the sensitivity analysis of 'time to treatment failure for any reason related to treatment' in which individuals classified as experiencing generalised onset seizures and age at onset &gt; 30 years were reclassified as uncertain seizure type, a large, but non‐significant advantage for phenytoin was shown in the uncertain seizure type group: (pooled HR 6.83, 0.82 to 57.16), which was substantially different in the direction of effect from estimates for the 'focal onset seizures' subgroup (pooled HR 0.83, 95% CI 0.50 to 1.38), and 'generalised onset seizures' groups (pooled HR 0.77, 95% CI 0.42 to 1.41), both indicating a non‐significant advantage for valproate. There was, however, still no evidence of an association between epilepsy type and treatment effect in this analysis (Chi² = 3.80, df = 2; (P = 0.15), I² = 47.3%) and the result within the uncertain seizure type group should be interpreted with caution due to relatively small numbers of individuals with uncertain seizure types failing treatment in each trial. </p> <p>The sensitivity analysis could not be performed for 'time to treatment failure due to adverse events' or 'due to lack of efficacy' due to very small numbers of participants failing treatment for these reasons in the uncertain epilepsy type groups in each trial. </p> <p>Heterogeneity present within analyses for individuals with generalised onset seizures (see <a href="./references#CD001769-fig-0019" title="">Analysis 1.4</a> and <a href="./references#CD001769-fig-0020" title="">Analysis 1.5</a>), does not seem to be explained by the potential misclassification of seizure type; therefore results for individuals with generalised onset seizures should be interpreted with caution due to this unexplained inconsistency in results. </p> </section> </section> </section> <section id="CD001769-sec-0077"> <h4 class="title">Secondary outcomes</h4> <section id="CD001769-sec-0078"> <h5 class="title">Time to first seizure post‐randomisation</h5> <p>For this outcome, a HR less than one indicates a clinical advantage for valproate.</p> <p>Data for 639 individuals (96% of those providing IPD) from five trials were available for the analysis of this outcome. Seizure recurrence occurred in 371 out of 639 participants (58%), 189 out of 333 (57%) on valproate and 181 out of 306 (59%) on phenytoin. </p> <p>The overall pooled HR (for 639 participants) was 1.04 (95% CI 0.85 to 1.28, P = 0.70; low‐quality evidence) indicating no clear advantage for either drug. There was no important statistical heterogeneity between trials (I² = 5%; <a href="./references#CD001769-fig-0022" title="">Analysis 1.7</a>). </p> <section id="CD001769-sec-0079"> <h6 class="title">Subgroup analyses: epilepsy type (focal versus generalised onset)</h6> <p>For individuals with generalised seizures (395 participants from 5 trials), the pooled HR was 0.97 (95% CI 0.72 to 1.30, P = 0.82; low‐quality evidence), indicating no clear advantage for either drug. For individuals with focal onset seizures (244 participants from 4 trials), the pooled HR was 1.20 (95% CI 0.90 to 1.60, P = 0.22; low‐quality evidence), suggesting an advantage for phenytoin (i.e. that first seizure recurrence may occur later on phenytoin compared to valproate), but this advantage is not statistically significant. Overall, the pooled HR (adjusted for seizure type for 639 participants) was 1.08 (95% CI 0.88 to 1.33, P = 0.47; low‐quality evidence), suggesting a slight advantage for phenytoin which is not statistically significant. There was no evidence of an interaction between epilepsy type (focal onset versus generalised onset) and treatment effect (Chi² = 1.06, df = 1 (P = 0.30), I² = 5.6%) and no heterogeneity was present in any analysis (I² = 0%; <a href="./references#CD001769-fig-0023" title="">Analysis 1.8</a>). </p> </section> <section id="CD001769-sec-0080"> <h6 class="title">Sensitivity analysis</h6> <p>A sensitivity analysis including generalised seizures of all types during follow‐up (only recorded in <a href="./references#CD001769-bbs2-0007" title="RamsayRE , WilderBJ , MurphyJV , HolmesGL , UthmanB , SlaterJ , et al. Efficacy and safety of valproic acid versus phenytoin as sole therapy for newly diagnosed primary generalized tonic‐clonic seizures. Journal of Epilepsy1992;5(1):55‐60. ">Ramsay 1992</a>), produced the following results: for individuals with generalised seizures, the pooled HR was 0.95 (95% CI 0.71 to 1.27, P = 0.74), indicating no clear advantage for either drug. For individuals with focal onset seizures, the pooled HR was unchanged: 1.20 (95% CI 0.90 to 1.60, P = 0.22), suggesting an advantage for phenytoin which is not statistically significant. Overall, the pooled HR (adjusted for seizure type) was 1.08 (95% CI 0.86 to 1.32, P = 0.49), suggesting an advantage for phenytoin which is not statistically significant. Numerical results are very similar to those presented in <a href="./references#CD001769-fig-0022" title="">Analysis 1.7</a> and <a href="./references#CD001769-fig-0023" title="">Analysis 1.8</a> and overall conclusions are unchanged, therefore, results for time to first seizure (post‐randomisation) seem robust to the exclusion of other generalised seizure types (other than generalised tonic‐clonic seizures) in <a href="./references#CD001769-bbs2-0007" title="RamsayRE , WilderBJ , MurphyJV , HolmesGL , UthmanB , SlaterJ , et al. Efficacy and safety of valproic acid versus phenytoin as sole therapy for newly diagnosed primary generalized tonic‐clonic seizures. Journal of Epilepsy1992;5(1):55‐60. ">Ramsay 1992</a>. </p> <p>Sensitivity analyses were conducted to investigate misclassification of seizure type, reclassifying 171 individuals from four trials (<a href="./references#CD001769-bbs2-0002" title="CraigI , TallisR . Impact of valproate and phenytoin on cognitive function in elderly patients: results of a single‐blind randomized comparative study. Epilepsia1994;35(2):381‐90. ">Craig 1994</a>; <a href="./references#CD001769-bbs2-0006" title="HellerAJ , ChestermanP , ElwesRD , CrawfordP , ChadwickDW , JohnsonAL , et al. Phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed adult epilepsy: a randomised comparative monotherapy trial. Journal of Neurology, Neurosurgery, and Psychiatry1995;58:44‐50. ">Heller 1995</a>; <a href="./references#CD001769-bbs2-0007" title="RamsayRE , WilderBJ , MurphyJV , HolmesGL , UthmanB , SlaterJ , et al. Efficacy and safety of valproic acid versus phenytoin as sole therapy for newly diagnosed primary generalized tonic‐clonic seizures. Journal of Epilepsy1992;5(1):55‐60. ">Ramsay 1992</a>; <a href="./references#CD001769-bbs2-0011" title="TurnbullDM , HowelD , RawlinsMD , ChadwickDW . Which drug for the adult epileptic patient: phenytoin or valproate?. BMJ1985;290:815‐9. ">Turnbull 1985</a>) aged 30 or older with new onset generalised seizures to focal onset seizures or an uncertain seizure type. The results of the two sensitivity analyses are shown in <a href="#CD001769-tbl-0008">Table 6</a>. </p> <p>Within both of the sensitivity analyses, following reclassification, an association between epilepsy type and treatment effect is suggested. For generalised seizures, and age of onset &gt; 30 years reclassified as 'focal onset seizures', the result of the test for subgroup differences is statistically significant: Chi² = 5.46, df = 1 (P = 0.02), I² = 81.7% (<a href="./references#CD001769-fig-0024" title="">Analysis 1.9</a>). Within the focal onset seizure group, a non‐significant advantage to phenytoin is suggested: 1.23 (9% CI (0.96 to 1.57, P = 0.09), while in the generalised onset seizure group, a non‐significant advantage to valproate is suggested: pooled HR 0.72 (95% CI 0.50 to 1.05, P = 0.09); although neither result is statistically significant, the observed directions of effect within this sensitivity analysis was anticipated a priori (see <a href="#CD001769-sec-0026">How the intervention might work</a> and <a href="#CD001769-sec-0050">Subgroup analysis and investigation of heterogeneity</a>). </p> <p>For generalised seizures, and age of onset &gt; 30 years reclassified as 'uncertain seizure type', the result of the test for subgroup differences is not statistically significant, but subgroup analysis does suggest some potential differences between the epilepsy type subgroups: Chi² = 5.79, df = 2 (P = 0.06), I² = 65.5% (<a href="./references#CD001769-fig-0025" title="">Analysis 1.10</a>). </p> <p>The direction of effect for the 'uncertain seizure type' subgroup (pooled HR 1.35, 95% CI 0.85 to 2.14; P = 0.22) is similar to that of the 'focal onset' subgroup (pooled HR 1.20, 95% CI 0.90 to 1.60; P = 0.22), both indicating a non‐significant advantage for phenytoin and also suggesting that these individuals with 'uncertain' seizure types (who were originally classified as experiencing generalised onset seizures) are actually experiencing focal onset seizures. Furthermore, valproate now appears more effective in generalised onset seizures (pooled HR 0.72, 95% CI 0.50 to 1.05; P = 0.09) when compared to the original analysis (<a href="./references#CD001769-fig-0023" title="">Analysis 1.8</a>; <a href="./references#CD001769-fig-0025" title="">Analysis 1.10</a>). Again, although neither result is statistically significant, the observed directions of effect within this sensitivity analysis were anticipated a priori (see <a href="#CD001769-sec-0026">How the intervention might work</a> and <a href="#CD001769-sec-0050">Subgroup analysis and investigation of heterogeneity</a>). </p> <p>Therefore, due to the potential impact of any misclassification of epilepsy type on the numerical results and conclusions for the outcome, 'time to first seizure', results of <a href="./references#CD001769-fig-0022" title="">Analysis 1.7</a>, <a href="./references#CD001769-fig-0023" title="">Analysis 1.8</a>, <a href="./references#CD001769-fig-0024" title="">Analysis 1.9</a> and <a href="./references#CD001769-fig-0025" title="">Analysis 1.10</a> should be interpreted with caution. </p> </section> </section> <section id="CD001769-sec-0081"> <h5 class="title">Time to achieve 12‐month remission (seizure‐free period)</h5> <p>For this outcome, a HR less than one indicates a clinical advantage for phenytoin.</p> <p>Data for 514 individuals (77% of those providing IPD) from four trials were available for the analysis of this outcome (<a href="./references#CD001769-bbs2-0002" title="CraigI , TallisR . Impact of valproate and phenytoin on cognitive function in elderly patients: results of a single‐blind randomized comparative study. Epilepsia1994;35(2):381‐90. ">Craig 1994</a>; <a href="./references#CD001769-bbs2-0004" title="DeSilvaM , MacArdleB , McGowanM , HughesE , StewartJ , NevilleBGR , et al. Randomised comparative monotherapy trial of phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed childhood epilepsy. Lancet1996;347:709‐13. ">De Silva 1996</a>; <a href="./references#CD001769-bbs2-0006" title="HellerAJ , ChestermanP , ElwesRD , CrawfordP , ChadwickDW , JohnsonAL , et al. Phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed adult epilepsy: a randomised comparative monotherapy trial. Journal of Neurology, Neurosurgery, and Psychiatry1995;58:44‐50. ">Heller 1995</a>; <a href="./references#CD001769-bbs2-0011" title="TurnbullDM , HowelD , RawlinsMD , ChadwickDW . Which drug for the adult epileptic patient: phenytoin or valproate?. BMJ1985;290:815‐9. ">Turnbull 1985</a>; see <a href="#CD001769-tbl-0006">Table 4</a>). Individuals were only followed up for six months in the fifth trial (<a href="./references#CD001769-bbs2-0007" title="RamsayRE , WilderBJ , MurphyJV , HolmesGL , UthmanB , SlaterJ , et al. Efficacy and safety of valproic acid versus phenytoin as sole therapy for newly diagnosed primary generalized tonic‐clonic seizures. Journal of Epilepsy1992;5(1):55‐60. ">Ramsay 1992</a>), which could not contribute data to this outcome. Twelve‐month remission was achieved by 302 out of 514 participants (59%); 147 out of 256 (57%) on valproate and 155 out of 258 (60%) on phenytoin. The overall pooled HR (for 514 participants) was 1.03 (95% CI 0.82 to 1.29, P = 0.80; moderate‐quality evidence), indicating no clear advantage to either drug. There is no evidence of statistical heterogeneity between trials (I² = 0%; <a href="./references#CD001769-fig-0026" title="">Analysis 1.11</a>). </p> <section id="CD001769-sec-0082"> <h6 class="title">Subgroup analyses: epilepsy type (focal versus generalised onset)</h6> <p>For individuals with generalised seizures (270 participants from 4 trials), the pooled HR was 0.96 (95% CI 0.71 to 1.29, P = 0.79; moderate‐quality evidence), indicating no clear advantage for either drug. For individuals with focal onset seizures (244 participants from 4 trials), the pooled HR was 1.11 (95% CI 0.78 to 1.60, P = 0.56; moderate‐quality evidence), indicating a slight advantage for valproate ((i.e. that 12‐month remission may occur slightly earlier on valproate than phenytoin), but this advantage is not statistically significant. Overall, the pooled HR (adjusted for epilepsy type for 514 participants) was 1.02 (95% CI 0.81 to 1.28, P = 0.87; moderate‐quality evidence), suggesting no clear clinical advantage for either drug. There was no evidence of an interaction between epilepsy type (focal onset versus generalised onset) and treatment (Chi² = 0.39, df = 1, P = 0.53, I² = 0%) and no heterogeneity was present in any analysis (I² = 0%; <a href="./references#CD001769-fig-0027" title="">Analysis 1.12</a>). </p> </section> <section id="CD001769-sec-0083"> <h6 class="title">Sensitivity analysis</h6> <p>Sensitivity analyses were conducted to investigate misclassification of seizure type, reclassifying 145 individuals from three (<a href="./references#CD001769-bbs2-0002" title="CraigI , TallisR . Impact of valproate and phenytoin on cognitive function in elderly patients: results of a single‐blind randomized comparative study. Epilepsia1994;35(2):381‐90. ">Craig 1994</a>; <a href="./references#CD001769-bbs2-0006" title="HellerAJ , ChestermanP , ElwesRD , CrawfordP , ChadwickDW , JohnsonAL , et al. Phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed adult epilepsy: a randomised comparative monotherapy trial. Journal of Neurology, Neurosurgery, and Psychiatry1995;58:44‐50. ">Heller 1995</a>; <a href="./references#CD001769-bbs2-0011" title="TurnbullDM , HowelD , RawlinsMD , ChadwickDW . Which drug for the adult epileptic patient: phenytoin or valproate?. BMJ1985;290:815‐9. ">Turnbull 1985</a>) aged 30 or older with new onset generalised seizures to focal onset seizures or an uncertain seizure type. The results of the two sensitivity analyses are shown in <a href="#CD001769-tbl-0008">Table 6</a>. </p> <p>Results are numerically similar for individuals with focal onset seizures, individuals with generalised onset seizures and overall for all participants; conclusions are unchanged and there is no evidence of an association between epilepsy type and treatment effect following reclassification. </p> </section> </section> <section id="CD001769-sec-0084"> <h5 class="title">Time to achieve six‐month remission (seizure‐free period)</h5> <p>For this outcome, a HR less than one indicates a clinical advantage for phenytoin.</p> <p>Data for 639 individuals (96% of those providing IPD) from five trials were available for the analysis of this outcome (see <a href="#CD001769-tbl-0006">Table 4</a>). Six‐month remission was achieved by 434 out of 639 participants (68%); 228 out of 333 (68%) on valproate and 206 out of 306 (67%) on phenytoin. The overall pooled HR (for 639 participants) was 1.08 (95% CI 0.89 to 1.30, P = 0.44; moderate‐quality evidence), suggesting a slight advantage to valproate (i.e. that six‐month remission may occur slightly earlier on valproate than phenytoin), but this advantage is not statistically significant. There is no evidence of statistical heterogeneity between trials (I² = 0%; see <a href="./references#CD001769-fig-0028" title="">Analysis 1.13</a>). </p> <section id="CD001769-sec-0085"> <h6 class="title">Subgroup analyses: epilepsy type (focal versus generalised onset)</h6> <p>For individuals with generalised seizures (395 participants from 5 trials), the pooled HR was 1.08 (95% CI 0.84 to 1.38, P = 0.54; moderate‐quality evidence), suggesting an advantage for valproate which is not statistically significant. For individuals with focal onset seizures (244 participants from 4 trials), the pooled HR was 1.00 (95% CI 0.73 to 1.35, P = 0.98; moderate‐quality evidence), indicating no clear advantage for either drug. Overall, the pooled HR (adjusted for epilepsy type for 639 participants) was 1.05 (95% CI 0.86 to 1.27, P = 0.64; moderate‐quality evidence), suggesting no clear advantage for either drug. There was no evidence of an interaction between epilepsy type (focal onset versus generalised onset) and treatment (Chi² = 0.16, df = 1, P = 0.69, I² = 0%) and no heterogeneity was present in any analysis (I² = 0%; <a href="./references#CD001769-fig-0029" title="">Analysis 1.14</a>). </p> </section> <section id="CD001769-sec-0086"> <h6 class="title">Sensitivity analyses</h6> <p>A sensitivity analysis including generalised seizures of all types during follow‐up (only recorded in <a href="./references#CD001769-bbs2-0007" title="RamsayRE , WilderBJ , MurphyJV , HolmesGL , UthmanB , SlaterJ , et al. Efficacy and safety of valproic acid versus phenytoin as sole therapy for newly diagnosed primary generalized tonic‐clonic seizures. Journal of Epilepsy1992;5(1):55‐60. ">Ramsay 1992</a>) produced the following results: for individuals with generalised seizures (395 participants from 5 trials), the pooled HR was 1.19 (95% CI 0.88 to 1.61, P = 0.26), suggesting an advantage for valproate, which is not statistically significant. For individuals with focal onset seizures (244 participants from 4 trials), the pooled HR was unchanged: 1.00 (95% CI 0.73 to 1.35, P = 0.98), indicating no clear advantage for either drug. Overall, the pooled HR (adjusted for epilepsy type) was 1.09 (95% CI 0.88 to 1.37, P = 0.40), suggesting an advantage for valproate, which is not statistically significant. </p> <p>By including information on other generalised seizure types in the trial by <a href="./references#CD001769-bbs2-0007" title="RamsayRE , WilderBJ , MurphyJV , HolmesGL , UthmanB , SlaterJ , et al. Efficacy and safety of valproic acid versus phenytoin as sole therapy for newly diagnosed primary generalized tonic‐clonic seizures. Journal of Epilepsy1992;5(1):55‐60. ">Ramsay 1992</a>, a very slightly greater advantage for valproate emerges. However, as numerical results are similar to those presented in <a href="./references#CD001769-fig-0028" title="">Analysis 1.13</a> and <a href="./references#CD001769-fig-0029" title="">Analysis 1.14</a> and overall conclusions are unchanged, results for time to six‐month remission seem robust to the exclusion of other generalised seizure types (other than generalised tonic‐clonic seizures) in <a href="./references#CD001769-bbs2-0007" title="RamsayRE , WilderBJ , MurphyJV , HolmesGL , UthmanB , SlaterJ , et al. Efficacy and safety of valproic acid versus phenytoin as sole therapy for newly diagnosed primary generalized tonic‐clonic seizures. Journal of Epilepsy1992;5(1):55‐60. ">Ramsay 1992</a>. </p> <p>Sensitivity analyses were conducted to investigate misclassification of seizure type, reclassifying 171 individuals from four trials (<a href="./references#CD001769-bbs2-0002" title="CraigI , TallisR . Impact of valproate and phenytoin on cognitive function in elderly patients: results of a single‐blind randomized comparative study. Epilepsia1994;35(2):381‐90. ">Craig 1994</a>; <a href="./references#CD001769-bbs2-0006" title="HellerAJ , ChestermanP , ElwesRD , CrawfordP , ChadwickDW , JohnsonAL , et al. Phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed adult epilepsy: a randomised comparative monotherapy trial. Journal of Neurology, Neurosurgery, and Psychiatry1995;58:44‐50. ">Heller 1995</a>; <a href="./references#CD001769-bbs2-0007" title="RamsayRE , WilderBJ , MurphyJV , HolmesGL , UthmanB , SlaterJ , et al. Efficacy and safety of valproic acid versus phenytoin as sole therapy for newly diagnosed primary generalized tonic‐clonic seizures. Journal of Epilepsy1992;5(1):55‐60. ">Ramsay 1992</a>; <a href="./references#CD001769-bbs2-0011" title="TurnbullDM , HowelD , RawlinsMD , ChadwickDW . Which drug for the adult epileptic patient: phenytoin or valproate?. BMJ1985;290:815‐9. ">Turnbull 1985</a>) aged 30 or older with new onset generalised seizures to focal onset seizures or an uncertain seizure type. The results of the two sensitivity analyses are shown in <a href="#CD001769-tbl-0008">Table 6</a>. </p> <p>Results are numerically similar for individuals with focal onset seizures, individuals with generalised onset seizures and overall for all participants; conclusions are unchanged and there is no evidence of an association between epilepsy type and treatment effect following reclassification. </p> </section> </section> <section id="CD001769-sec-0087"> <h5 class="title">Incidence of adverse events</h5> <p>See <a href="#CD001769-tbl-0009">Table 7</a> for details of all adverse event data provided in the studies included in this review. It is difficult to summarise the 'most common' adverse events overall across the 11 studies due to the differences in methods and differences in the levels of detail in the reporting of adverse event data across the studies. In summary, the adverse events reported by two or more studies in this review are the following. </p> <div class="table" id="CD001769-tbl-0009"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 7.</span> <span class="table-title">Adverse event data (narrative report)</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Trial</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Adverse event data<sup>a</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Summary of reported results</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Phenytoin (PHT)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>SV (sodium valproate)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001769-bbs2-0001" title="CallaghanN , KennyRA , O'NeillB , CrowleyM , GogginT . A prospective study between carbamazepine, phenytoin and sodium valproate as monotherapy in previously untreated and recently diagnosed patients with epilepsy. Journal of Neurology, Neurosurgery and Psychiatry1985;48:639‐44. ">Callaghan 1985</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All adverse events developed (by drug) and adverse events leading to discontinuation of treatment </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PHT (n = 58): gum hypertrophy (n = 2), rash (n = 2), ataxia (n = 2)</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SV (n = 64): weight gain (n = 4: all discontinued treatment), drowsiness (n = 2), aggressive behaviour (n = 1: discontinued treatment) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001769-bbs2-0002" title="CraigI , TallisR . Impact of valproate and phenytoin on cognitive function in elderly patients: results of a single‐blind randomized comparative study. Epilepsia1994;35(2):381‐90. ">Craig 1994</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse event frequency (spontaneous reports)<sup>b</sup> </p> <p>Discontinuations due to adverse events<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PHT (n = 25): unsteadiness (n = 9), sleepiness (n = 7), drowsiness (n = 2), impaired concentration (n = 2), confusion (n = 1), constipation (n = 1), diarrhoea (n = 1), dysarthria (n = 1), lethargy (n = 1), nystagmus (n = 1), rash (n = 1), tired legs (n = 1) </p> <p>PHT discontinuations (n = 6): rash (n =1), diarrhoea (n = 1), confusion (n = 1), unsteadiness (n = 1), constipation (n = 1), sleepiness (n = 1) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SV (n = 17): unsteadiness (n = 2), sleepiness (n = 3), tremor (n = 5), oedema (n = 3), alopecia (n = 2), depression (n = 2), weight gain (n = 2) </p> <p>SV discontinuations (n = 2): weight gain and depression (n = 1), unsteadiness (n =1)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001769-bbs2-0003" title="CzapinskiP , TerczynskiA , CzapinskaE . Randomised 36‐month comparative study of valproic acid, phenytoin, phenobarbital and carbamazepine efficacy in patients with newly diagnosed epilepsy with partial complex seizures. Epilepsia1997;38(Suppl 3):42. ">Czapinski 1997a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"Exclusions" due to adverse events or no efficacy<sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Proportion "excluded": PHT: 33.3%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Proportion "excluded": SV: 23.3%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001769-bbs2-0004" title="DeSilvaM , MacArdleB , McGowanM , HughesE , StewartJ , NevilleBGR , et al. Randomised comparative monotherapy trial of phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed childhood epilepsy. Lancet1996;347:709‐13. ">De Silva 1996</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"Unacceptable" adverse events leading to drug withdrawal<sup>e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PHT (n = 54): drowsiness (n = 2), skin rash (n = 1) blood dyscrasia (n = 1), hirsutism (n = 1) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SV (n = 49): behavioural (n = 1), tremor (n = 1)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001769-bbs2-0005" title="ForsytheI , ButlerR , BergI , McGuireR . Cognitive impairment in new cases of epilepsy randomly assigned to carbamazepine, phenytoin and sodium valproate. Developmental Medicine and Child Neurology1991;33:524‐34. ">Forsythe 1991</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No adverse event data reported</p> <p>(treatment withdrawal data only reported)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 participant (PHT) withdrew from the study due to depression and anorexia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No adverse event data (or treatment withdrawals due to adverse events) reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001769-bbs2-0006" title="HellerAJ , ChestermanP , ElwesRD , CrawfordP , ChadwickDW , JohnsonAL , et al. Phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed adult epilepsy: a randomised comparative monotherapy trial. Journal of Neurology, Neurosurgery, and Psychiatry1995;58:44‐50. ">Heller 1995</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>“Unacceptable” adverse events leading to drug withdrawal<sup>e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PHT (n = 63): myalgia (n = 1), irritability (n = 1)</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SV (n = 61): dizziness (n = 2) abnormal liver function test (n = 1)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001769-bbs2-0007" title="RamsayRE , WilderBJ , MurphyJV , HolmesGL , UthmanB , SlaterJ , et al. Efficacy and safety of valproic acid versus phenytoin as sole therapy for newly diagnosed primary generalized tonic‐clonic seizures. Journal of Epilepsy1992;5(1):55‐60. ">Ramsay 1992</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Most common adverse events (by treatment group)<sup>f</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PHT (n = 50): dyspepsia (n = 1), nausea (n = 2), dizziness (n = 2), somnolence (n = 5), tremor (n = 2), rash (n = 4) </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SV (n = 86): dyspepsia (n = 7), nausea (n = 10), dizziness (n = 5), somnolence (n = 8), tremor (n = 5), rash (n = 3) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001769-bbs2-0008" title="RastogiP , MehrotraTN , AgarwalaRK , SinghVS . Comparison of sodium valproate and phenytoin as single drug treatment in generalised and partial epilepsy. Journal of the Association of Physicians of India1991;39(8):606‐8. ">Rastogi 1991</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Commonest adverse events (reported as percentages by treatment group)<sup>f</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PHT (n = 45): gum hyperplasia (17.7%), nystagmus (13.33%), ataxia (2.2%), gastrointestinal disturbances (4.44%), drowsiness (4.44%) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SV (n = 49): gastrointestinal disturbances (12%), drowsiness (6.12%), weight gain (2.04%) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001769-bbs2-0009" title="ShakirRA , JohnsonRH , LambieDG , MelvilleID , NandaRN . Comparison of sodium valproate and phenytoin as single drug treatment in epilepsy. Epilepsia1981;22:27‐33. ">Shakir 1981</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse events (narrative description)<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PHT (n = 15): 1 case of ataxia, 5 cases of acne</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SV (n = 18): 2 cases of gastrointestinal symptoms, 2 cases of hair loss, 4 cases of weight gain </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001769-bbs2-0010" title="ThilothammalN , BanuK , RatnamRS . Comparison of phenobarbitone, phenytoin with sodium valproate: randomized, double‐blind study. Indian Pediatrics1996;33:549‐55. ">Thilothammal 1996</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Assessment of adverse events<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PHT (n = 52): 33 participants reported at least one side effect</p> <p>Reported frequencies: gingival hypertrophy (n = 30), ataxia (n = 13), sedation (n = 12), nausea and vomiting (n = 1) </p> <p>Other reported adverse events (no frequencies): nystagmus, confusion</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SV (n = 48): 15 participants reported at least one side effect</p> <p>Reported frequencies: hyperactivity (n = 6), impaired school performance (n = 4), severe skin allergy (n = 1) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001769-bbs2-0011" title="TurnbullDM , HowelD , RawlinsMD , ChadwickDW . Which drug for the adult epileptic patient: phenytoin or valproate?. BMJ1985;290:815‐9. ">Turnbull 1985</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Treatment withdrawals due to dose‐related and idiosyncratic adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PHT (n = 70): 11 treatment withdrawals due to dose‐related adverse events (nystagmus, ataxia, tremor, diplopia and mental change) </p> <p>5 treatment withdrawals due to idiosyncratic adverse events (skin eruption, erythroderma and jaundice) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SV (n = 70): 9 treatment withdrawals due to dose‐related adverse events (tremor, irritability, restlessness and alopecia) </p> <p>No treatment withdrawals due to idiosyncratic adverse events</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><sup>a</sup>Adverse event data, as reported narratively in the publications. Adverse event data were not requested in original IPD requests but will be for all future IPD requests. For numbers of treatment withdrawals due to adverse events in studies for which IPD were provided (<a href="./references#CD001769-bbs2-0004" title="DeSilvaM , MacArdleB , McGowanM , HughesE , StewartJ , NevilleBGR , et al. Randomised comparative monotherapy trial of phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed childhood epilepsy. Lancet1996;347:709‐13. ">De Silva 1996</a>; <a href="./references#CD001769-bbs2-0006" title="HellerAJ , ChestermanP , ElwesRD , CrawfordP , ChadwickDW , JohnsonAL , et al. Phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed adult epilepsy: a randomised comparative monotherapy trial. Journal of Neurology, Neurosurgery, and Psychiatry1995;58:44‐50. ">Heller 1995</a>; <a href="./references#CD001769-bbs2-0007" title="RamsayRE , WilderBJ , MurphyJV , HolmesGL , UthmanB , SlaterJ , et al. Efficacy and safety of valproic acid versus phenytoin as sole therapy for newly diagnosed primary generalized tonic‐clonic seizures. Journal of Epilepsy1992;5(1):55‐60. ">Ramsay 1992</a>; <a href="./references#CD001769-bbs2-0011" title="TurnbullDM , HowelD , RawlinsMD , ChadwickDW . Which drug for the adult epileptic patient: phenytoin or valproate?. BMJ1985;290:815‐9. ">Turnbull 1985</a>) see <a href="#CD001769-tbl-0007">Table 5</a>.<br/> <sup>b</sup>Participants may report more than one adverse event.<br/> <sup>c</sup>The published paper, <a href="./references#CD001769-bbs2-0002" title="CraigI , TallisR . Impact of valproate and phenytoin on cognitive function in elderly patients: results of a single‐blind randomized comparative study. Epilepsia1994;35(2):381‐90. ">Craig 1994</a>, reports on a subset of 38 participants, so the adverse event data summary applies only to this subset. IPD were provided for 166 participants (no additional adverse event data provided).<br/> <sup>d</sup><a href="./references#CD001769-bbs2-0003" title="CzapinskiP , TerczynskiA , CzapinskaE . Randomised 36‐month comparative study of valproic acid, phenytoin, phenobarbital and carbamazepine efficacy in patients with newly diagnosed epilepsy with partial complex seizures. Epilepsia1997;38(Suppl 3):42. ">Czapinski 1997a</a> is an abstract only so very little information is reported.<br/> <sup>e</sup>Participants may have withdrawn due to adverse event alone or a combination of adverse events and poor efficacy (seizures).<br/> <sup>f</sup>Most commonly reported adverse events only, no indication of overall frequency of all adverse events. </p> </div> </div> <p>For valproate:</p> <p> <ul id="CD001769-list-0040"> <li> <p>drowsiness/somnolence/sedation (reported by <a href="./references#CD001769-bbs2-0001" title="CallaghanN , KennyRA , O'NeillB , CrowleyM , GogginT . A prospective study between carbamazepine, phenytoin and sodium valproate as monotherapy in previously untreated and recently diagnosed patients with epilepsy. Journal of Neurology, Neurosurgery and Psychiatry1985;48:639‐44. ">Callaghan 1985</a>; <a href="./references#CD001769-bbs2-0002" title="CraigI , TallisR . Impact of valproate and phenytoin on cognitive function in elderly patients: results of a single‐blind randomized comparative study. Epilepsia1994;35(2):381‐90. ">Craig 1994</a>; <a href="./references#CD001769-bbs2-0004" title="DeSilvaM , MacArdleB , McGowanM , HughesE , StewartJ , NevilleBGR , et al. Randomised comparative monotherapy trial of phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed childhood epilepsy. Lancet1996;347:709‐13. ">De Silva 1996</a>; <a href="./references#CD001769-bbs2-0007" title="RamsayRE , WilderBJ , MurphyJV , HolmesGL , UthmanB , SlaterJ , et al. Efficacy and safety of valproic acid versus phenytoin as sole therapy for newly diagnosed primary generalized tonic‐clonic seizures. Journal of Epilepsy1992;5(1):55‐60. ">Ramsay 1992</a>; <a href="./references#CD001769-bbs2-0008" title="RastogiP , MehrotraTN , AgarwalaRK , SinghVS . Comparison of sodium valproate and phenytoin as single drug treatment in generalised and partial epilepsy. Journal of the Association of Physicians of India1991;39(8):606‐8. ">Rastogi 1991</a>); </p> </li> <li> <p>weight gain (reported by <a href="./references#CD001769-bbs2-0001" title="CallaghanN , KennyRA , O'NeillB , CrowleyM , GogginT . A prospective study between carbamazepine, phenytoin and sodium valproate as monotherapy in previously untreated and recently diagnosed patients with epilepsy. Journal of Neurology, Neurosurgery and Psychiatry1985;48:639‐44. ">Callaghan 1985</a>; <a href="./references#CD001769-bbs2-0002" title="CraigI , TallisR . Impact of valproate and phenytoin on cognitive function in elderly patients: results of a single‐blind randomized comparative study. Epilepsia1994;35(2):381‐90. ">Craig 1994</a>; <a href="./references#CD001769-bbs2-0008" title="RastogiP , MehrotraTN , AgarwalaRK , SinghVS . Comparison of sodium valproate and phenytoin as single drug treatment in generalised and partial epilepsy. Journal of the Association of Physicians of India1991;39(8):606‐8. ">Rastogi 1991</a>; <a href="./references#CD001769-bbs2-0009" title="ShakirRA , JohnsonRH , LambieDG , MelvilleID , NandaRN . Comparison of sodium valproate and phenytoin as single drug treatment in epilepsy. Epilepsia1981;22:27‐33. ">Shakir 1981</a>); </p> </li> <li> <p>tremor (reported by <a href="./references#CD001769-bbs2-0002" title="CraigI , TallisR . Impact of valproate and phenytoin on cognitive function in elderly patients: results of a single‐blind randomized comparative study. Epilepsia1994;35(2):381‐90. ">Craig 1994</a>; <a href="./references#CD001769-bbs2-0004" title="DeSilvaM , MacArdleB , McGowanM , HughesE , StewartJ , NevilleBGR , et al. Randomised comparative monotherapy trial of phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed childhood epilepsy. Lancet1996;347:709‐13. ">De Silva 1996</a>; <a href="./references#CD001769-bbs2-0007" title="RamsayRE , WilderBJ , MurphyJV , HolmesGL , UthmanB , SlaterJ , et al. Efficacy and safety of valproic acid versus phenytoin as sole therapy for newly diagnosed primary generalized tonic‐clonic seizures. Journal of Epilepsy1992;5(1):55‐60. ">Ramsay 1992</a>; <a href="./references#CD001769-bbs2-0011" title="TurnbullDM , HowelD , RawlinsMD , ChadwickDW . Which drug for the adult epileptic patient: phenytoin or valproate?. BMJ1985;290:815‐9. ">Turnbull 1985</a>); </p> </li> <li> <p>alopecia/hair loss (reported by <a href="./references#CD001769-bbs2-0002" title="CraigI , TallisR . Impact of valproate and phenytoin on cognitive function in elderly patients: results of a single‐blind randomized comparative study. Epilepsia1994;35(2):381‐90. ">Craig 1994</a>; <a href="./references#CD001769-bbs2-0009" title="ShakirRA , JohnsonRH , LambieDG , MelvilleID , NandaRN . Comparison of sodium valproate and phenytoin as single drug treatment in epilepsy. Epilepsia1981;22:27‐33. ">Shakir 1981</a>; <a href="./references#CD001769-bbs2-0011" title="TurnbullDM , HowelD , RawlinsMD , ChadwickDW . Which drug for the adult epileptic patient: phenytoin or valproate?. BMJ1985;290:815‐9. ">Turnbull 1985</a>); </p> </li> <li> <p>dizziness/unsteadiness (reported by <a href="./references#CD001769-bbs2-0002" title="CraigI , TallisR . Impact of valproate and phenytoin on cognitive function in elderly patients: results of a single‐blind randomized comparative study. Epilepsia1994;35(2):381‐90. ">Craig 1994</a>; <a href="./references#CD001769-bbs2-0006" title="HellerAJ , ChestermanP , ElwesRD , CrawfordP , ChadwickDW , JohnsonAL , et al. Phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed adult epilepsy: a randomised comparative monotherapy trial. Journal of Neurology, Neurosurgery, and Psychiatry1995;58:44‐50. ">Heller 1995</a>; <a href="./references#CD001769-bbs2-0007" title="RamsayRE , WilderBJ , MurphyJV , HolmesGL , UthmanB , SlaterJ , et al. Efficacy and safety of valproic acid versus phenytoin as sole therapy for newly diagnosed primary generalized tonic‐clonic seizures. Journal of Epilepsy1992;5(1):55‐60. ">Ramsay 1992</a>); </p> </li> <li> <p>skin allergy/rash (reported by <a href="./references#CD001769-bbs2-0007" title="RamsayRE , WilderBJ , MurphyJV , HolmesGL , UthmanB , SlaterJ , et al. Efficacy and safety of valproic acid versus phenytoin as sole therapy for newly diagnosed primary generalized tonic‐clonic seizures. Journal of Epilepsy1992;5(1):55‐60. ">Ramsay 1992</a>; <a href="./references#CD001769-bbs2-0010" title="ThilothammalN , BanuK , RatnamRS . Comparison of phenobarbitone, phenytoin with sodium valproate: randomized, double‐blind study. Indian Pediatrics1996;33:549‐55. ">Thilothammal 1996</a>); and </p> </li> <li> <p>gastrointestinal problems (reported by <a href="./references#CD001769-bbs2-0008" title="RastogiP , MehrotraTN , AgarwalaRK , SinghVS . Comparison of sodium valproate and phenytoin as single drug treatment in generalised and partial epilepsy. Journal of the Association of Physicians of India1991;39(8):606‐8. ">Rastogi 1991</a>; <a href="./references#CD001769-bbs2-0009" title="ShakirRA , JohnsonRH , LambieDG , MelvilleID , NandaRN . Comparison of sodium valproate and phenytoin as single drug treatment in epilepsy. Epilepsia1981;22:27‐33. ">Shakir 1981</a>). </p> </li> </ul> </p> <p>For phenytoin:</p> <p> <ul id="CD001769-list-0041"> <li> <p>gingival (gum) hypertrophy/hyperplasia (reported by <a href="./references#CD001769-bbs2-0001" title="CallaghanN , KennyRA , O'NeillB , CrowleyM , GogginT . A prospective study between carbamazepine, phenytoin and sodium valproate as monotherapy in previously untreated and recently diagnosed patients with epilepsy. Journal of Neurology, Neurosurgery and Psychiatry1985;48:639‐44. ">Callaghan 1985</a>; <a href="./references#CD001769-bbs2-0008" title="RastogiP , MehrotraTN , AgarwalaRK , SinghVS . Comparison of sodium valproate and phenytoin as single drug treatment in generalised and partial epilepsy. Journal of the Association of Physicians of India1991;39(8):606‐8. ">Rastogi 1991</a>; <a href="./references#CD001769-bbs2-0010" title="ThilothammalN , BanuK , RatnamRS . Comparison of phenobarbitone, phenytoin with sodium valproate: randomized, double‐blind study. Indian Pediatrics1996;33:549‐55. ">Thilothammal 1996</a>); </p> </li> <li> <p>rash (reported by <a href="./references#CD001769-bbs2-0001" title="CallaghanN , KennyRA , O'NeillB , CrowleyM , GogginT . A prospective study between carbamazepine, phenytoin and sodium valproate as monotherapy in previously untreated and recently diagnosed patients with epilepsy. Journal of Neurology, Neurosurgery and Psychiatry1985;48:639‐44. ">Callaghan 1985</a>; <a href="./references#CD001769-bbs2-0002" title="CraigI , TallisR . Impact of valproate and phenytoin on cognitive function in elderly patients: results of a single‐blind randomized comparative study. Epilepsia1994;35(2):381‐90. ">Craig 1994</a>; <a href="./references#CD001769-bbs2-0004" title="DeSilvaM , MacArdleB , McGowanM , HughesE , StewartJ , NevilleBGR , et al. Randomised comparative monotherapy trial of phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed childhood epilepsy. Lancet1996;347:709‐13. ">De Silva 1996</a>; <a href="./references#CD001769-bbs2-0007" title="RamsayRE , WilderBJ , MurphyJV , HolmesGL , UthmanB , SlaterJ , et al. Efficacy and safety of valproic acid versus phenytoin as sole therapy for newly diagnosed primary generalized tonic‐clonic seizures. Journal of Epilepsy1992;5(1):55‐60. ">Ramsay 1992</a>); </p> </li> <li> <p>ataxia (reported by <a href="./references#CD001769-bbs2-0001" title="CallaghanN , KennyRA , O'NeillB , CrowleyM , GogginT . A prospective study between carbamazepine, phenytoin and sodium valproate as monotherapy in previously untreated and recently diagnosed patients with epilepsy. Journal of Neurology, Neurosurgery and Psychiatry1985;48:639‐44. ">Callaghan 1985</a>; <a href="./references#CD001769-bbs2-0008" title="RastogiP , MehrotraTN , AgarwalaRK , SinghVS . Comparison of sodium valproate and phenytoin as single drug treatment in generalised and partial epilepsy. Journal of the Association of Physicians of India1991;39(8):606‐8. ">Rastogi 1991</a>; <a href="./references#CD001769-bbs2-0009" title="ShakirRA , JohnsonRH , LambieDG , MelvilleID , NandaRN . Comparison of sodium valproate and phenytoin as single drug treatment in epilepsy. Epilepsia1981;22:27‐33. ">Shakir 1981</a>; <a href="./references#CD001769-bbs2-0010" title="ThilothammalN , BanuK , RatnamRS . Comparison of phenobarbitone, phenytoin with sodium valproate: randomized, double‐blind study. Indian Pediatrics1996;33:549‐55. ">Thilothammal 1996</a>; <a href="./references#CD001769-bbs2-0011" title="TurnbullDM , HowelD , RawlinsMD , ChadwickDW . Which drug for the adult epileptic patient: phenytoin or valproate?. BMJ1985;290:815‐9. ">Turnbull 1985</a>); </p> </li> <li> <p>nausea (reported by <a href="./references#CD001769-bbs2-0007" title="RamsayRE , WilderBJ , MurphyJV , HolmesGL , UthmanB , SlaterJ , et al. Efficacy and safety of valproic acid versus phenytoin as sole therapy for newly diagnosed primary generalized tonic‐clonic seizures. Journal of Epilepsy1992;5(1):55‐60. ">Ramsay 1992</a>; <a href="./references#CD001769-bbs2-0010" title="ThilothammalN , BanuK , RatnamRS . Comparison of phenobarbitone, phenytoin with sodium valproate: randomized, double‐blind study. Indian Pediatrics1996;33:549‐55. ">Thilothammal 1996</a>); </p> </li> <li> <p>dizziness/unsteadiness (reported by <a href="./references#CD001769-bbs2-0002" title="CraigI , TallisR . Impact of valproate and phenytoin on cognitive function in elderly patients: results of a single‐blind randomized comparative study. Epilepsia1994;35(2):381‐90. ">Craig 1994</a>; <a href="./references#CD001769-bbs2-0007" title="RamsayRE , WilderBJ , MurphyJV , HolmesGL , UthmanB , SlaterJ , et al. Efficacy and safety of valproic acid versus phenytoin as sole therapy for newly diagnosed primary generalized tonic‐clonic seizures. Journal of Epilepsy1992;5(1):55‐60. ">Ramsay 1992</a>); </p> </li> <li> <p>nystagmus (reported by <a href="./references#CD001769-bbs2-0002" title="CraigI , TallisR . Impact of valproate and phenytoin on cognitive function in elderly patients: results of a single‐blind randomized comparative study. Epilepsia1994;35(2):381‐90. ">Craig 1994</a>; <a href="./references#CD001769-bbs2-0008" title="RastogiP , MehrotraTN , AgarwalaRK , SinghVS . Comparison of sodium valproate and phenytoin as single drug treatment in generalised and partial epilepsy. Journal of the Association of Physicians of India1991;39(8):606‐8. ">Rastogi 1991</a>; <a href="./references#CD001769-bbs2-0010" title="ThilothammalN , BanuK , RatnamRS . Comparison of phenobarbitone, phenytoin with sodium valproate: randomized, double‐blind study. Indian Pediatrics1996;33:549‐55. ">Thilothammal 1996</a>; <a href="./references#CD001769-bbs2-0011" title="TurnbullDM , HowelD , RawlinsMD , ChadwickDW . Which drug for the adult epileptic patient: phenytoin or valproate?. BMJ1985;290:815‐9. ">Turnbull 1985</a>); </p> </li> <li> <p>drowsiness/somnolence/sedation (reported by <a href="./references#CD001769-bbs2-0002" title="CraigI , TallisR . Impact of valproate and phenytoin on cognitive function in elderly patients: results of a single‐blind randomized comparative study. Epilepsia1994;35(2):381‐90. ">Craig 1994</a>; <a href="./references#CD001769-bbs2-0004" title="DeSilvaM , MacArdleB , McGowanM , HughesE , StewartJ , NevilleBGR , et al. Randomised comparative monotherapy trial of phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed childhood epilepsy. Lancet1996;347:709‐13. ">De Silva 1996</a>; <a href="./references#CD001769-bbs2-0007" title="RamsayRE , WilderBJ , MurphyJV , HolmesGL , UthmanB , SlaterJ , et al. Efficacy and safety of valproic acid versus phenytoin as sole therapy for newly diagnosed primary generalized tonic‐clonic seizures. Journal of Epilepsy1992;5(1):55‐60. ">Ramsay 1992</a>; <a href="./references#CD001769-bbs2-0008" title="RastogiP , MehrotraTN , AgarwalaRK , SinghVS . Comparison of sodium valproate and phenytoin as single drug treatment in generalised and partial epilepsy. Journal of the Association of Physicians of India1991;39(8):606‐8. ">Rastogi 1991</a>; <a href="./references#CD001769-bbs2-0010" title="ThilothammalN , BanuK , RatnamRS . Comparison of phenobarbitone, phenytoin with sodium valproate: randomized, double‐blind study. Indian Pediatrics1996;33:549‐55. ">Thilothammal 1996</a>); and </p> </li> <li> <p>tremor (reported by <a href="./references#CD001769-bbs2-0007" title="RamsayRE , WilderBJ , MurphyJV , HolmesGL , UthmanB , SlaterJ , et al. Efficacy and safety of valproic acid versus phenytoin as sole therapy for newly diagnosed primary generalized tonic‐clonic seizures. Journal of Epilepsy1992;5(1):55‐60. ">Ramsay 1992</a>; <a href="./references#CD001769-bbs2-0011" title="TurnbullDM , HowelD , RawlinsMD , ChadwickDW . Which drug for the adult epileptic patient: phenytoin or valproate?. BMJ1985;290:815‐9. ">Turnbull 1985</a>). </p> </li> </ul> </p> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD001769-sec-0088" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD001769-sec-0088"></div> <section id="CD001769-sec-0089"> <h3 class="title" id="CD001769-sec-0089">Summary of main results</h3> <p>The results of this review do not demonstrate a statistically significant effect in favour of either valproate or phenytoin for the primary global outcome 'time to treatment failure for any reason related to the treatment (retention time)'. This outcome is influenced by both the relative efficacy of the two drugs, and differences in tolerability and safety. </p> <p>As a difference in efficacy in one direction may be confounded by a difference in tolerability in the other, it may not be surprising that any estimated differences are small, yet when considering specific reasons for treatment failure (adverse events or lack of efficacy), still no statistically significant differences were found between the two drugs. The confidence intervals for the treatment failure outcomes are relatively wide; too wide to confirm equivalence and clinically important differences have not been excluded, particularly when results for generalised and focal onset seizure subgroups are examined. Furthermore, as at least three of the trials contributing individual participant data (IPD) to this outcome were open‐label, clinical preconceptions about the two treatments, such as that valproate is more effective in generalised seizures, while phenytoin is more effective in focal onset seizures, and lack of masking, may have influenced the treatment failure rates of the two treatments. </p> <p>Similarly for the secondary outcomes 'time to achieve 12‐month remission (seizure‐free period)', 'time to achieve six‐month remission (seizure‐free period)', and 'time to first seizure', although no statistically significant differences were found between valproate and phenytoin, the confidence intervals are too wide to confirm equivalence. </p> </section> <section id="CD001769-sec-0090"> <h3 class="title" id="CD001769-sec-0090">Overall completeness and applicability of evidence</h3> <p>We have gratefully received IPD for 669 individuals (60% of individuals from all eligible trials) from the authors of five trials, which included a comparison of phenytoin with valproate for the treatment of epilepsy (<a href="./references#CD001769-bbs2-0002" title="CraigI , TallisR . Impact of valproate and phenytoin on cognitive function in elderly patients: results of a single‐blind randomized comparative study. Epilepsia1994;35(2):381‐90. ">Craig 1994</a>; <a href="./references#CD001769-bbs2-0004" title="DeSilvaM , MacArdleB , McGowanM , HughesE , StewartJ , NevilleBGR , et al. Randomised comparative monotherapy trial of phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed childhood epilepsy. Lancet1996;347:709‐13. ">De Silva 1996</a>; <a href="./references#CD001769-bbs2-0006" title="HellerAJ , ChestermanP , ElwesRD , CrawfordP , ChadwickDW , JohnsonAL , et al. Phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed adult epilepsy: a randomised comparative monotherapy trial. Journal of Neurology, Neurosurgery, and Psychiatry1995;58:44‐50. ">Heller 1995</a>; <a href="./references#CD001769-bbs2-0007" title="RamsayRE , WilderBJ , MurphyJV , HolmesGL , UthmanB , SlaterJ , et al. Efficacy and safety of valproic acid versus phenytoin as sole therapy for newly diagnosed primary generalized tonic‐clonic seizures. Journal of Epilepsy1992;5(1):55‐60. ">Ramsay 1992</a>; <a href="./references#CD001769-bbs2-0011" title="TurnbullDM , HowelD , RawlinsMD , ChadwickDW . Which drug for the adult epileptic patient: phenytoin or valproate?. BMJ1985;290:815‐9. ">Turnbull 1985</a>). However, 376 individuals (34%) from four relevant trials could not be included in any analysis, as IPD were not available and outcomes of interest were not reported in the published reports (<a href="./references#CD001769-bbs2-0001" title="CallaghanN , KennyRA , O'NeillB , CrowleyM , GogginT . A prospective study between carbamazepine, phenytoin and sodium valproate as monotherapy in previously untreated and recently diagnosed patients with epilepsy. Journal of Neurology, Neurosurgery and Psychiatry1985;48:639‐44. ">Callaghan 1985</a>; <a href="./references#CD001769-bbs2-0003" title="CzapinskiP , TerczynskiA , CzapinskaE . Randomised 36‐month comparative study of valproic acid, phenytoin, phenobarbital and carbamazepine efficacy in patients with newly diagnosed epilepsy with partial complex seizures. Epilepsia1997;38(Suppl 3):42. ">Czapinski 1997a</a>; <a href="./references#CD001769-bbs2-0008" title="RastogiP , MehrotraTN , AgarwalaRK , SinghVS . Comparison of sodium valproate and phenytoin as single drug treatment in generalised and partial epilepsy. Journal of the Association of Physicians of India1991;39(8):606‐8. ">Rastogi 1991</a>; <a href="./references#CD001769-bbs2-0010" title="ThilothammalN , BanuK , RatnamRS . Comparison of phenobarbitone, phenytoin with sodium valproate: randomized, double‐blind study. Indian Pediatrics1996;33:549‐55. ">Thilothammal 1996</a>). Sufficient data for 74 individuals (6%) were published in two trials to contribute to analysis for the primary outcome 'time to treatment failure' (<a href="./references#CD001769-bbs2-0005" title="ForsytheI , ButlerR , BergI , McGuireR . Cognitive impairment in new cases of epilepsy randomly assigned to carbamazepine, phenytoin and sodium valproate. Developmental Medicine and Child Neurology1991;33:524‐34. ">Forsythe 1991</a>; <a href="./references#CD001769-bbs2-0009" title="ShakirRA , JohnsonRH , LambieDG , MelvilleID , NandaRN . Comparison of sodium valproate and phenytoin as single drug treatment in epilepsy. Epilepsia1981;22:27‐33. ">Shakir 1981</a>), but insufficient data were available to include these individuals in the analyses of other outcomes. Having to exclude data for one‐third of eligible participants due to lack of IPD and insufficient reporting in study publications is likely to impact on the applicability of the evidence, however it is difficult to quantify exactly how large this impact could be. </p> <p>We did not find evidence of an interaction between treatment and seizure type in any analysis using the epileptic seizure types that participants were classified with in the original analysis. This result is surprising, given the strong clinical impression that valproate is more effective in generalised onset seizures while phenytoin is more effective in focal onset seizures. </p> <p>It may well be that an interaction does not exist. Alternatively, it may be that an interaction does exist but that our meta‐analysis may not have the statistical power needed to detect an interaction; it must be understood that the confidence intervals around the estimates are wide, and that these results do not exclude the possibility of important differences existing. Additionally, subgroup analyses by epilepsy type show some inconsistent results, such as for our primary outcome 'time to treatment failure for any reason related to the treatment', treatment effect estimates indicate a potentially important advantage for valproate for focal onset seizures, with no clear advantage for either drug for generalised tonic‐clonic seizures, which goes against current practice and belief. Furthermore, a substantial amount of statistical heterogeneity was present in some analyses of 'time to treatment failure,' particularly within analyses of individuals with generalised onset seizures, which could not be explained by sensitivity analyses. </p> <p>The impression that valproate is better for generalised seizures may derive from its effects on generalised seizures other than tonic‐clonic, but important differences could exist for absence and myoclonus seizure types. However, were this the case, we might have expected to see a treatment‐seizure type interaction for the outcome 'time to treatment failure', if treatment had failed or a further drug added to combat other seizure types. We were unable to investigate these seizure types in detail in this review as most of the trials providing IPD did not record post‐randomisation generalised seizure types other than tonic‐clonic occurring post‐randomisation. </p> <p>The results of the original trials, and hence this meta‐analysis, may have been confounded by classification bias, i.e. individuals with generalised seizures may have been misclassified as having focal onset seizures and vice versa. There is good evidence from our three reviews in our series of pair‐wise reviews for monotherapy in epilepsy comparing carbamazepine to phenobarbitone, phenytoin and valproate that misclassification is indeed an important issue in epilepsy trials (<a href="./references#CD001769-bbs2-0064" title="MarsonAG , WilliamsonPR , HuttonJL , CloughHE , ChadwickDW . Carbamazepine versus valproate monotherapy for epilepsy. Cochrane Database of Systematic Reviews2000, Issue 3. [DOI: 10.1002/14651858.CD001030] ">Marson 2000</a>; <a href="./references#CD001769-bbs2-0078" title="NolanSJ , MarsonAG , WestonJ , Tudur SmithC . Carbamazepine versus phenobarbitone monotherapy for epilepsy: an individual participant data review. Cochrane Database of Systematic Reviews2016, Issue 12. [DOI: 10.1002/14651858.CD001904.pub2] ">Nolan 2016c</a>; <a href="./references#CD001769-bbs2-0070" title="NevittSJ , MarsonAG , WestonJ , Tudur‐SmithC . Carbamazepine versus phenytoin monotherapy for epilepsy: an individual participant data review. Cochrane Database of Systematic Reviews2017, Issue 2. [DOI: 10.1002/14651858.CD001911.pub3] ">Nevitt 2017b</a>). Within our review, the most striking indication that misclassification may be a problem is the classification of subjects in <a href="./references#CD001769-bbs2-0002" title="CraigI , TallisR . Impact of valproate and phenytoin on cognitive function in elderly patients: results of a single‐blind randomized comparative study. Epilepsia1994;35(2):381‐90. ">Craig 1994</a>. In this trial, 95 out of 166 (56%) of the recruited individuals were classified as having a generalised epilepsy, which seems unlikely given that the individuals were newly diagnosed and over the age of 60 (<a href="./references#CD001769-bbs2-0063" title="MalafosseA , GentonP , HirschE , MarescauxC , BroglinD , BernasconiR , editor(s) , et al. Idiopathic Generalised Epilepsies: Clinical, Experimental and Genetic Aspects. Eastleigh: John Libbey and Company, 1994. [0861964365] ">Malafosse 1994</a>). It is also interesting to note that <a href="./references#CD001769-bbs2-0007" title="RamsayRE , WilderBJ , MurphyJV , HolmesGL , UthmanB , SlaterJ , et al. Efficacy and safety of valproic acid versus phenytoin as sole therapy for newly diagnosed primary generalized tonic‐clonic seizures. Journal of Epilepsy1992;5(1):55‐60. ">Ramsay 1992</a> is the only trial in this review that attempted to recruit only individuals with generalised tonic‐clonic seizures, However, this trial recruited too few individuals to have the power to detect a difference between valproate and phenytoin. In this trial, for a subgroup of individuals with definite electroencephalographic (EEG) changes to support a diagnosis of an idiopathic generalised epilepsy, there appeared to be a greater (but not significant) advantage for valproate, compared to the trial population overall. This could again be interpreted as supporting the potential for misclassification, which in turn could confound an interaction between treatment and seizure type. We were unable to test for the effects of EEG changes on the interaction between treatment and seizure type due to EEG data not being collected for all trials, and even where it was available, it was not done in a uniform way. It is likely that these trials were initiated before the publication of the International League Against Epilepsy Classification of Epileptic Syndromes in 1989 (<a href="./references#CD001769-bbs2-0042" title="Commission on Classification and Terminology of the International League Against Epilepsy. Proposal for revised classification of epilepsies and epileptic syndromes. Epilepsia1989;30(4):389‐99. ">Commission 1989</a>), but they did use the International League Against Epilepsy Classification of Epileptic Seizures that was published in 1981 (<a href="./references#CD001769-bbs2-0041" title="Commission on Classification and Terminology of the International League Against Epilepsy. Proposal for revised clinical and electroencephalographic classification of epileptic seizures. Epilepsia1981;22(4):489‐501. ">Commission 1981</a>), which does allow individuals to be classified as those with focal onset or generalised seizures. The age of onset distribution of individuals classified as having generalised seizures indicates misclassification is likely to have occurred in up to 188 out of 384 (49%) individuals classified as having generalised onset seizures. Our results, based on reclassifying the 188 individuals, indicate that classification bias is a potentially important confounder of the results of this review, particularly the outcome 'time to first seizure'. </p> <p>Finally, it should be mentioned that the preparation of valproate used in the included trials may have influenced the results. The trials conducted in the UK all used valproate (Epilim) (<a href="./references#CD001769-bbs2-0002" title="CraigI , TallisR . Impact of valproate and phenytoin on cognitive function in elderly patients: results of a single‐blind randomized comparative study. Epilepsia1994;35(2):381‐90. ">Craig 1994</a>; <a href="./references#CD001769-bbs2-0004" title="DeSilvaM , MacArdleB , McGowanM , HughesE , StewartJ , NevilleBGR , et al. Randomised comparative monotherapy trial of phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed childhood epilepsy. Lancet1996;347:709‐13. ">De Silva 1996</a>; <a href="./references#CD001769-bbs2-0006" title="HellerAJ , ChestermanP , ElwesRD , CrawfordP , ChadwickDW , JohnsonAL , et al. Phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed adult epilepsy: a randomised comparative monotherapy trial. Journal of Neurology, Neurosurgery, and Psychiatry1995;58:44‐50. ">Heller 1995</a>; <a href="./references#CD001769-bbs2-0011" title="TurnbullDM , HowelD , RawlinsMD , ChadwickDW . Which drug for the adult epileptic patient: phenytoin or valproate?. BMJ1985;290:815‐9. ">Turnbull 1985</a>). <a href="./references#CD001769-bbs2-0007" title="RamsayRE , WilderBJ , MurphyJV , HolmesGL , UthmanB , SlaterJ , et al. Efficacy and safety of valproic acid versus phenytoin as sole therapy for newly diagnosed primary generalized tonic‐clonic seizures. Journal of Epilepsy1992;5(1):55‐60. ">Ramsay 1992</a>, conducted in the USA, used valproic acid (Depakene) which is thought to cause more gastrointestinal side effects than preparations containing either a mixture of valproate and valproic acid, or valproate alone. There is no evidence from RCTs to support this, but there are some data from observational studies (<a href="./references#CD001769-bbs2-0034" title="BrasfieldKH . Pilot study of divalproex sodium valproate versus valproic acid: drug acquisition costs versus all related costs. Current Therapeutic Research1999;60(3):138‐44. ">Brasfield 1999</a>; <a href="./references#CD001769-bbs2-0043" title="CranorCW , SawyerWT , CarsonSW , EarlyJJ . Clinical and economic impact of replacing divalproex sodium with valproic acid. American Journal of Health‐System Pharmacy1997;54:1716‐22. ">Cranor 1997</a>; <a href="./references#CD001769-bbs2-0098" title="WilderBJ , KarasBJ , PenryJK , AsconapeJ . Gastrointestinal tolerance of divalproex sodium. Neurology1983;33:808‐11. ">Wilder 1983a</a>). Given that this meta‐analysis, and a similar meta‐analysis comparing valproate and carbamazepine have failed to find convincing evidence of differences in effect between different drugs (<a href="./references#CD001769-bbs2-0064" title="MarsonAG , WilliamsonPR , HuttonJL , CloughHE , ChadwickDW . Carbamazepine versus valproate monotherapy for epilepsy. Cochrane Database of Systematic Reviews2000, Issue 3. [DOI: 10.1002/14651858.CD001030] ">Marson 2000</a>), it seems unlikely that differing preparations of the same drug are likely to have a major effect. </p> </section> <section id="CD001769-sec-0091"> <h3 class="title" id="CD001769-sec-0091">Quality of the evidence</h3> <p>The five trials for which IPD were made available were of generally good quality, with all five trials describing adequate methods of randomisation, and <a href="./references#CD001769-bbs2-0002" title="CraigI , TallisR . Impact of valproate and phenytoin on cognitive function in elderly patients: results of a single‐blind randomized comparative study. Epilepsia1994;35(2):381‐90. ">Craig 1994</a>, <a href="./references#CD001769-bbs2-0004" title="DeSilvaM , MacArdleB , McGowanM , HughesE , StewartJ , NevilleBGR , et al. Randomised comparative monotherapy trial of phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed childhood epilepsy. Lancet1996;347:709‐13. ">De Silva 1996</a> and <a href="./references#CD001769-bbs2-0006" title="HellerAJ , ChestermanP , ElwesRD , CrawfordP , ChadwickDW , JohnsonAL , et al. Phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed adult epilepsy: a randomised comparative monotherapy trial. Journal of Neurology, Neurosurgery, and Psychiatry1995;58:44‐50. ">Heller 1995</a> also describing adequate methods of allocation concealment. However, none of the five trials described a method of blinding of participants and personnel, and only one trial stated that cognitive outcome assessors were blinded to treatment allocation, raising the possibility of performance and detection bias (<a href="./references#CD001769-bbs2-0002" title="CraigI , TallisR . Impact of valproate and phenytoin on cognitive function in elderly patients: results of a single‐blind randomized comparative study. Epilepsia1994;35(2):381‐90. ">Craig 1994</a>). Three trials were designed as open‐label for "practical and ethical reasons" (<a href="./references#CD001769-bbs2-0004" title="DeSilvaM , MacArdleB , McGowanM , HughesE , StewartJ , NevilleBGR , et al. Randomised comparative monotherapy trial of phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed childhood epilepsy. Lancet1996;347:709‐13. ">De Silva 1996</a>; <a href="./references#CD001769-bbs2-0006" title="HellerAJ , ChestermanP , ElwesRD , CrawfordP , ChadwickDW , JohnsonAL , et al. Phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed adult epilepsy: a randomised comparative monotherapy trial. Journal of Neurology, Neurosurgery, and Psychiatry1995;58:44‐50. ">Heller 1995</a>; <a href="./references#CD001769-bbs2-0007" title="RamsayRE , WilderBJ , MurphyJV , HolmesGL , UthmanB , SlaterJ , et al. Efficacy and safety of valproic acid versus phenytoin as sole therapy for newly diagnosed primary generalized tonic‐clonic seizures. Journal of Epilepsy1992;5(1):55‐60. ">Ramsay 1992</a>); for example, <a href="./references#CD001769-bbs2-0007" title="RamsayRE , WilderBJ , MurphyJV , HolmesGL , UthmanB , SlaterJ , et al. Efficacy and safety of valproic acid versus phenytoin as sole therapy for newly diagnosed primary generalized tonic‐clonic seizures. Journal of Epilepsy1992;5(1):55‐60. ">Ramsay 1992</a> stated that the side effects of the respective drugs would "quickly unblind" the trial anyway. A further difference between the five trials was the population recruited; two trials recruited adults of all ages (<a href="./references#CD001769-bbs2-0006" title="HellerAJ , ChestermanP , ElwesRD , CrawfordP , ChadwickDW , JohnsonAL , et al. Phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed adult epilepsy: a randomised comparative monotherapy trial. Journal of Neurology, Neurosurgery, and Psychiatry1995;58:44‐50. ">Heller 1995</a>; <a href="./references#CD001769-bbs2-0011" title="TurnbullDM , HowelD , RawlinsMD , ChadwickDW . Which drug for the adult epileptic patient: phenytoin or valproate?. BMJ1985;290:815‐9. ">Turnbull 1985</a>), one recruited children only (<a href="./references#CD001769-bbs2-0004" title="DeSilvaM , MacArdleB , McGowanM , HughesE , StewartJ , NevilleBGR , et al. Randomised comparative monotherapy trial of phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed childhood epilepsy. Lancet1996;347:709‐13. ">De Silva 1996</a>), one recruited adults and children (<a href="./references#CD001769-bbs2-0007" title="RamsayRE , WilderBJ , MurphyJV , HolmesGL , UthmanB , SlaterJ , et al. Efficacy and safety of valproic acid versus phenytoin as sole therapy for newly diagnosed primary generalized tonic‐clonic seizures. Journal of Epilepsy1992;5(1):55‐60. ">Ramsay 1992</a>), and one recruited adults over the age of 60 only (<a href="./references#CD001769-bbs2-0002" title="CraigI , TallisR . Impact of valproate and phenytoin on cognitive function in elderly patients: results of a single‐blind randomized comparative study. Epilepsia1994;35(2):381‐90. ">Craig 1994</a>). </p> <p>As explained within <a href="#CD001769-sec-0090">Overall completeness and applicability of evidence</a>, misclassification of seizure type (classification bias) is likely to have impacted upon the results of the outcome 'time to first seizure' and for treatment failure outcomes, unexplained heterogeneity was present in analysis, following subgroup analysis and sensitivity analysis (including reclassification of seizure type). </p> <p>For the reasons outlined in this section, we judged the quality of the evidence to be moderate to low for 'time to treatment failure' due to risk of detection bias and unexplained heterogeneity (<a href="./full#CD001769-tbl-0001">summary of findings Table for the main comparison</a>), and low/moderate for the outcomes of 'time to first seizure' and 'time to 12‐month remission' respectively, due to risk of detection bias and classification bias (see <a href="./full#CD001769-tbl-0002">summary of findings Table 2</a>). </p> </section> <section id="CD001769-sec-0092"> <h3 class="title" id="CD001769-sec-0092">Potential biases in the review process</h3> <p>We were able to include IPD up to 743 out of 1119 eligible participants (66%) from seven out of 11 trials in this review in the analysis of at least one outcome. Such an approach has many advantages, such as allowing the standardisation of definitions of outcomes across trials, and attrition and reporting biases are reduced as we can perform additional analyses and calculate additional outcomes from unpublished data. For the outcomes we used in this review that are of a time‐to‐event nature, an IPD approach is considered to be the 'gold standard' approach to analysis (<a href="./references#CD001769-bbs2-0084" title="ParmarMKB , TorriV , StewartL . Extracting summary statistics to perform meta‐analysis of the published literature for survival endpoints. Statistics in Medicine1998;17:2815‐34. ">Parmar 1998</a>). </p> <p>For reasons outside of our control, we were unable to obtain or extract any IPD for 376 participants (34%) from four trials for inclusion in any outcomes of this review; it is difficult to quantify whether the exclusion of at least 34% of eligible participants from analyses is likely to have impacted on the conclusions of this review. </p> <p>Finally, we made some assumptions in the statistical methodology used in this review. Firstly, when we received only follow‐up dates and seizure frequencies, we used linear interpolation to estimate. We are aware that an individual's seizure patterns may be non‐linear; therefore for this reason, in addition to the reasons outlined in <a href="#CD001769-sec-0090">Overall completeness and applicability of evidence</a>, we recommend caution when interpreting the numerical results of the seizure‐related outcomes. </p> </section> <section id="CD001769-sec-0093"> <h3 class="title" id="CD001769-sec-0093">Agreements and disagreements with other studies or reviews</h3> <p>No single trial has found convincing differences between valproate and phenytoin with respect to seizure control or seizure type (<a href="./references#CD001769-bbs2-0001" title="CallaghanN , KennyRA , O'NeillB , CrowleyM , GogginT . A prospective study between carbamazepine, phenytoin and sodium valproate as monotherapy in previously untreated and recently diagnosed patients with epilepsy. Journal of Neurology, Neurosurgery and Psychiatry1985;48:639‐44. ">Callaghan 1985</a>; <a href="./references#CD001769-bbs2-0002" title="CraigI , TallisR . Impact of valproate and phenytoin on cognitive function in elderly patients: results of a single‐blind randomized comparative study. Epilepsia1994;35(2):381‐90. ">Craig 1994</a>; <a href="./references#CD001769-bbs2-0003" title="CzapinskiP , TerczynskiA , CzapinskaE . Randomised 36‐month comparative study of valproic acid, phenytoin, phenobarbital and carbamazepine efficacy in patients with newly diagnosed epilepsy with partial complex seizures. Epilepsia1997;38(Suppl 3):42. ">Czapinski 1997a</a>; <a href="./references#CD001769-bbs2-0004" title="DeSilvaM , MacArdleB , McGowanM , HughesE , StewartJ , NevilleBGR , et al. Randomised comparative monotherapy trial of phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed childhood epilepsy. Lancet1996;347:709‐13. ">De Silva 1996</a>; <a href="./references#CD001769-bbs2-0005" title="ForsytheI , ButlerR , BergI , McGuireR . Cognitive impairment in new cases of epilepsy randomly assigned to carbamazepine, phenytoin and sodium valproate. Developmental Medicine and Child Neurology1991;33:524‐34. ">Forsythe 1991</a>; <a href="./references#CD001769-bbs2-0006" title="HellerAJ , ChestermanP , ElwesRD , CrawfordP , ChadwickDW , JohnsonAL , et al. Phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed adult epilepsy: a randomised comparative monotherapy trial. Journal of Neurology, Neurosurgery, and Psychiatry1995;58:44‐50. ">Heller 1995</a>; <a href="./references#CD001769-bbs2-0007" title="RamsayRE , WilderBJ , MurphyJV , HolmesGL , UthmanB , SlaterJ , et al. Efficacy and safety of valproic acid versus phenytoin as sole therapy for newly diagnosed primary generalized tonic‐clonic seizures. Journal of Epilepsy1992;5(1):55‐60. ">Ramsay 1992</a>; <a href="./references#CD001769-bbs2-0008" title="RastogiP , MehrotraTN , AgarwalaRK , SinghVS . Comparison of sodium valproate and phenytoin as single drug treatment in generalised and partial epilepsy. Journal of the Association of Physicians of India1991;39(8):606‐8. ">Rastogi 1991</a>; <a href="./references#CD001769-bbs2-0009" title="ShakirRA , JohnsonRH , LambieDG , MelvilleID , NandaRN . Comparison of sodium valproate and phenytoin as single drug treatment in epilepsy. Epilepsia1981;22:27‐33. ">Shakir 1981</a>; <a href="./references#CD001769-bbs2-0010" title="ThilothammalN , BanuK , RatnamRS . Comparison of phenobarbitone, phenytoin with sodium valproate: randomized, double‐blind study. Indian Pediatrics1996;33:549‐55. ">Thilothammal 1996</a>; <a href="./references#CD001769-bbs2-0011" title="TurnbullDM , HowelD , RawlinsMD , ChadwickDW . Which drug for the adult epileptic patient: phenytoin or valproate?. BMJ1985;290:815‐9. ">Turnbull 1985</a>). However, confidence intervals around estimates have been wide and equivalence cannot be inferred. Furthermore, this systematic review and meta‐analysis has not found any statistically significant differences between valproate and phenytoin for any of the outcomes measures. To our knowledge, this is the only systematic review and meta‐analysis which compares valproate and phenytoin monotherapy for focal onset seizures and generalised onset tonic‐clonic seizures. A network meta‐analysis has been published (<a href="./references#CD001769-bbs2-0069" title="NevittSJ , SudellM , WestonJ , Tudur SmithC , MarsonA . Antiepileptic drug monotherapy for epilepsy: a network meta‐analysis of individual participant data. Cochrane Database of Systematic Reviews2017, Issue 12. [DOI: 10.1002/14651858.CD011412.pub3] ">Nevitt 2017a</a>), comparing all direct and indirect evidence from phenytoin, valproate and other standard and new antiepileptic drugs licensed for monotherapy, and it also found no differences between valproate and phenytoin for the outcomes specified in this review. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD001769-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001769.pub4/media/CDSR/CD001769/urn:x-wiley:14651858:media:CD001769:CD001769-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001769.pub4/media/CDSR/CD001769/image_t/tCD001769-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD001769-fig-0001" src="/cdsr/doi/10.1002/14651858.CD001769.pub4/media/CDSR/CD001769/image_n/nCD001769-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001769.pub4/full#CD001769-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001769.pub4/media/CDSR/CD001769/image_n/nCD001769-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001769-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001769.pub4/media/CDSR/CD001769/urn:x-wiley:14651858:media:CD001769:CD001769-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001769.pub4/media/CDSR/CD001769/image_t/tCD001769-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD001769-fig-0002" src="/cdsr/doi/10.1002/14651858.CD001769.pub4/media/CDSR/CD001769/image_n/nCD001769-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001769.pub4/full#CD001769-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001769.pub4/media/CDSR/CD001769/image_n/nCD001769-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001769-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001769.pub4/media/CDSR/CD001769/urn:x-wiley:14651858:media:CD001769:CD001769-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001769.pub4/media/CDSR/CD001769/image_t/tCD001769-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study." data-id="CD001769-fig-0003" src="/cdsr/doi/10.1002/14651858.CD001769.pub4/media/CDSR/CD001769/image_n/nCD001769-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001769.pub4/full#CD001769-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001769.pub4/media/CDSR/CD001769/image_n/nCD001769-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001769-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001769.pub4/media/CDSR/CD001769/urn:x-wiley:14651858:media:CD001769:CD001769-AFig-FIG04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001769.pub4/media/CDSR/CD001769/image_t/tCD001769-AFig-FIG04.png" target="_blank"><b></b></a></p> </div><img alt="Time to treatment failure ‐ any reason related to the treatment (PHT: phenytoin; SV: sodium valproate)" data-id="CD001769-fig-0004" src="/cdsr/doi/10.1002/14651858.CD001769.pub4/media/CDSR/CD001769/image_n/nCD001769-AFig-FIG04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Time to treatment failure ‐ any reason related to the treatment (PHT: phenytoin; SV: sodium valproate) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001769.pub4/full#CD001769-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001769.pub4/media/CDSR/CD001769/image_n/nCD001769-AFig-FIG04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001769-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001769.pub4/media/CDSR/CD001769/urn:x-wiley:14651858:media:CD001769:CD001769-AFig-FIG05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001769.pub4/media/CDSR/CD001769/image_t/tCD001769-AFig-FIG05.png" target="_blank"><b></b></a></p> </div><img alt="Time to treatment failure ‐ any reason related to the treatment, by epilepsy type (PHT: phenytoin; SV: sodium valproate)" data-id="CD001769-fig-0005" src="/cdsr/doi/10.1002/14651858.CD001769.pub4/media/CDSR/CD001769/image_n/nCD001769-AFig-FIG05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 5</div> <div class="figure-caption"> <p>Time to treatment failure ‐ any reason related to the treatment, by epilepsy type (PHT: phenytoin; SV: sodium valproate) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001769.pub4/full#CD001769-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001769.pub4/media/CDSR/CD001769/image_n/nCD001769-AFig-FIG05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001769-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001769.pub4/media/CDSR/CD001769/urn:x-wiley:14651858:media:CD001769:CD001769-AFig-FIG06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001769.pub4/media/CDSR/CD001769/image_t/tCD001769-AFig-FIG06.png" target="_blank"><b></b></a></p> </div><img alt="Time to treatment failure due to adverse events (PHT: phenytoin; SV: sodium valproate)" data-id="CD001769-fig-0006" src="/cdsr/doi/10.1002/14651858.CD001769.pub4/media/CDSR/CD001769/image_n/nCD001769-AFig-FIG06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 6</div> <div class="figure-caption"> <p>Time to treatment failure due to adverse events (PHT: phenytoin; SV: sodium valproate)</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001769.pub4/full#CD001769-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001769.pub4/media/CDSR/CD001769/image_n/nCD001769-AFig-FIG06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001769-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001769.pub4/media/CDSR/CD001769/urn:x-wiley:14651858:media:CD001769:CD001769-AFig-FIG07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001769.pub4/media/CDSR/CD001769/image_t/tCD001769-AFig-FIG07.png" target="_blank"><b></b></a></p> </div><img alt="Time to treatment failure due to adverse events, by epilepsy type (PHT: phenytoin; SV: sodium valproate)" data-id="CD001769-fig-0007" src="/cdsr/doi/10.1002/14651858.CD001769.pub4/media/CDSR/CD001769/image_n/nCD001769-AFig-FIG07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 7</div> <div class="figure-caption"> <p>Time to treatment failure due to adverse events, by epilepsy type (PHT: phenytoin; SV: sodium valproate) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001769.pub4/full#CD001769-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001769.pub4/media/CDSR/CD001769/image_n/nCD001769-AFig-FIG07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001769-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001769.pub4/media/CDSR/CD001769/urn:x-wiley:14651858:media:CD001769:CD001769-AFig-FIG08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001769.pub4/media/CDSR/CD001769/image_t/tCD001769-AFig-FIG08.png" target="_blank"><b></b></a></p> </div><img alt="Time to treatment failure due to lack of efficacy (PHT: phenytoin; SV: sodium valproate)" data-id="CD001769-fig-0008" src="/cdsr/doi/10.1002/14651858.CD001769.pub4/media/CDSR/CD001769/image_n/nCD001769-AFig-FIG08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 8</div> <div class="figure-caption"> <p>Time to treatment failure due to lack of efficacy (PHT: phenytoin; SV: sodium valproate)</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001769.pub4/full#CD001769-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001769.pub4/media/CDSR/CD001769/image_n/nCD001769-AFig-FIG08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001769-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001769.pub4/media/CDSR/CD001769/urn:x-wiley:14651858:media:CD001769:CD001769-AFig-FIG09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001769.pub4/media/CDSR/CD001769/image_t/tCD001769-AFig-FIG09.png" target="_blank"><b></b></a></p> </div><img alt="Time to treatment failure due to lack of efficacy, by epilepsy type (PHT: phenytoin; SV: sodium valproate)" data-id="CD001769-fig-0009" src="/cdsr/doi/10.1002/14651858.CD001769.pub4/media/CDSR/CD001769/image_n/nCD001769-AFig-FIG09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 9</div> <div class="figure-caption"> <p>Time to treatment failure due to lack of efficacy, by epilepsy type (PHT: phenytoin; SV: sodium valproate) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001769.pub4/full#CD001769-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001769.pub4/media/CDSR/CD001769/image_n/nCD001769-AFig-FIG09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001769-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001769.pub4/media/CDSR/CD001769/urn:x-wiley:14651858:media:CD001769:CD001769-AFig-FIG10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001769.pub4/media/CDSR/CD001769/image_t/tCD001769-AFig-FIG10.png" target="_blank"><b></b></a></p> </div><img alt="Time to first seizure (PHT: phenytoin; SV: sodium valproate)" data-id="CD001769-fig-0010" src="/cdsr/doi/10.1002/14651858.CD001769.pub4/media/CDSR/CD001769/image_n/nCD001769-AFig-FIG10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 10</div> <div class="figure-caption"> <p>Time to first seizure (PHT: phenytoin; SV: sodium valproate)</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001769.pub4/full#CD001769-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001769.pub4/media/CDSR/CD001769/image_n/nCD001769-AFig-FIG10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001769-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001769.pub4/media/CDSR/CD001769/urn:x-wiley:14651858:media:CD001769:CD001769-AFig-FIG11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001769.pub4/media/CDSR/CD001769/image_t/tCD001769-AFig-FIG11.png" target="_blank"><b></b></a></p> </div><img alt="Time to first seizure ‐ by epilepsy type. (PHT: phenytoin; SV: sodium valproate)" data-id="CD001769-fig-0011" src="/cdsr/doi/10.1002/14651858.CD001769.pub4/media/CDSR/CD001769/image_n/nCD001769-AFig-FIG11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 11</div> <div class="figure-caption"> <p>Time to first seizure ‐ by epilepsy type. (PHT: phenytoin; SV: sodium valproate)</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001769.pub4/full#CD001769-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001769.pub4/media/CDSR/CD001769/image_n/nCD001769-AFig-FIG11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001769-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001769.pub4/media/CDSR/CD001769/urn:x-wiley:14651858:media:CD001769:CD001769-AFig-FIG12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001769.pub4/media/CDSR/CD001769/image_t/tCD001769-AFig-FIG12.png" target="_blank"><b></b></a></p> </div><img alt="Time to achieve 12‐month remission (PHT: phenytoin; SV: sodium valproate)" data-id="CD001769-fig-0012" src="/cdsr/doi/10.1002/14651858.CD001769.pub4/media/CDSR/CD001769/image_n/nCD001769-AFig-FIG12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 12</div> <div class="figure-caption"> <p>Time to achieve 12‐month remission (PHT: phenytoin; SV: sodium valproate)</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001769.pub4/full#CD001769-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001769.pub4/media/CDSR/CD001769/image_n/nCD001769-AFig-FIG12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001769-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001769.pub4/media/CDSR/CD001769/urn:x-wiley:14651858:media:CD001769:CD001769-AFig-FIG13" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001769.pub4/media/CDSR/CD001769/image_t/tCD001769-AFig-FIG13.png" target="_blank"><b></b></a></p> </div><img alt="Time to achieve 12‐month remission ‐ by epilepsy type. (PHT: phenytoin; SV: sodium valproate)" data-id="CD001769-fig-0013" src="/cdsr/doi/10.1002/14651858.CD001769.pub4/media/CDSR/CD001769/image_n/nCD001769-AFig-FIG13.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 13</div> <div class="figure-caption"> <p>Time to achieve 12‐month remission ‐ by epilepsy type. (PHT: phenytoin; SV: sodium valproate) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001769.pub4/full#CD001769-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001769.pub4/media/CDSR/CD001769/image_n/nCD001769-AFig-FIG13.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001769-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001769.pub4/media/CDSR/CD001769/urn:x-wiley:14651858:media:CD001769:CD001769-AFig-FIG14" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001769.pub4/media/CDSR/CD001769/image_t/tCD001769-AFig-FIG14.png" target="_blank"><b></b></a></p> </div><img alt="Time to achieve six‐month remission (PHT: phenytoin; SV: sodium valproate)" data-id="CD001769-fig-0014" src="/cdsr/doi/10.1002/14651858.CD001769.pub4/media/CDSR/CD001769/image_n/nCD001769-AFig-FIG14.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 14</div> <div class="figure-caption"> <p>Time to achieve six‐month remission (PHT: phenytoin; SV: sodium valproate)</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001769.pub4/full#CD001769-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001769.pub4/media/CDSR/CD001769/image_n/nCD001769-AFig-FIG14.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001769-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001769.pub4/media/CDSR/CD001769/urn:x-wiley:14651858:media:CD001769:CD001769-AFig-FIG15" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001769.pub4/media/CDSR/CD001769/image_t/tCD001769-AFig-FIG15.png" target="_blank"><b></b></a></p> </div><img alt="Time to achieve six‐month remission (PHT: phenytoin; SV: sodium valproate)" data-id="CD001769-fig-0015" src="/cdsr/doi/10.1002/14651858.CD001769.pub4/media/CDSR/CD001769/image_n/nCD001769-AFig-FIG15.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 15</div> <div class="figure-caption"> <p>Time to achieve six‐month remission (PHT: phenytoin; SV: sodium valproate)</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001769.pub4/full#CD001769-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001769.pub4/media/CDSR/CD001769/image_n/nCD001769-AFig-FIG15.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001769-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001769.pub4/media/CDSR/CD001769/urn:x-wiley:14651858:media:CD001769:CD001769-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001769.pub4/media/CDSR/CD001769/image_t/tCD001769-CMP-001-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Sodium valproate versus phenytoin, Outcome 1 Time to treatment failure (any reason related to the treatment)." data-id="CD001769-fig-0016" src="/cdsr/doi/10.1002/14651858.CD001769.pub4/media/CDSR/CD001769/image_n/nCD001769-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Sodium valproate versus phenytoin, Outcome 1 Time to treatment failure (any reason related to the treatment). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001769.pub4/references#CD001769-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001769.pub4/media/CDSR/CD001769/image_n/nCD001769-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001769-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001769.pub4/media/CDSR/CD001769/urn:x-wiley:14651858:media:CD001769:CD001769-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001769.pub4/media/CDSR/CD001769/image_t/tCD001769-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Sodium valproate versus phenytoin, Outcome 2 Time to treatment failure due to adverse events." data-id="CD001769-fig-0017" src="/cdsr/doi/10.1002/14651858.CD001769.pub4/media/CDSR/CD001769/image_n/nCD001769-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Sodium valproate versus phenytoin, Outcome 2 Time to treatment failure due to adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001769.pub4/references#CD001769-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001769.pub4/media/CDSR/CD001769/image_n/nCD001769-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001769-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001769.pub4/media/CDSR/CD001769/urn:x-wiley:14651858:media:CD001769:CD001769-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001769.pub4/media/CDSR/CD001769/image_t/tCD001769-CMP-001-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Sodium valproate versus phenytoin, Outcome 3 Time to treatment failure due to lack of efficacy." data-id="CD001769-fig-0018" src="/cdsr/doi/10.1002/14651858.CD001769.pub4/media/CDSR/CD001769/image_n/nCD001769-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 Sodium valproate versus phenytoin, Outcome 3 Time to treatment failure due to lack of efficacy. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001769.pub4/references#CD001769-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001769.pub4/media/CDSR/CD001769/image_n/nCD001769-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001769-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001769.pub4/media/CDSR/CD001769/urn:x-wiley:14651858:media:CD001769:CD001769-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001769.pub4/media/CDSR/CD001769/image_t/tCD001769-CMP-001-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Sodium valproate versus phenytoin, Outcome 4 Time to treatment failure (any reason related to the treatment) ‐ by epilepsy type." data-id="CD001769-fig-0019" src="/cdsr/doi/10.1002/14651858.CD001769.pub4/media/CDSR/CD001769/image_n/nCD001769-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 Sodium valproate versus phenytoin, Outcome 4 Time to treatment failure (any reason related to the treatment) ‐ by epilepsy type. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001769.pub4/references#CD001769-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001769.pub4/media/CDSR/CD001769/image_n/nCD001769-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001769-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001769.pub4/media/CDSR/CD001769/urn:x-wiley:14651858:media:CD001769:CD001769-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001769.pub4/media/CDSR/CD001769/image_t/tCD001769-CMP-001-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Sodium valproate versus phenytoin, Outcome 5 Time to treatment failure due to adverse events ‐ by epilepsy type." data-id="CD001769-fig-0020" src="/cdsr/doi/10.1002/14651858.CD001769.pub4/media/CDSR/CD001769/image_n/nCD001769-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 Sodium valproate versus phenytoin, Outcome 5 Time to treatment failure due to adverse events ‐ by epilepsy type. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001769.pub4/references#CD001769-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001769.pub4/media/CDSR/CD001769/image_n/nCD001769-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001769-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001769.pub4/media/CDSR/CD001769/urn:x-wiley:14651858:media:CD001769:CD001769-CMP-001-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001769.pub4/media/CDSR/CD001769/image_t/tCD001769-CMP-001-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Sodium valproate versus phenytoin, Outcome 6 Time to treatment failure due to lack of efficacy ‐ by epilepsy type." data-id="CD001769-fig-0021" src="/cdsr/doi/10.1002/14651858.CD001769.pub4/media/CDSR/CD001769/image_n/nCD001769-CMP-001-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1 Sodium valproate versus phenytoin, Outcome 6 Time to treatment failure due to lack of efficacy ‐ by epilepsy type. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001769.pub4/references#CD001769-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001769.pub4/media/CDSR/CD001769/image_n/nCD001769-CMP-001-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001769-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001769.pub4/media/CDSR/CD001769/urn:x-wiley:14651858:media:CD001769:CD001769-CMP-001-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001769.pub4/media/CDSR/CD001769/image_t/tCD001769-CMP-001-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Sodium valproate versus phenytoin, Outcome 7 Time to first seizure." data-id="CD001769-fig-0022" src="/cdsr/doi/10.1002/14651858.CD001769.pub4/media/CDSR/CD001769/image_n/nCD001769-CMP-001-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1 Sodium valproate versus phenytoin, Outcome 7 Time to first seizure.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001769.pub4/references#CD001769-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001769.pub4/media/CDSR/CD001769/image_n/nCD001769-CMP-001-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001769-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001769.pub4/media/CDSR/CD001769/urn:x-wiley:14651858:media:CD001769:CD001769-CMP-001-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001769.pub4/media/CDSR/CD001769/image_t/tCD001769-CMP-001-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Sodium valproate versus phenytoin, Outcome 8 Time to first seizure ‐ by epilepsy type." data-id="CD001769-fig-0023" src="/cdsr/doi/10.1002/14651858.CD001769.pub4/media/CDSR/CD001769/image_n/nCD001769-CMP-001-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1 Sodium valproate versus phenytoin, Outcome 8 Time to first seizure ‐ by epilepsy type. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001769.pub4/references#CD001769-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001769.pub4/media/CDSR/CD001769/image_n/nCD001769-CMP-001-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001769-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001769.pub4/media/CDSR/CD001769/urn:x-wiley:14651858:media:CD001769:CD001769-CMP-001-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001769.pub4/media/CDSR/CD001769/image_t/tCD001769-CMP-001-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Sodium valproate versus phenytoin, Outcome 9 Time to first seizure ‐ epilepsy type reclassified to focal for generalised and age of onset &gt; 30 years." data-id="CD001769-fig-0024" src="/cdsr/doi/10.1002/14651858.CD001769.pub4/media/CDSR/CD001769/image_n/nCD001769-CMP-001-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1 Sodium valproate versus phenytoin, Outcome 9 Time to first seizure ‐ epilepsy type reclassified to focal for generalised and age of onset &gt; 30 years. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001769.pub4/references#CD001769-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001769.pub4/media/CDSR/CD001769/image_n/nCD001769-CMP-001-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001769-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001769.pub4/media/CDSR/CD001769/urn:x-wiley:14651858:media:CD001769:CD001769-CMP-001-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001769.pub4/media/CDSR/CD001769/image_t/tCD001769-CMP-001-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Sodium valproate versus phenytoin, Outcome 10 Time to first seizure ‐ epilepsy type reclassified to uncertain for generalised and age of onset &gt; 30 years." data-id="CD001769-fig-0025" src="/cdsr/doi/10.1002/14651858.CD001769.pub4/media/CDSR/CD001769/image_n/nCD001769-CMP-001-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.10</div> <div class="figure-caption"> <p>Comparison 1 Sodium valproate versus phenytoin, Outcome 10 Time to first seizure ‐ epilepsy type reclassified to uncertain for generalised and age of onset &gt; 30 years. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001769.pub4/references#CD001769-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001769.pub4/media/CDSR/CD001769/image_n/nCD001769-CMP-001-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001769-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001769.pub4/media/CDSR/CD001769/urn:x-wiley:14651858:media:CD001769:CD001769-CMP-001-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001769.pub4/media/CDSR/CD001769/image_t/tCD001769-CMP-001-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Sodium valproate versus phenytoin, Outcome 11 Time to achieve 12‐month remission." data-id="CD001769-fig-0026" src="/cdsr/doi/10.1002/14651858.CD001769.pub4/media/CDSR/CD001769/image_n/nCD001769-CMP-001-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.11</div> <div class="figure-caption"> <p>Comparison 1 Sodium valproate versus phenytoin, Outcome 11 Time to achieve 12‐month remission. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001769.pub4/references#CD001769-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001769.pub4/media/CDSR/CD001769/image_n/nCD001769-CMP-001-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001769-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001769.pub4/media/CDSR/CD001769/urn:x-wiley:14651858:media:CD001769:CD001769-CMP-001-12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001769.pub4/media/CDSR/CD001769/image_t/tCD001769-CMP-001-12.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Sodium valproate versus phenytoin, Outcome 12 Time to achieve 12‐month remission ‐ by epilepsy type." data-id="CD001769-fig-0027" src="/cdsr/doi/10.1002/14651858.CD001769.pub4/media/CDSR/CD001769/image_n/nCD001769-CMP-001-12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.12</div> <div class="figure-caption"> <p>Comparison 1 Sodium valproate versus phenytoin, Outcome 12 Time to achieve 12‐month remission ‐ by epilepsy type. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001769.pub4/references#CD001769-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001769.pub4/media/CDSR/CD001769/image_n/nCD001769-CMP-001-12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001769-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001769.pub4/media/CDSR/CD001769/urn:x-wiley:14651858:media:CD001769:CD001769-CMP-001-13" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001769.pub4/media/CDSR/CD001769/image_t/tCD001769-CMP-001-13.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Sodium valproate versus phenytoin, Outcome 13 Time to achieve six‐month remission." data-id="CD001769-fig-0028" src="/cdsr/doi/10.1002/14651858.CD001769.pub4/media/CDSR/CD001769/image_n/nCD001769-CMP-001-13.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.13</div> <div class="figure-caption"> <p>Comparison 1 Sodium valproate versus phenytoin, Outcome 13 Time to achieve six‐month remission. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001769.pub4/references#CD001769-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001769.pub4/media/CDSR/CD001769/image_n/nCD001769-CMP-001-13.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001769-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001769.pub4/media/CDSR/CD001769/urn:x-wiley:14651858:media:CD001769:CD001769-CMP-001-14" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001769.pub4/media/CDSR/CD001769/image_t/tCD001769-CMP-001-14.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Sodium valproate versus phenytoin, Outcome 14 Time to achieve six‐month remission ‐ by epilepsy type." data-id="CD001769-fig-0029" src="/cdsr/doi/10.1002/14651858.CD001769.pub4/media/CDSR/CD001769/image_n/nCD001769-CMP-001-14.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.14</div> <div class="figure-caption"> <p>Comparison 1 Sodium valproate versus phenytoin, Outcome 14 Time to achieve six‐month remission ‐ by epilepsy type. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001769.pub4/references#CD001769-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001769.pub4/media/CDSR/CD001769/image_n/nCD001769-CMP-001-14.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD001769-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Sodium valproate compared with phenytoin monotherapy for epilepsy (primary outcome)</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Sodium valproate compared with phenytoin monotherapy for epilepsy</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> adults and children with newly‐onset focal onset or generalised tonic‐clonic seizures </p> <p><b>Settings:</b> outpatients </p> <p><b>Intervention:</b> sodium valproate </p> <p><b>Comparison:</b> phenytoin </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No. of Participants<br/> (studies)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Phenytoin</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Sodium valproate</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Time to treatment failure (any reason related to treatment)</b> </p> <p><i>All participants</i> </p> <p>Range of follow‐up: 0 to 4256 days</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The median time to treatment failure was 2361 days in the phenytoin group</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The median time to treatment failure was 2545 days (184 days longer) in the sodium valproate group </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HR 0.88</b> </p> <p>(0.61 to 1.27)<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>528<br/> (5 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HR &lt; 1 indicates a clinical advantage for valproate</p> <p>There was also no statistically significant difference between drugs in treatment failure due to adverse events: HR 0.77 (95% CI 0.44 to 1.37, P = 0.38) or treatment failure due to lack of efficacy: HR 1.16 (95% CI 0.71 to 1.89, P = 0.55) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Time to treatment failure (any reason related to treatment)</b> </p> <p><i>Subgroup: focal onset seizures</i> </p> <p>Range of follow‐up: 0 to 4256 days</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The median time to treatment failure was 1838 days in the phenytoin group</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The median time to treatment failure was 1772 days (66 days shorter) in the sodium valproate group </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HR 0.83</b> </p> <p>(0.50 to 1.38)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>187</p> <p>(4 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HR &lt; 1 indicates a clinical advantage for valproate</p> <p>There was also no statistically significant difference between drugs in treatment failure due to adverse events: HR 0.81 (95% CI 0.34 to 1.90, P = 0.62) or treatment failure due to lack of efficacy: HR 1.01 (95% CI 0.55 to 1.85, P = 0.98) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Time to treatment failure (any reason related to treatment)</b> </p> <p><i>Subgroup: generalised onset seizures (tonic‐clonic only)</i> </p> <p>Range of follow‐up: 0 to 4394 days</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The 25th percentile** of time to treatment failure was 1488 days in the phenytoin group </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The 25th percentile** of time to treatment failure was 1778 days (290 days longer) in the sodium valproate group </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HR 0.94</b> </p> <p>(0.55 to 1.61)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>341<br/> (5 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Low</b><sup>b, c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HR &lt; 1 indicates a clinical advantage for valproate</p> <p>There was also no statistically significant difference between drugs in treatment failure due to adverse events: HR 0.75 (95% CI 0.35 to 1.60, P = 0.46) or treatment failure due to lack of efficacy: HR 1.51 (95% CI 0.66 to 3.45, P = 0.33) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>* Illustrative risks in the sodium valproate and phenytoin groups are calculated at the median time to treatment failure (i.e. the time to 50% of participants failing or withdrawing from allocated treatment) within each group across all trials. The relative effect (pooled HR) shows the comparison of 'time to treatment failure' between the treatment groups. </p> <p>** The 25th percentile of time to treatment failure (i.e. the time to 25% of participants failing or withdrawing from allocated treatment) is presented for the subgroup with generalised seizures as less than 50% of participants failed/withdrew from treatment, therefore the median time could not be calculated. </p> <p><b>Abbreviations: CI</b> : confidence interval; <b>HR</b>: hazard ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Pooled HR for all participants adjusted for seizure type.<br/> <sup>b</sup>Downgraded once as risk of bias judged high for three unblinded studies (<a href="./references#CD001769-bbs2-0004" title="DeSilvaM , MacArdleB , McGowanM , HughesE , StewartJ , NevilleBGR , et al. Randomised comparative monotherapy trial of phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed childhood epilepsy. Lancet1996;347:709‐13. ">De Silva 1996</a>; <a href="./references#CD001769-bbs2-0006" title="HellerAJ , ChestermanP , ElwesRD , CrawfordP , ChadwickDW , JohnsonAL , et al. Phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed adult epilepsy: a randomised comparative monotherapy trial. Journal of Neurology, Neurosurgery, and Psychiatry1995;58:44‐50. ">Heller 1995</a>; <a href="./references#CD001769-bbs2-0007" title="RamsayRE , WilderBJ , MurphyJV , HolmesGL , UthmanB , SlaterJ , et al. Efficacy and safety of valproic acid versus phenytoin as sole therapy for newly diagnosed primary generalized tonic‐clonic seizures. Journal of Epilepsy1992;5(1):55‐60. ">Ramsay 1992</a>); lack of blinding may have impacted on the withdrawal rates and treatment failure rates in the trials.<br/> <sup>c</sup>Downgraded once due to inconsistency: a large amount of heterogeneity is present within analysis (I² = 59%) which could not be explained by sensitivity analysis for potential misclassification of epilepsy type. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Sodium valproate compared with phenytoin monotherapy for epilepsy (primary outcome)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001769.pub4/full#CD001769-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD001769-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Sodium valproate compared with phenytoin monotherapy for epilepsy (secondary outcomes)</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Valproate compared with phenytoin monotherapy for epilepsy</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> adults and children with newly‐onset focal onset or generalised tonic‐clonic seizures </p> <p><b>Settings:</b> outpatients </p> <p><b>Intervention:</b> sodium valproate </p> <p><b>Comparison:</b> phenytoin </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No. of Participants<br/> (studies)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Phenytoin</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Sodium valproate</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Time to first seizure (post‐randomisation)</b> </p> <p><i>All participants</i> </p> <p>Range of follow‐up: 0 to 4859 days</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The median time to first seizure post‐randomisation was 275 days in the phenytoin group </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The median time to first seizure post‐randomisation was 267 days (7 days shorter) in the sodium valproate group </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HR 1.08</b> </p> <p>(0.88 to 1.33)<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>639</p> <p>(5 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>b, c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HR &lt; 1 indicates a clinical<br/> advantage for valproate </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Time to first seizure (post‐randomisation)</b> </p> <p><i>Subgroup: focal onset seizures</i> </p> <p>Range of follow‐up: 0 to 4859 days</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The median time to first seizure post‐randomisation was 75 days in the phenytoin group</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The median time to first seizure post‐randomisation was 41 days (34 days shorter) in the sodium valproate group </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HR 1.20</b> </p> <p>(0.90 to 1.60)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>244</p> <p>(4 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>b, c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HR &lt; 1 indicates a clinical<br/> advantage for valproate </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Time to first seizure (post‐randomisation)</b> </p> <p><i>Subgroup: generalised onset seizures (tonic‐clonic only)</i> </p> <p>Range of follow‐up: 1 to 4520 days</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The median time to first seizure post‐randomisation was 572 days in the phenytoin group </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The median time to first seizure post‐randomisation was 549 days (23 days shorter) in the sodium valproate group </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HR 0.97</b> </p> <p>(0.72 to 1.30)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>395</p> <p>(5 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>b, c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HR &lt; 1 indicates a clinical<br/> advantage for valproate </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Time to achieve 12‐month remission (seizure‐free period)</b> </p> <p><i>All participants</i> </p> <p>Range of follow‐up: 5 to 4614 days</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The median time to achieve 12‐month remission was 380 days in the phenytoin group</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The median time to achieve 12‐month remission was 386 days (6 days longer) in the sodium valproate group </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HR 1.02</b> </p> <p>(0.81 to 1.28)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>514</p> <p>(4 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HR &lt; 1 indicates a clinical<br/> advantage for phenytoin </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Time to achieve 12‐month remission (seizure‐free period)</b> </p> <p><i>Subgroup: focal onset seizures</i> </p> <p>Range of follow‐up: 5 to 4614 days</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The median time to achieve 12‐month remission was 575 days in the phenytoin group</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The median time to achieve 12‐month remission was 549 days (26 days shorter) in the sodium valproate group </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HR 1.11</b> </p> <p>(0.78 to 1.60)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>244</p> <p>(4 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> M<b>oderate</b><sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HR &lt; 1 indicates a clinical<br/> advantage for phenytoin </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Time to achieve 12‐month remission (seizure‐free period)</b> </p> <p><i>Subgroup: generalised onset seizures (tonic‐clonic only)</i> </p> <p>Range of follow‐up: 7 to 4544 days</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The median time to achieve 12‐month remission was 365 days in the phenytoin group</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The median time to achieve 12‐month remission was 366 days (1 day longer) in the sodium valproate group </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HR 0.96</b> </p> <p>(0.71 to 1.29)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>270</p> <p>(4 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> M<b>oderate</b><sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HR &lt; 1 indicates a clinical<br/> advantage for phenytoin </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>* Illustrative risks in the phenytoin and sodium valproate groups are calculated at the median time to first seizure or time to 12‐month remission (i.e. the time to 50% of participants experiencing a first seizure or 12 months of remission) within each group across all trials. The relative effect (pooled HR) shows the comparison of 'time to first seizure' or 'time to 12‐month remission' between the treatment groups. </p> <p><b>Abbreviations: CI</b> : confidence interval; <b>HR</b>: hazard ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Pooled HR for all participants adjusted for seizure type.<br/> <sup>b</sup>Downgraded once as risk of bias judged high for four unblinded studies (<a href="./references#CD001769-bbs2-0002" title="CraigI , TallisR . Impact of valproate and phenytoin on cognitive function in elderly patients: results of a single‐blind randomized comparative study. Epilepsia1994;35(2):381‐90. ">Craig 1994</a>; <a href="./references#CD001769-bbs2-0004" title="DeSilvaM , MacArdleB , McGowanM , HughesE , StewartJ , NevilleBGR , et al. Randomised comparative monotherapy trial of phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed childhood epilepsy. Lancet1996;347:709‐13. ">De Silva 1996</a>; <a href="./references#CD001769-bbs2-0006" title="HellerAJ , ChestermanP , ElwesRD , CrawfordP , ChadwickDW , JohnsonAL , et al. Phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed adult epilepsy: a randomised comparative monotherapy trial. Journal of Neurology, Neurosurgery, and Psychiatry1995;58:44‐50. ">Heller 1995</a>; <a href="./references#CD001769-bbs2-0007" title="RamsayRE , WilderBJ , MurphyJV , HolmesGL , UthmanB , SlaterJ , et al. Efficacy and safety of valproic acid versus phenytoin as sole therapy for newly diagnosed primary generalized tonic‐clonic seizures. Journal of Epilepsy1992;5(1):55‐60. ">Ramsay 1992</a>). <br/> <sup>c</sup>Downgraded once due to applicability: as up to 49% in the 5 trials classified as experiencing generalised onset seizures may have had their seizure type wrongly classified; sensitivity analyses show misclassification has an impact on results and conclusions. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Sodium valproate compared with phenytoin monotherapy for epilepsy (secondary outcomes)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001769.pub4/full#CD001769-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD001769-tbl-0003"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Demographic characteristics of trial participants (trials providing individual participant data (IPD))</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""></td> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Focal seizures: n (%)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Male gender: n (%)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Age at entry (years):</b> </p> <p><b>Mean (SD), range</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Aged &gt; 30 years and generalised seizures: n (%)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Epilepsy duration (years): mean (SD), range</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Number of seizures in prior 6 months: median (range)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>SV</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>PHT</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Missing</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>SV</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>PHT</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Missing</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>SV</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>PHT</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Missing</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>SV</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>PHT</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Missing</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>SV</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>PHT</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Missing</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>SV</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>PHT</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Missing</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001769-bbs2-0002" title="CraigI , TallisR . Impact of valproate and phenytoin on cognitive function in elderly patients: results of a single‐blind randomized comparative study. Epilepsia1994;35(2):381‐90. ">Craig 1994</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>37 (44%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>43 (53%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38 (46%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33 (41%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>77.6 (7.2), 61 to 95</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>78.7 (7.0), 64 to 95</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>46</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>166</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 (0 to 60)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 (1 to 99)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001769-bbs2-0004" title="DeSilvaM , MacArdleB , McGowanM , HughesE , StewartJ , NevilleBGR , et al. Randomised comparative monotherapy trial of phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed childhood epilepsy. Lancet1996;347:709‐13. ">De Silva 1996</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25 (51%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30 (56%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18 (37%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34 (63%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11.3 (3.3), 2 to 15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9.5 (3.4), 3 to 15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.2 (1.5), 0 to 4.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.0 (2.1), 0 to 13.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 (1 to 900)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 (1 to 404)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001769-bbs2-0006" title="HellerAJ , ChestermanP , ElwesRD , CrawfordP , ChadwickDW , JohnsonAL , et al. Phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed adult epilepsy: a randomised comparative monotherapy trial. Journal of Neurology, Neurosurgery, and Psychiatry1995;58:44‐50. ">Heller 1995</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25 (41%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28 (44%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28 (46%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34 (54%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32.0 (15.6), 14 to 67</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33.5 (14.3), 14 to 72</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.6 (3.9), 0 to 17.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.8 (5.4), 0 to 24.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 (1 to 181)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 (1 to 575)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001769-bbs2-0007" title="RamsayRE , WilderBJ , MurphyJV , HolmesGL , UthmanB , SlaterJ , et al. Efficacy and safety of valproic acid versus phenytoin as sole therapy for newly diagnosed primary generalized tonic‐clonic seizures. Journal of Epilepsy1992;5(1):55‐60. ">Ramsay 1992</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 (0%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 (0%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48 (56%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25 (50%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21.1 (14.4), 3 to 64</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20.6 (14.0), 4 to 63</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.1 (0.3), 0 to 1.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.2 (0.5), 0 to 3.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>136</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001769-bbs2-0011" title="TurnbullDM , HowelD , RawlinsMD , ChadwickDW . Which drug for the adult epileptic patient: phenytoin or valproate?. BMJ1985;290:815‐9. ">Turnbull 1985</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32 (46%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31 (44%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34 (49%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>39 (56%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35.1 (16.5), 14 to 69</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35.3 (15.9), 16 to 70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.2 (2.9), 0.1 to 11.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.1 (4.2), 0.1 to 30.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 (0 to 60)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 (1 to 60)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="19"> <div class="table-footnote"> <p>SV= sodium valproate; PHT= Phenytoin; n = number of participants; NA = not available; SD = standard deviation. </p> <p>Proportions (%) are calculated based on non‐missing data.</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Demographic characteristics of trial participants (trials providing individual participant data (IPD))</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001769.pub4/full#CD001769-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD001769-tbl-0004"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Baseline neurologic characteristics of participants (trials providing individual participant data (IPD))</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""></td> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>EEG normal: n (%)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>CT scan normal: n (%)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>Neurological exam normal: n (%)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>SV</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>PHT</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Missing</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>SV</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>PHT</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Missing</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>SV</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>PHT</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Missing</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001769-bbs2-0002" title="CraigI , TallisR . Impact of valproate and phenytoin on cognitive function in elderly patients: results of a single‐blind randomized comparative study. Epilepsia1994;35(2):381‐90. ">Craig 1994</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20 (30%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8 (16%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>64</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>166</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>166</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001769-bbs2-0004" title="DeSilvaM , MacArdleB , McGowanM , HughesE , StewartJ , NevilleBGR , et al. Randomised comparative monotherapy trial of phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed childhood epilepsy. Lancet1996;347:709‐13. ">De Silva 1996</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>103</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>103</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>43 (88%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>48 (89%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001769-bbs2-0006" title="HellerAJ , ChestermanP , ElwesRD , CrawfordP , ChadwickDW , JohnsonAL , et al. Phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed adult epilepsy: a randomised comparative monotherapy trial. Journal of Neurology, Neurosurgery, and Psychiatry1995;58:44‐50. ">Heller 1995</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>124</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>124</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>56 (95%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>54 (86%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001769-bbs2-0007" title="RamsayRE , WilderBJ , MurphyJV , HolmesGL , UthmanB , SlaterJ , et al. Efficacy and safety of valproic acid versus phenytoin as sole therapy for newly diagnosed primary generalized tonic‐clonic seizures. Journal of Epilepsy1992;5(1):55‐60. ">Ramsay 1992</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>136</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>136</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>136</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001769-bbs2-0011" title="TurnbullDM , HowelD , RawlinsMD , ChadwickDW . Which drug for the adult epileptic patient: phenytoin or valproate?. BMJ1985;290:815‐9. ">Turnbull 1985</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30 (46%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>38 (54%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6 (50%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11 (73%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>70</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="10"> <div class="table-footnote"> <p>EEG = electroencephalographic; SV= sodium valproate; PHT= Phenytoin; n = number of participants; NA = not available. </p> <p>Proportions (%) are calculated based on non‐missing data.</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Baseline neurologic characteristics of participants (trials providing individual participant data (IPD))</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001769.pub4/full#CD001769-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD001769-tbl-0005"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Outcomes considered and summary of results for trials with no individual participant data (IPD)</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Trial</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Outcomes reported</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Summary of results</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001769-bbs2-0001" title="CallaghanN , KennyRA , O'NeillB , CrowleyM , GogginT . A prospective study between carbamazepine, phenytoin and sodium valproate as monotherapy in previously untreated and recently diagnosed patients with epilepsy. Journal of Neurology, Neurosurgery and Psychiatry1985;48:639‐44. ">Callaghan 1985</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD001769-list-0020"> <li> <p>Seizure control</p> <ul id="CD001769-list-0021"> <li> <p>excellent (seizure‐free)</p> </li> <li> <p>good (&gt; 50% reduction)</p> </li> <li> <p>poor (&lt; 50% reduction)</p> </li> </ul> </li> </ul> <ul id="CD001769-list-0022"> <li> <p>Adverse events</p> </li> </ul> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD001769-list-0023"> <li> <p>PHT (n = 58); SV (n = 64)</p> <ul id="CD001769-list-0024"> <li> <p>39 (67%); 34 (53%)</p> </li> <li> <p>7 (12%); 16 (25%)</p> </li> <li> <p>12 (21%); 14 (22%)</p> </li> </ul> </li> </ul> <ul id="CD001769-list-0025"> <li> <p>2.6 (10%); 7 (11%)</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001769-bbs2-0003" title="CzapinskiP , TerczynskiA , CzapinskaE . Randomised 36‐month comparative study of valproic acid, phenytoin, phenobarbital and carbamazepine efficacy in patients with newly diagnosed epilepsy with partial complex seizures. Epilepsia1997;38(Suppl 3):42. ">Czapinski 1997a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD001769-list-0026"> <li> <p>Proportion achieving 24‐month remission at 3 years (PHT: 59%; SV: 64%)</p> </li> <li> <p>Proportion excluded after randomisation due to adverse events or no efficacy (PHT: 23%; SV: 23%) </p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001769-bbs2-0005" title="ForsytheI , ButlerR , BergI , McGuireR . Cognitive impairment in new cases of epilepsy randomly assigned to carbamazepine, phenytoin and sodium valproate. Developmental Medicine and Child Neurology1991;33:524‐34. ">Forsythe 1991</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD001769-list-0027"> <li> <p>Cognitive assessments</p> </li> <li> <p>Withdrawals from randomised drug</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD001769-list-0028"> <li> <p>Significant difference favouring SV test of speed of information processing (P &lt; 0.01)</p> </li> </ul> </p> <p>No significant differences between treatment groups for any other cognitive tests</p> <p> <ul id="CD001769-list-0029"> <li> <p>PHT: 6/20 (30%); SV: 7/21 (33%)</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001769-bbs2-0008" title="RastogiP , MehrotraTN , AgarwalaRK , SinghVS . Comparison of sodium valproate and phenytoin as single drug treatment in generalised and partial epilepsy. Journal of the Association of Physicians of India1991;39(8):606‐8. ">Rastogi 1991</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD001769-list-0030"> <li> <p>Reduction in frequency of seizures at 24 weeks</p> <ul id="CD001769-list-0031"> <li> <p>excellent (100% reduction)</p> </li> <li> <p>good (75% ‐ 99% reduction)</p> </li> <li> <p>fair (50% ‐ 74% reduction)</p> </li> <li> <p>poor (&lt; 50% reduction)</p> </li> </ul> </li> </ul> <ul id="CD001769-list-0032"> <li> <p>Adverse events</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD001769-list-0033"> <li> <p>PHT (n = 45); SV (n = 49)</p> <ul id="CD001769-list-0034"> <li> <p>23 (51%); 24 (49%)</p> </li> <li> <p>13 (24%); 17 (35%)</p> </li> <li> <p>8 (18%); 5(10%)</p> </li> <li> <p>1 (2%); 3 (6%)</p> </li> </ul> </li> <li> <p>All reported adverse events were minor</p> <ul id="CD001769-list-0035"> <li> <p>PHT: gum hyperplasia (18%), nystagmus (13%), gastrointestinal symptoms (4%), drowsiness (4%), ataxia (2%) </p> </li> <li> <p>SV: gastrointestinal symptoms (12%), drowsiness (6%), weight gain (2%)</p> </li> </ul> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001769-bbs2-0009" title="ShakirRA , JohnsonRH , LambieDG , MelvilleID , NandaRN . Comparison of sodium valproate and phenytoin as single drug treatment in epilepsy. Epilepsia1981;22:27‐33. ">Shakir 1981</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD001769-list-0036"> <li> <p>Seizures during treatment</p> </li> <li> <p>Adverse events</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD001769-list-0037"> <li> <p>PHT: 5 (33%); SV: 7 (39%)</p> </li> <li> <p>PHT: 1 case of ataxia, 5 cases of acne</p> </li> <li> <p>SV: 2 cases of gastrointestinal symptoms, 2 cases of hair loss, 4 cases of weight gain </p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001769-bbs2-0010" title="ThilothammalN , BanuK , RatnamRS . Comparison of phenobarbitone, phenytoin with sodium valproate: randomized, double‐blind study. Indian Pediatrics1996;33:549‐55. ">Thilothammal 1996</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD001769-list-0038"> <li> <p>Recurrence of seizures</p> </li> <li> <p>Adverse events</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD001769-list-0039"> <li> <p>PHT: 14/52 (27%)/SV: 10/48 (21%)</p> </li> <li> <p>PHT: 33/52 (63%)/SV: 15/48 (31%)</p> </li> </ul> </p> <p>           </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="3"> <div class="table-footnote"> <p>n = number of participants; PHT: phenytoin; SV: sodium valproate.</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Outcomes considered and summary of results for trials with no individual participant data (IPD)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001769.pub4/full#CD001769-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD001769-tbl-0006"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Number of individuals contributing to each analysis</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Trial</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>Number randomised</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>Time to treatment failure (for any reason related to treatment)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>Time to achieve 12‐month remission</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>Time to achieve 6‐month remission</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>Time to first seizure</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>PHT</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>SV</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Total</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>PHT</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>SV</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Total</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>PHT</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>SV</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Total</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>PHT</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>SV</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Total</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>PHT</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>SV</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Total</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001769-bbs2-0002" title="CraigI , TallisR . Impact of valproate and phenytoin on cognitive function in elderly patients: results of a single‐blind randomized comparative study. Epilepsia1994;35(2):381‐90. ">Craig 1994</a><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>81</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>85</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>166</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>71</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>76</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>147</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>71</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>76</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>147</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>71</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>76</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>147</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001769-bbs2-0004" title="DeSilvaM , MacArdleB , McGowanM , HughesE , StewartJ , NevilleBGR , et al. Randomised comparative monotherapy trial of phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed childhood epilepsy. Lancet1996;347:709‐13. ">De Silva 1996</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>54</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>49</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>103</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>53</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>47</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>54</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>49</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>103</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>54</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>49</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>103</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>54</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>49</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>103</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001769-bbs2-0005" title="ForsytheI , ButlerR , BergI , McGuireR . Cognitive impairment in new cases of epilepsy randomly assigned to carbamazepine, phenytoin and sodium valproate. Developmental Medicine and Child Neurology1991;33:524‐34. ">Forsythe 1991</a><sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001769-bbs2-0006" title="HellerAJ , ChestermanP , ElwesRD , CrawfordP , ChadwickDW , JohnsonAL , et al. Phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed adult epilepsy: a randomised comparative monotherapy trial. Journal of Neurology, Neurosurgery, and Psychiatry1995;58:44‐50. ">Heller 1995</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>63</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>61</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>124</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>61</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>58</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>119</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>63</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>61</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>124</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>63</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>61</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>124</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>63</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>61</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>124</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001769-bbs2-0007" title="RamsayRE , WilderBJ , MurphyJV , HolmesGL , UthmanB , SlaterJ , et al. Efficacy and safety of valproic acid versus phenytoin as sole therapy for newly diagnosed primary generalized tonic‐clonic seizures. Journal of Epilepsy1992;5(1):55‐60. ">Ramsay 1992</a><sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>86</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>136</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>86</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>136</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>77</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>125</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>77</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>125</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001769-bbs2-0011" title="TurnbullDM , HowelD , RawlinsMD , ChadwickDW . Which drug for the adult epileptic patient: phenytoin or valproate?. BMJ1985;290:815‐9. ">Turnbull 1985</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>140</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>140</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>140</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>140</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>140</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001769-bbs2-0009" title="ShakirRA , JohnsonRH , LambieDG , MelvilleID , NandaRN . Comparison of sodium valproate and phenytoin as single drug treatment in epilepsy. Epilepsia1981;22:27‐33. ">Shakir 1981</a><sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Total</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>353</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>390</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>743</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>269</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>300</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>569</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>258</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>256</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>514</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>306</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>333</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>639</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>306</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>333</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>639</b> </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="16"> <div class="table-footnote"> <p><sup>a</sup>Treatment failure information not provided for <a href="./references#CD001769-bbs2-0002" title="CraigI , TallisR . Impact of valproate and phenytoin on cognitive function in elderly patients: results of a single‐blind randomized comparative study. Epilepsia1994;35(2):381‐90. ">Craig 1994</a>, so cannot contribute to 'time to treatment failure'.<br/> <sup>b</sup>Data extracted from <a href="./references#CD001769-bbs2-0005" title="ForsytheI , ButlerR , BergI , McGuireR . Cognitive impairment in new cases of epilepsy randomly assigned to carbamazepine, phenytoin and sodium valproate. Developmental Medicine and Child Neurology1991;33:524‐34. ">Forsythe 1991</a> and <a href="./references#CD001769-bbs2-0009" title="ShakirRA , JohnsonRH , LambieDG , MelvilleID , NandaRN . Comparison of sodium valproate and phenytoin as single drug treatment in epilepsy. Epilepsia1981;22:27‐33. ">Shakir 1981</a> publications to calculate time to treatment failure. Insufficient published data to calculate other outcomes.<br/> <sup>c</sup>Follow‐up for <a href="./references#CD001769-bbs2-0007" title="RamsayRE , WilderBJ , MurphyJV , HolmesGL , UthmanB , SlaterJ , et al. Efficacy and safety of valproic acid versus phenytoin as sole therapy for newly diagnosed primary generalized tonic‐clonic seizures. Journal of Epilepsy1992;5(1):55‐60. ">Ramsay 1992</a> is less than 12 months so cannot contribute to 'time to achieve 12‐month remission'. </p> <p>PHT: phenytoin; SV: sodium valproate.</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Number of individuals contributing to each analysis</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001769.pub4/full#CD001769-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD001769-tbl-0007"> <div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Reasons for premature discontinuation (treatment failure)</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Reason for early termination</b> </p> <p><b>(and classification in time‐to‐event analysis)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><a href="./references#CD001769-bbs2-0004" title="DeSilvaM , MacArdleB , McGowanM , HughesE , StewartJ , NevilleBGR , et al. Randomised comparative monotherapy trial of phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed childhood epilepsy. Lancet1996;347:709‐13. ">De Silva 1996</a><b><sup>b</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><a href="./references#CD001769-bbs2-0006" title="HellerAJ , ChestermanP , ElwesRD , CrawfordP , ChadwickDW , JohnsonAL , et al. Phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed adult epilepsy: a randomised comparative monotherapy trial. Journal of Neurology, Neurosurgery, and Psychiatry1995;58:44‐50. ">Heller 1995</a><b><sup>b, c</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><a href="./references#CD001769-bbs2-0007" title="RamsayRE , WilderBJ , MurphyJV , HolmesGL , UthmanB , SlaterJ , et al. Efficacy and safety of valproic acid versus phenytoin as sole therapy for newly diagnosed primary generalized tonic‐clonic seizures. Journal of Epilepsy1992;5(1):55‐60. "><b>Ramsay 1992</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><a href="./references#CD001769-bbs2-0011" title="TurnbullDM , HowelD , RawlinsMD , ChadwickDW . Which drug for the adult epileptic patient: phenytoin or valproate?. BMJ1985;290:815‐9. "><b>Turnbull 1985</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><a href="./references#CD001769-bbs2-0005" title="ForsytheI , ButlerR , BergI , McGuireR . Cognitive impairment in new cases of epilepsy randomly assigned to carbamazepine, phenytoin and sodium valproate. Developmental Medicine and Child Neurology1991;33:524‐34. "><b>Forsythe 1991</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><a href="./references#CD001769-bbs2-0009" title="ShakirRA , JohnsonRH , LambieDG , MelvilleID , NandaRN . Comparison of sodium valproate and phenytoin as single drug treatment in epilepsy. Epilepsia1981;22:27‐33. ">Shakir 1981</a><b><sup>d</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Total<sup>a</sup> </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>SV</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>PHT</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>SV</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>PHT</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>SV</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>PHT</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>SV</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>PHT</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>SV</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>PHT</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>SV</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>PHT</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>SV</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>PHT</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>All</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse events (event)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>42</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lack of efficacy (event)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>54</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Both adverse events and lack of efficacy (event)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Non‐compliance/protocol violation (event)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Illness or death (not treatment‐related, censored)<sup>e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participant went into remission (censored)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>67</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lost to follow‐up (censored)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>27</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Other (censored)<sup>f</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Completed the study (censored)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>49</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>178</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>150</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>328</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Total</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>47</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>53</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>58</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>63</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>86</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>50</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>70</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>70</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>21</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>20</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>18</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>15</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>300</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>271</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>571</b> </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="16"> <div class="table-footnote"> <p>PHT: phenytoin; SV: sodium valproate<br/> <sup>a</sup>IPD for 'time to treatment failure' was not provided for <a href="./references#CD001769-bbs2-0002" title="CraigI , TallisR . Impact of valproate and phenytoin on cognitive function in elderly patients: results of a single‐blind randomized comparative study. Epilepsia1994;35(2):381‐90. ">Craig 1994</a>.<br/> <sup>b</sup>Three participants for <a href="./references#CD001769-bbs2-0006" title="HellerAJ , ChestermanP , ElwesRD , CrawfordP , ChadwickDW , JohnsonAL , et al. Phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed adult epilepsy: a randomised comparative monotherapy trial. Journal of Neurology, Neurosurgery, and Psychiatry1995;58:44‐50. ">Heller 1995</a> (all SV) and three for <a href="./references#CD001769-bbs2-0004" title="DeSilvaM , MacArdleB , McGowanM , HughesE , StewartJ , NevilleBGR , et al. Randomised comparative monotherapy trial of phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed childhood epilepsy. Lancet1996;347:709‐13. ">De Silva 1996</a> (one PHT and two SV) have missing reasons for treatment failure.<br/> <sup>c</sup>Four participants from <a href="./references#CD001769-bbs2-0006" title="HellerAJ , ChestermanP , ElwesRD , CrawfordP , ChadwickDW , JohnsonAL , et al. Phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed adult epilepsy: a randomised comparative monotherapy trial. Journal of Neurology, Neurosurgery, and Psychiatry1995;58:44‐50. ">Heller 1995</a> had missing treatment failure times and did not contribute to analysis but reasons for treatment failure are given.<br/> <sup>d</sup>Nine participants in <a href="./references#CD001769-bbs2-0009" title="ShakirRA , JohnsonRH , LambieDG , MelvilleID , NandaRN . Comparison of sodium valproate and phenytoin as single drug treatment in epilepsy. Epilepsia1981;22:27‐33. ">Shakir 1981</a> were listed as having started on a second drug due to 'failure to respond.' This reason was classified as treatment failure due to lack of efficacy.<br/> <sup>e</sup>Death due to reasons not related to the study drug.<br/> <sup>f</sup>Other reasons from <a href="./references#CD001769-bbs2-0007" title="RamsayRE , WilderBJ , MurphyJV , HolmesGL , UthmanB , SlaterJ , et al. Efficacy and safety of valproic acid versus phenytoin as sole therapy for newly diagnosed primary generalized tonic‐clonic seizures. Journal of Epilepsy1992;5(1):55‐60. ">Ramsay 1992</a> – two participants withdrew due to pregnancy and one for personal reasons. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Reasons for premature discontinuation (treatment failure)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001769.pub4/full#CD001769-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD001769-tbl-0008"> <div class="table-heading"><span class="table-label">Table 6.</span> <span class="table-title">Sensitivity analysis ‐ epilepsy type misclassification</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Outcome</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Original analysis</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Generalised onset and age at onset &gt; 30 years</b> </p> <p><b>classified as focal onset</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Generalised onset and age at onset &gt; 30 years</b> </p> <p><b>classified as uncertain seizure type</b> </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Pooled HR (95% CI)</b> </p> <p><b>fixed‐effects</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Test of subgroup</b> </p> <p><b>differences</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Pooled HR (95% CI)</b> </p> <p><b>fixed‐effects</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Test of subgroup</b> </p> <p><b>differences</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Pooled HR (95% CI)</b> </p> <p><b>fixed‐effects</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Test of subgroup</b> </p> <p><b>differences</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Time to treatment failure</p> <p>(for any reason related to treatment)<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>F: 0.83 (0.50 to 1.38)</p> <p>G: 0.94 (0.55 to 1.61)</p> <p>O: 0.88 (0.61 to 1.27)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Chi² = 0.10, df = 1</p> <p>(P = 0.75), I² = 0%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>F: 0.95 (0.59 to 1.52)</p> <p>G: 0.77 (0.42 to 1.41)</p> <p>O: 0.88 (0.60 to 1.27)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Chi² = 0.29, df = 1</p> <p>(P = 0.59), I² = 0%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>F: 0.83 (0.50 to 1.38)</p> <p>G: 0.77 (0.42 to 1.41)</p> <p>U: 6.83 (0.82 to 57.16)</p> <p>O: 0.86 (0.59 to 1.27)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Chi² = 3.80, df = 2</p> <p>(P = 0.15), I² = 47.3%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Time to treatment failure due to adverse events<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>F: 0.75 (0.35 to 1.60)</p> <p>G: 0.81 (0.34 to 1.90)</p> <p>O: 0.77 (0.44 to 1.37)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Chi² = 0.02, df = 1</p> <p>(P = 0.90), I² = 0%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>F: 0.87 (0.42 to 1.80)</p> <p>G: 0.64 (0.26 to 1.59)</p> <p>O: 0.77 (0.44 to 1.36)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Chi² = 0.26, df = 1</p> <p>(P = 0.61), I² = 0%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not calculated<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not calculated<sup>b</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Time to treatment failure due to lack of efficacy<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>F: 1.01 (0.55 to 1.85)</p> <p>G: 1.51 (0.66 to 3.45)</p> <p>O: 1.16 (0.71 to 1.89)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Chi² = 0.60, df = 1</p> <p>(P = 0.44), I² = 0%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>F: 1.00 (0.51 to 1.96)</p> <p>G: 1.73 (0.56 to 5.35)</p> <p>O: 1.16 (0.65 to 2.06)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Chi² = 0.66, df = 1</p> <p>(P = 0.42), I² = 0%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not calculated<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not calculated<sup>b</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Time to first seizure<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>F: 1.20 (0.90 to 1.60)</p> <p>G: 0.97 (0.72 to 1.30)</p> <p>O: 1.08 (0.88 to 1.33)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Chi² = 1.06, df = 1</p> <p>(P = 0.30), I² = 5.6%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>F: 1.23 (0.96 to 1.57)</p> <p>G: 0.72 (0.50 to 1.05)</p> <p>O: 1.05 (0.86 to 1.29)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Chi² = 5.46, df = 1</p> <p>(P = 0.02), I² = 81.7%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>F: 1.20 (0.90 to 1.60)</p> <p>G: 0.72 (0.50 to 1.05)</p> <p>U: 1.35 (0.85 to 2.14)</p> <p>O: 1.06 (0.86 to 1.30)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Chi² = 5.79, df = 2</p> <p>(P = 0.06), I² = 65.5%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Time to 12‐month remission<sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>F: 1.11 (0.78 to 1.60)</p> <p>G: 0.96 (0.71 to 1.29)</p> <p>O: 1.02 (0.81 to 1.28)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Chi² = 0.39, df = 1</p> <p>(P = 0.53), I² = 0%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>F: 0.99 (0.75 to 1.32)</p> <p>G: 1.07 (0.72 to 1.59)</p> <p>O: 1.02 (0.81 to 1.28)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Chi² = 0.10, df = 1</p> <p>(P = 0.75), I² = 0%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>F: 1.11 (0.78 to 1.60)</p> <p>G: 1.07 (0.72 to 1.59)</p> <p>U: 0.74 (0.46 to 1.18)</p> <p>O: 0.99 (0.79 to 1.25)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Chi² = 2.07, df = 2</p> <p>(P = 0.36), I² = 3.3%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Time to 6‐month remission<sup>e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>F: 1.00 (0.73 to 1.35)</p> <p>G: 1.08 (0.84 to 1.38)</p> <p>O: 1.05 (0.86 to 1.27)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Chi² = 0.16, df = 1</p> <p>(P = 0.69), I² = 0%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>F: 1.00 (0.79 to 1.26)</p> <p>G: 1.14 (0.80 to 1.61)</p> <p>O: 1.04 (0.85 to 1.26)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Chi² = 0.38, df = 1</p> <p>(P = 0.54), I² = 0%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>F: 1.00 (0.73 to 1.35)</p> <p>G: 1.14 (0.80 to 1.61)</p> <p>U: 0.90 (0.62 to 1.31)</p> <p>O: 1.01 (0.83 to 1.23)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Chi² = 0.80, df = 2</p> <p>(P = 0.67), I² = 0%</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>Chi²: Chi² statistic; df: degrees of freedom of Chi² distribution; F: focal epilepsy; G: generalised epilepsy; O: overall (all participants); U: uncertain epilepsy; P: P value (&lt; 0.05 are classified as statistically significant). </p> <p><sup>a</sup>100 participants reclassified to focal epilepsy or uncertain epilepsy type for outcome 'time to treatment failure (for any reason related to treatment)'; see <a href="./references#CD001769-fig-0019" title="">Analysis 1.4</a> for original analysis.<br/> <sup>b</sup>100 participants reclassified to focal epilepsy or uncertain epilepsy type for outcomes 'time to treatment failure due to adverse events' and 'time to treatment failure due to lack of efficacy'; see <a href="./references#CD001769-fig-0020" title="">Analysis 1.5</a> and <a href="./references#CD001769-fig-0021" title="">Analysis 1.6</a> for original analyses. Forest plots not presented for sensitivity analysis for generalised and age at onset &gt; 30 years reclassified as focal epilepsy as results were numerically similar and conclusions are unchanged. Sensitivity analysis for generalised and age at onset &gt; 30 years reclassified as uncertain epilepsy type not performed due to small numbers of participants failing treatment for these reasons in the uncertain epilepsy type groups in each trial.<br/> <sup>c</sup>171 participants reclassified to focal epilepsy or uncertain epilepsy type for outcome 'time to first seizure'; see <a href="./references#CD001769-fig-0023" title="">Analysis 1.8</a> for original analysis and see <a href="./references#CD001769-fig-0025" title="">Analysis 1.10</a> and <a href="./references#CD001769-fig-0024" title="">Analysis 1.9</a> for forest plots of 'time to first seizure' sensitivity analyses for generalised and age at onset &gt; 30 years reclassified as focal epilepsy and uncertain epilepsy type, respectively.<br/> <sup>d</sup>145 participants reclassified to focal epilepsy or uncertain epilepsy type for outcome 'time to achieve 12‐month remission', see <a href="./references#CD001769-fig-0027" title="">Analysis 1.12</a> for original analysis. As results were numerically similar and conclusions are unchanged, forest plots are not presented.<br/> <sup>e</sup>171 participants reclassified to focal epilepsy or uncertain epilepsy type for outcome 'time to achieve 6‐month remission', see <a href="./references#CD001769-fig-0029" title="">Analysis 1.14</a> for original analysis. As results were numerically similar and conclusions are unchanged, forest plots are not presented. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 6.</span> <span class="table-title">Sensitivity analysis ‐ epilepsy type misclassification</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001769.pub4/full#CD001769-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD001769-tbl-0009"> <div class="table-heading"><span class="table-label">Table 7.</span> <span class="table-title">Adverse event data (narrative report)</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Trial</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Adverse event data<sup>a</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Summary of reported results</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Phenytoin (PHT)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>SV (sodium valproate)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001769-bbs2-0001" title="CallaghanN , KennyRA , O'NeillB , CrowleyM , GogginT . A prospective study between carbamazepine, phenytoin and sodium valproate as monotherapy in previously untreated and recently diagnosed patients with epilepsy. Journal of Neurology, Neurosurgery and Psychiatry1985;48:639‐44. ">Callaghan 1985</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All adverse events developed (by drug) and adverse events leading to discontinuation of treatment </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PHT (n = 58): gum hypertrophy (n = 2), rash (n = 2), ataxia (n = 2)</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SV (n = 64): weight gain (n = 4: all discontinued treatment), drowsiness (n = 2), aggressive behaviour (n = 1: discontinued treatment) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001769-bbs2-0002" title="CraigI , TallisR . Impact of valproate and phenytoin on cognitive function in elderly patients: results of a single‐blind randomized comparative study. Epilepsia1994;35(2):381‐90. ">Craig 1994</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse event frequency (spontaneous reports)<sup>b</sup> </p> <p>Discontinuations due to adverse events<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PHT (n = 25): unsteadiness (n = 9), sleepiness (n = 7), drowsiness (n = 2), impaired concentration (n = 2), confusion (n = 1), constipation (n = 1), diarrhoea (n = 1), dysarthria (n = 1), lethargy (n = 1), nystagmus (n = 1), rash (n = 1), tired legs (n = 1) </p> <p>PHT discontinuations (n = 6): rash (n =1), diarrhoea (n = 1), confusion (n = 1), unsteadiness (n = 1), constipation (n = 1), sleepiness (n = 1) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SV (n = 17): unsteadiness (n = 2), sleepiness (n = 3), tremor (n = 5), oedema (n = 3), alopecia (n = 2), depression (n = 2), weight gain (n = 2) </p> <p>SV discontinuations (n = 2): weight gain and depression (n = 1), unsteadiness (n =1)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001769-bbs2-0003" title="CzapinskiP , TerczynskiA , CzapinskaE . Randomised 36‐month comparative study of valproic acid, phenytoin, phenobarbital and carbamazepine efficacy in patients with newly diagnosed epilepsy with partial complex seizures. Epilepsia1997;38(Suppl 3):42. ">Czapinski 1997a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"Exclusions" due to adverse events or no efficacy<sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Proportion "excluded": PHT: 33.3%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Proportion "excluded": SV: 23.3%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001769-bbs2-0004" title="DeSilvaM , MacArdleB , McGowanM , HughesE , StewartJ , NevilleBGR , et al. Randomised comparative monotherapy trial of phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed childhood epilepsy. Lancet1996;347:709‐13. ">De Silva 1996</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"Unacceptable" adverse events leading to drug withdrawal<sup>e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PHT (n = 54): drowsiness (n = 2), skin rash (n = 1) blood dyscrasia (n = 1), hirsutism (n = 1) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SV (n = 49): behavioural (n = 1), tremor (n = 1)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001769-bbs2-0005" title="ForsytheI , ButlerR , BergI , McGuireR . Cognitive impairment in new cases of epilepsy randomly assigned to carbamazepine, phenytoin and sodium valproate. Developmental Medicine and Child Neurology1991;33:524‐34. ">Forsythe 1991</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No adverse event data reported</p> <p>(treatment withdrawal data only reported)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 participant (PHT) withdrew from the study due to depression and anorexia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No adverse event data (or treatment withdrawals due to adverse events) reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001769-bbs2-0006" title="HellerAJ , ChestermanP , ElwesRD , CrawfordP , ChadwickDW , JohnsonAL , et al. Phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed adult epilepsy: a randomised comparative monotherapy trial. Journal of Neurology, Neurosurgery, and Psychiatry1995;58:44‐50. ">Heller 1995</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>“Unacceptable” adverse events leading to drug withdrawal<sup>e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PHT (n = 63): myalgia (n = 1), irritability (n = 1)</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SV (n = 61): dizziness (n = 2) abnormal liver function test (n = 1)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001769-bbs2-0007" title="RamsayRE , WilderBJ , MurphyJV , HolmesGL , UthmanB , SlaterJ , et al. Efficacy and safety of valproic acid versus phenytoin as sole therapy for newly diagnosed primary generalized tonic‐clonic seizures. Journal of Epilepsy1992;5(1):55‐60. ">Ramsay 1992</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Most common adverse events (by treatment group)<sup>f</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PHT (n = 50): dyspepsia (n = 1), nausea (n = 2), dizziness (n = 2), somnolence (n = 5), tremor (n = 2), rash (n = 4) </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SV (n = 86): dyspepsia (n = 7), nausea (n = 10), dizziness (n = 5), somnolence (n = 8), tremor (n = 5), rash (n = 3) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001769-bbs2-0008" title="RastogiP , MehrotraTN , AgarwalaRK , SinghVS . Comparison of sodium valproate and phenytoin as single drug treatment in generalised and partial epilepsy. Journal of the Association of Physicians of India1991;39(8):606‐8. ">Rastogi 1991</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Commonest adverse events (reported as percentages by treatment group)<sup>f</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PHT (n = 45): gum hyperplasia (17.7%), nystagmus (13.33%), ataxia (2.2%), gastrointestinal disturbances (4.44%), drowsiness (4.44%) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SV (n = 49): gastrointestinal disturbances (12%), drowsiness (6.12%), weight gain (2.04%) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001769-bbs2-0009" title="ShakirRA , JohnsonRH , LambieDG , MelvilleID , NandaRN . Comparison of sodium valproate and phenytoin as single drug treatment in epilepsy. Epilepsia1981;22:27‐33. ">Shakir 1981</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse events (narrative description)<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PHT (n = 15): 1 case of ataxia, 5 cases of acne</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SV (n = 18): 2 cases of gastrointestinal symptoms, 2 cases of hair loss, 4 cases of weight gain </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001769-bbs2-0010" title="ThilothammalN , BanuK , RatnamRS . Comparison of phenobarbitone, phenytoin with sodium valproate: randomized, double‐blind study. Indian Pediatrics1996;33:549‐55. ">Thilothammal 1996</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Assessment of adverse events<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PHT (n = 52): 33 participants reported at least one side effect</p> <p>Reported frequencies: gingival hypertrophy (n = 30), ataxia (n = 13), sedation (n = 12), nausea and vomiting (n = 1) </p> <p>Other reported adverse events (no frequencies): nystagmus, confusion</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SV (n = 48): 15 participants reported at least one side effect</p> <p>Reported frequencies: hyperactivity (n = 6), impaired school performance (n = 4), severe skin allergy (n = 1) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001769-bbs2-0011" title="TurnbullDM , HowelD , RawlinsMD , ChadwickDW . Which drug for the adult epileptic patient: phenytoin or valproate?. BMJ1985;290:815‐9. ">Turnbull 1985</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Treatment withdrawals due to dose‐related and idiosyncratic adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PHT (n = 70): 11 treatment withdrawals due to dose‐related adverse events (nystagmus, ataxia, tremor, diplopia and mental change) </p> <p>5 treatment withdrawals due to idiosyncratic adverse events (skin eruption, erythroderma and jaundice) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SV (n = 70): 9 treatment withdrawals due to dose‐related adverse events (tremor, irritability, restlessness and alopecia) </p> <p>No treatment withdrawals due to idiosyncratic adverse events</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="4"> <div class="table-footnote"> <p><sup>a</sup>Adverse event data, as reported narratively in the publications. Adverse event data were not requested in original IPD requests but will be for all future IPD requests. For numbers of treatment withdrawals due to adverse events in studies for which IPD were provided (<a href="./references#CD001769-bbs2-0004" title="DeSilvaM , MacArdleB , McGowanM , HughesE , StewartJ , NevilleBGR , et al. Randomised comparative monotherapy trial of phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed childhood epilepsy. Lancet1996;347:709‐13. ">De Silva 1996</a>; <a href="./references#CD001769-bbs2-0006" title="HellerAJ , ChestermanP , ElwesRD , CrawfordP , ChadwickDW , JohnsonAL , et al. Phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed adult epilepsy: a randomised comparative monotherapy trial. Journal of Neurology, Neurosurgery, and Psychiatry1995;58:44‐50. ">Heller 1995</a>; <a href="./references#CD001769-bbs2-0007" title="RamsayRE , WilderBJ , MurphyJV , HolmesGL , UthmanB , SlaterJ , et al. Efficacy and safety of valproic acid versus phenytoin as sole therapy for newly diagnosed primary generalized tonic‐clonic seizures. Journal of Epilepsy1992;5(1):55‐60. ">Ramsay 1992</a>; <a href="./references#CD001769-bbs2-0011" title="TurnbullDM , HowelD , RawlinsMD , ChadwickDW . Which drug for the adult epileptic patient: phenytoin or valproate?. BMJ1985;290:815‐9. ">Turnbull 1985</a>) see <a href="#CD001769-tbl-0007">Table 5</a>.<br/> <sup>b</sup>Participants may report more than one adverse event.<br/> <sup>c</sup>The published paper, <a href="./references#CD001769-bbs2-0002" title="CraigI , TallisR . Impact of valproate and phenytoin on cognitive function in elderly patients: results of a single‐blind randomized comparative study. Epilepsia1994;35(2):381‐90. ">Craig 1994</a>, reports on a subset of 38 participants, so the adverse event data summary applies only to this subset. IPD were provided for 166 participants (no additional adverse event data provided).<br/> <sup>d</sup><a href="./references#CD001769-bbs2-0003" title="CzapinskiP , TerczynskiA , CzapinskaE . Randomised 36‐month comparative study of valproic acid, phenytoin, phenobarbital and carbamazepine efficacy in patients with newly diagnosed epilepsy with partial complex seizures. Epilepsia1997;38(Suppl 3):42. ">Czapinski 1997a</a> is an abstract only so very little information is reported.<br/> <sup>e</sup>Participants may have withdrawn due to adverse event alone or a combination of adverse events and poor efficacy (seizures).<br/> <sup>f</sup>Most commonly reported adverse events only, no indication of overall frequency of all adverse events. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 7.</span> <span class="table-title">Adverse event data (narrative report)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001769.pub4/full#CD001769-tbl-0009">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD001769-tbl-0010"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Sodium valproate versus phenytoin</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Time to treatment failure (any reason related to the treatment) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>569</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.67, 1.32]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Time to treatment failure due to adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>495</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.68 [0.40, 1.17]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Time to treatment failure due to lack of efficacy <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>569</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.23 [0.77, 1.97]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Time to treatment failure (any reason related to the treatment) ‐ by epilepsy type <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>528</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.88 [0.61, 1.27]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Focal onset seizures</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>187</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.83 [0.50, 1.38]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 Generalised onset seizures (tonic‐clonic only)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>341</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.55, 1.61]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Time to treatment failure due to adverse events ‐ by epilepsy type <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>418</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.77 [0.44, 1.37]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Focal onset seizures</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>168</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.75 [0.35, 1.60]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 Generalised onset seizures (tonic‐clonic only)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>250</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.81 [0.34, 1.90]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Time to treatment failure due to lack of efficacy ‐ by epilepsy type <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>451</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.16 [0.71, 1.89]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 Focal onset seizures</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>187</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.55, 1.85]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 Generalised onset seizures (tonic‐clonic only)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>264</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.51 [0.66, 3.45]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Time to first seizure <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>639</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.04 [0.85, 1.28]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Time to first seizure ‐ by epilepsy type <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>639</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.08 [0.88, 1.33]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1 Focal onset seizures</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>244</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.20 [0.90, 1.60]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.2 Generalised onset seizures (tonic‐clonic only)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>395</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.72, 1.30]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Time to first seizure ‐ epilepsy type reclassified to focal for generalised and age of onset &gt; 30 years <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>639</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.05 [0.86, 1.29]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1 Focal onset seizures</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>416</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.23 [0.96, 1.57]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.2 Generalised onset seizures (tonic‐clonic only)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>223</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.72 [0.50, 1.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Time to first seizure ‐ epilepsy type reclassified to uncertain for generalised and age of onset &gt; 30 years <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>649</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.06 [0.86, 1.30]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.1 Focal onset seizures</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>255</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.20 [0.90, 1.60]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.2 Generalised onset seizures (tonic‐clonic only)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>223</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.72 [0.50, 1.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.3 Uncertain seizure type</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>171</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.35 [0.85, 2.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Time to achieve 12‐month remission <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>514</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.82, 1.29]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12 Time to achieve 12‐month remission ‐ by epilepsy type <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>514</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.81, 1.28]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.1 Focal onset seizures</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>244</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.11 [0.78, 1.60]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.2 Generalised onset seizures (tonic‐clonic only)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>270</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.71, 1.29]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13 Time to achieve six‐month remission <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>639</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.08 [0.89, 1.30]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14 Time to achieve six‐month remission ‐ by epilepsy type <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>639</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.05 [0.86, 1.27]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.1 Focal onset seizures</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>244</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.73, 1.35]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.2 Generalised onset seizures (tonic‐clonic only)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>395</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.08 [0.84, 1.38]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Sodium valproate versus phenytoin</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001769.pub4/references#CD001769-tbl-0010">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD001769.pub4&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD001769-note-0003">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD001769-note-0014">فارسی</a> </li> <li class="section-language"> <a class="" href="ms#CD001769-note-0002">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD001769-note-0001">简体中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734064000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734064000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772746000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001769\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD001769\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001769\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD001769\x2epub4"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001769\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD001769\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001769\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD001769\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001769\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD001769\x2epub4"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001769\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD001769\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001769\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD001769\x2epub4"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001769\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD001769\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001769\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD001769\x2epub4"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=8ranHhTh&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD001769.pub4&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD001769.pub4';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD001769.pub4/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD001769.pub4/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD001769.pub4%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740720156456"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD001769.pub4/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740720156461"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD001769.pub4/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918dfa4ac8c79377',t:'MTc0MDcyMDE1Ni4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 